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‘I  could  tell  you  my  adventures  —  beginning  from  this  morning,’
said  Alice  a  little  timidly:  ‘but  it’s  no  use  going  back  to  yesterday,    
because  I  was  a  different  person  then.’
‘Explain  all  that,’  said  the  Mock  Turtle.
‘No,  no!  The  adventures  first,’  said  the  Gryphon  in  an  impatient  tone:
  ‘explanations  take  such  a  dreadful  time.’
(Lewis  Carroll:  Alice’s  Adventures  in  Wonderland)  
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9Abstract
The  immune  response  is  operated  by  two  integrated  systems,  the  adaptive  and  innate  
immune  responses.  Innate  immunity  includes  both  cellular  and  soluble  components.  
The   cellular   part   consists   of   host   cells   at   the   front   line   of   defence  –  macrophages,  
monocytes,  dendritic  cells,  neutrophils,  endothelial  cells  and  mast  cells  –  that  express  
receptors  capable  of  recognizing  common  pathogen  constituents,  hence  called  pattern-­
recognition  receptors,  PRRs.  Several  cooperating  PRR  families,  for  example  Toll-­like  
receptors   (TLRs)   and   receptors   with   nucleotide-­binding   domain   leucine-­rich  
???????????????? ???????????????????? ???????????????????????????????????????????????????
pathogen-­associated  molecular  patterns  and  non-­microbial,  danger-­associated  molecular  
patterns.  The  soluble   component  of   the   innate   immune  system   includes  an  arsenal  
of  acute-­phase  proteins,   the  expression  of  which   is   induced  during   the  acute-­phase  
response   (APR),   an   immediate   systemic   reaction   triggered   by   a   local   or   systemic  
abnormal  condition,  such  as  tissue  injury,  infection  or  trauma.  In  addition,  the  innate  
? ????????????????????????????????????????????????????????????????????????????
most   notably   interleukin   (IL-­)   1ß.   The   activity   of   IL-­1ß   is   tightly   controlled;;   the  
induction  of  gene  expression  and  the  activation  of  pro-­IL-­1ß  require  separate  stimuli.  
?????? ?????????????????????????????????????????????????????????????????????????????
which  NLRP3  is  the  most  characterized.
The   major   acute-­phase   proteins   in   human   are   C-­reactive   protein   and   serum  
?????????????????????????????????????????????????? ???????????????????????????????
plasma  can   increase  up   to  1000-­fold.  SAA  circulates   in  association  with  high-­density  
lipoprotein   and   is,   thus,   suggested   to   play   a   role   in   lipid  metabolism   and   transport.  
??? ?????????? ???? ?????????? ??????? ?????????????? ???? ??????????????? ???????????? ??
pathogenic  role  for  SAA  has  most  clearly  been  implicated  in  AA  amyloidosis,  a  systemic  
???????? ?????????? ???????????? ??? ?????????? ??????????????????? ??????????? ???????
evidence  indicates  that  SAA  is  also  as  an  active  mediator  in  cardiovascular  diseases.
The  aim  of  the  study  was  to  elucidate  the  interaction  between  SAA  and  two  types  
of  innate  immune  system  cells,  human  mast  cells  and  macrophages,  and  the  consequences  
of  this  interaction  in  the  pathogenesis  of  AA  amyloidosis  and  atherosclerosis,  as  well  
??????????????????????????????????????????????????????????????????????????????????
activator  of  mast  cells  and  macrophages,  as  indicated  by  a  dose-­dependent  production  
??? ???? ??????????????? ??????????? ?????? ???? ?????? ????????? ??????? ??? ??? ????? ?????
types.   In  mast   cells,   this  activation   led   to   the  degradation  of  SAA  by   the  mast   cell-­
derived  protease  tryptase  and  to  the  formation  of  amyloid-­like  structures,  suggesting  
a  pathogenic  role  for  mast  cells  in  AA  amyloidosis.  The  secretion  of  IL-­1ß  was  studied  
in  more  detail  in  human  macrophages,  in  which  SAA  was  found  to  be  able  to  induce  
both  the  gene  expression  of  IL1B,  via  TLR2  and  TLR4,  and  the  activation  of  the  NLRP3  
?????????????????????????????????????????????????????????????????????????????????
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involved  the  ATP-­receptor  P2X7  and  cathepsin  B  activity.  Native  serum  lipoproteins  
were  shown  to  inhibit  the  activity  of  SAA  and  this  inhibition  was  further  enhanced  by  
lipoprotein  oxidation.  Besides  the  expression  of  IL1B,  oxidized  low-­density  lipoprotein  
??????????????????????????????????????????????????????????????????????????????????
???????????? ?????? ??????????? ???? ????????? ????? in   vivo,   suggesting   that   oxLDL,  
???????????????????? ??????????????????????????? ????????????????????????????????????
?????????? ??? ???? ????????? ??? ???????? ????????? ?????????? ???????????????? ????????? ????
??????????????????????????????????????????????????????????????????????????????????????
??? ???????????? ?????????? ????? ??? ????????????????? ???? ???????? ???? ????????? ?????
mechanisms  leading  to  AA  amyloidogenesis.
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I Introduction
The  immune  response  is  operated  by  two  integrated  systems,  the  adaptive  and  
innate  immune  responses.  The  innate  immune  system  constitutes  the  first  line  of  
defence  in  response  to  various  stimuli,  which  can  be  either  foreign  or  host-­derived,  
and  which  are  recognized  and  responded  to  in  a  generic,  non-­specific  manner.  In  
contrast   to   the  adaptive   immune  system  and   the  generation  of  antibodies,   the  
actions  of  the  innate  immune  system  do  not  confer  any  long-­lasting  or  protective  
immunity.  For  a  long  time,  the  role  of  innate  immunity  was  somewhat  overlooked  
and   also   contested,   culminating   in   the   debate   over   the   “dirty   little   secret”   of  
immunology:  the  inability  of  vaccines  to  stimulate  the  adaptive  immune  response  
unless  so-­called  adjuvants  are  used  to  evoke  the  innate  immune  system  (Janeway  
1992).  During  the  last  decade,  the  innate  immunity  has  been  under  extensive  study  
(Pelka  and  Latz  2011).  The  acute-­phase  response  (APR)  represents  an  integral  part  
of  the  innate  immune  system  (Cray  et  al.  2009).  It  can  be  described  as  an  immediate  
systemic   reaction   triggered  by  a   local  or   systemic  abnormal  condition  such  as  
tissue  injury,  infection  or  trauma.  Typical  characteristics  include  fever,  changes  in  
vascular  permeability  and  importantly,   induction  of  several  proteins  known  as  
acute-­phase  proteins  (APPs).  The  major  APPs   in  human  are  C-­reactive  protein  
(CRP)  and  serum  amyloid  A  (SAA)  (Gabay  and  Kushner  1999).
????????????????????????????????????????????????????????????????????????
can   increase   up   to   1000-­fold.   SAA   circulates   in   association  with   high-­density  
lipoprotein   (HDL),   which   is   why   it   has   been   suggested   to   play   a   role   in   lipid  
metabolism  and  transport.  In  addition,  SAA  has  been  implicated  in  host  defence  as  
???????????????????????????????????????????????????????????????????????????????
true  physiological   function  of  SAA  is  still  under  debate  (Kisilevsky  and  Manley  
2012).  The  pathological  potential  of  SAA  is  well  recognized  in  AA  amyloidosis,  a  
????????? ???????? ??????????? ???????? ????? ???? ??????????? ???????? ????????????
conditions  such  as  rheumatoid  arthritis  (RA).  However,  a  number  of  recent  studies  
?????????????????????????????????????????????????????????????????????????????
quickly  expanded  beyond  the  scope  of  AA  amyloidosis  and  RA.  Current  evidence  
???????????????????????????????????????????????????????????????????????????????
mediator  in  a  number  of  pathological  conditions  including  cancer  (Malle  et  al.  2009)  
as  well  as  cardiovascular  diseases  and  associated  preceeding  conditions,  such  as  
obesity  and  type  II  diabetes  (Herder  et  al.  2006,  Yang  et  al.  2006,  King  et  al.  2011).  
The  aim  of  this  thesis  was  to  investigate  the  interplay  between  SAA  and  
two  types  of  key   innate   immune  system  cells,  mast  cells  and  macrophages,  
and  the  consequences  of  this  interaction  on  the  pathogenesis  of  AA  amyloidosis,  
atherosclerosis   and   inf lammation   in   general.   Potential   mechanisms   for   the  
regulation  of  SAA  were  also  studied.
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II. Review of the Literature
1. The acute-phase response and innate immune system
The stimulated innate immune system initiates the inflammatory response by inducing the 
production of proinflammatory cytokines, notably interleukin (IL-) 1ß and tumor necrosis 
factor (TNF-) ?, as well as several chemokines, adhesion molecules and other stimulants. 
This results in the recruitment of immune cells to the site of infection. The response 
can also be evoked by various non-microbial substances, which gives rise to sterile 
inflammation (Chen and Nunez 2010). Innate immunity includes both cellular and soluble 
components. The cellular component consists of host cells with ready-made receptors 
capable of recognizing common pathogen constituents, hence called pattern-recognition 
receptors (PRRs). The soluble component includes an arsenal of acute-phase proteins 
(APPs), the expression of which is induced during the acute-phase response (APR), and the 
complement system, which functions as a bridge between adaptive and innate immunity. 
Indeed, despite the division, the two immune systems are tightly connected. If the 
innate immune system is not capable of eliminating the pathogen, the adaptive immune 
system is activated through a process known as antigen presentation. Macrophages and 
particularly dendritic cells can function as antigen-presenting cells (Gordon and Taylor 
2005). Furthermore, cytokines and growth-factors secreted from polarized subtypes 
of helper T cells (Th), the key players of the adaptive immune system, mediate cell 
differentiation and inflammatory cascades related to innate immunity (Libby 2002). 
1.1  Cells  of  the  innate  immune  system
The  cellular  component  of  the  innate  immune  system  includes  
cells  from  two  different  origins.  Macrophages,  dendritic  cells,  
mast  cells,  neutrophils,  basophils  and  eosinophils  originate  from  
common  myeloid  progenitor  cells  in  the  bone  marrow,  whereas  
natural   killer   cells   represent   the   lymphoid   lineage   in   human  
hematopoiesis.  Macrophages,   dendritic   cells   and   neutrophils  
have  many   similarities,   the   prime   example   of   which   is   their  
ability  to  engulf  foreign  particles,  bacteria  or  fragments  of  dying  
cells.   Macrophages   and   dendritic   cells   are   derived   from  
circulating  monocytes  and  they  differentiate  in  tissues,  whereas  
neutrophils  mature  already  in  the  bone  marrow  and  are  abundant  
in   blood   and   absent   in   healthy   tissues.  Neutrophils,   together  
with  the  closely  related  basophils  and  eosinophils,  are  further  
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characterized  by  the  so-­called  respiratory  burst,  an  oxygen-­consuming  metabolic  
pathway  that  aims  to  eliminate  the  phagocytosed  microbes.  This  is  achieved  by  
the  rapid  production  and  release  of  toxic  substances,  such  as  oxidized  halogens  
and  oxidizing  radicals,   into  the  phagosome  (Babior  1984,  Nathan  2006).  Mast  
cells  are  derived  from  the  common  progenitor  cells  that  are  released  as  such  from  
the  bone  marrow  and  the  differentiation  and  maturation  into  mast  cells  takes  
place  in  vascularized  tissues  (Galli  et  al.  2005).  Mast  cells  and  macrophages  that  
are  used  in  this  study  are  presented  in  more  detail  below.
1.1.1  Mast  cells
Mast  cells  are  derived   from  the  myeloid  progenitor   cells   that  migrate   into  
connective  or  mucosal  tissues,  differentiate,  mature  and  ultimately  reside  in  this  local  
environment  (Galli  et  al.  2005,  Galli  and  Tsai  2008).  With  tissue  macrophages  and  
????????????????? ????????????????????????????????????????????????????????????????????
with  environmental  antigens,  allergens,  toxins  and  pathogens.  That  is  why  they  are  
distributed  particularly  near  surfaces  that  are  exposed  to  the  environment,  such  as  the  
skin,  the  lungs  and  the  gastrointestinal  tract.  Mast  cell  differentiation  and  maturation  
is  mediated  principally  by  stem-­cell  factor  (SCF)  and  its  receptor  c-­kit,  but  locally  
???????????????????????????????????????????????????????????????????????????????h2-­
related  cytokines  IL-­3,  IL-­4  and  IL-­9,  and  nerve  growth  factor  contribute  as  well  (Galli  
et   al.   1993,  Galli   et   al.   2005,  Ryan   et   al.   2007).   The  most   distinctive   feature   of  
??????????????? ??????????????????????????????????????????????????????????????????????????
anti-­inflammatory   and   immunosuppressive   mediators   upon   activation.   These  
mediators  are  stored  in  cytoplasmic  granules  (preformed  mediators)  or  synthesized  on  
demand  (Schwartz  and  Austen  1984,  Marshall  and  Jawdat  2004).  The  original  name  
of  the  cells,  Mastzellen,  derived  from  the  German  word  “Mästung”,  “fattening”,  was  
given  by  Paul  Ehrlich,  and  it  refers  to  this  granular  and  “well-­fed”  appearance  of  mast  
cells   (Ehrlich  1879).  The  preformed  mediators   include  (1)   the  mast  cell  proteases  
chymase,  tryptase,  cathepsin  G  and  carboxypeptidase  A;;  (2)  the  proteoglycans  heparin  
and  chondroitin  sulfates  A  and  E;;  (3)  histamine;;  and  (4)  several  cytokines,  chemokines  
???????????????????????????? ???????????? ??????????????????????????????????????????
4  (MCP-­1,  3  and  4),  Regulated  upon  Activation,  Normal  T-­cell  Expressed  and  Secreted  
????????????????????????????????????????????????????????????????????????????????
???????????????et  al.  1988,  Gordon  and  Galli  1990,  Welle  1997,  Marshall  and  Jawdat  
2004).  Besides  this,  mast  cells  can  generate  numerous  lipid  mediators  and  additional  
cytokines   and   chemokines  de   novo?? ?????????? ??????? ??????? ?????? ??????? ???????
granulocyte-­macrophage  colony-­stimulating  factor  (GM-­CSF)  and  several  Th1  and  
Th2-­related  cytokines,  among  others  (Marshall  and  Jawdat  2004).
The  immunological  activation  of  mast  cells  that  is  seen  principally  in  allergy  
is  mediated  by  the  most  widely  known  mast  cell  activator,  immunoglobulin  E  (IgE).  
14
???????????????????????????????????????????????????????????????????????? ?????????
(Rao  and  Brown  2008).  Mast  cell  activation,  which  is  initiated  by  the  interaction  of  
????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????? ????????? ?????????????????????????
bacterial  infection  the  activation  can  also  proceed  independent  of  IgE.  Here,  mast  
cells   are   activated   via   PRRs   such   as   toll-­like   receptors   (TLRs,   see   below),   or  
complement   receptors   (Heib   et   al.   2007,   Heib   et   al.   2008).   In   addition,   the  
?????????????????????????????????????????????????????????????????????????et  al.  
2006).  Mast  cells  participate   in  host  defence  also  by  phagocytosing  and  killing  
bacteria  (Malaviya  et  al.  1994)  and  by  secreting  antimicrobial  substances  and  NO  
(Rao  and  Brown  2008).
Mast  cells  are  not  a  homogenous  cell  population  but  instead  differ  from  each  
other  in  terms  of  their  mediator  content,  ultrastructure,  size  and  shape,  receptor  
expression,   sensitivity   and   pharmacological   responsiveness   (Bradding   2009).  
Traditionally  human  mast  cells  are  divided  into  two  subtypes  according  to  their  
protease   content:   those   containing   predominantly   tryptase,   MCT,   and   those  
containing  both  tryptase  and  chymase  as  well  as  cathepsin  G  and  carboxypeptidase  
A,  MCTC  (Irani  et  al.  1986,  Schechter  et  al.  1990,  Irani  et  al.  1991).  The  MCT  type  is  
usually  found  at  mucosal  surfaces  while  the  MCTC  type  occupies  different  types  of  
connective  tissue  (Irani  et  al.  1986).  The  mast  cell  phenotype  can  change,  though,  
in  response  to  changes   in  the  microenvironment  of   the  cells.  For  example,   the  
????????????????????????????????????????????????????????????????????????????????
SCF  has  been  shown  to  enhance  chymase  expression  in  the  MCT  phenotype  in  vitro  
(Galli  et  al.  2011).
1.1.2  Macrophages
Macrophages,  the  name  of  which  originates  from  Greek  (makros  meaning  
“large”  and  phagein  “to  eat”;;  “big  eaters”),  are  derived  from  circulating  monocytes  
that  migrate  into  tissues  in  the  steady  state  or  in  response  to  inflammation  (Gordon  
and  Taylor  2005).  They  are  long-­lived  cells  found  throughout  the  body  but  they  are  
particularly  abundant  in  the  lungs,  the  gastrointestinal  tract,  the  liver,  the  spleen  
and  connective  tissue.  Monocyte  differentiation  into  tissue  macrophages  proceeds  
in  response  to  the   local  growth  factor  and  cytokine  environment  (explained  in  
more  detail  in  chapter  3.2.3).  Mature  tissue-­resident  macrophages  can  be  further  
classified   into   several   subpopulations  based  on   their   anatomical   location   and  
functional  phenotype:  microglia  in  the  brain,  alveolar  macrophages  in  the  lung,  
histiocytes  in  the  connective  tissue,  Kupffer  cells  in  the  liver,  osteoclasts  in  the  
bone,   as   well   as   general   inf lammatory   macrophages   or   tumour-­associated  
macrophages  (Gordon  and  Taylor  2005,  Lawrence  and  Natoli  2011).  Inflammatory  
macrophages  are  traditionally  divided  into  two  polarized  phenotypes:  M1  denoting  
Review of the Literature
15
classically  activated  and  M2  alternatively  activated  macrophages.  M1  polarization  
is  promoted  by  the  Th??????????????????????????????????????????????????????????????
??????????????????????????????????????? ????????????????????????????????
2008,  Mosser  and  Edwards  2008,  Krausgruber  et  al.  2011,  van  Tits  et  al.  2011).  M1  
macrophages  exhibit  proinf lammatory  activities  and   they  are   involved   in  host  
defence  and  antitumor  immunity;;  they  express  various  PRRs  and  are  capable  of  
producing  proinflammatory  cytokines,  reactive-­oxygen  species  (ROS)  and  nitric  
oxide  (NO).  The  M2  phenotype,  on  the  other  hand,  is  promoted  by  IL-­4  and  IL-­13  
originating  from  Th2  cells  or  by  macrophage  colony-­stimulating  factor  (M-­CSF),  
and  macrophages  of  this  phenotype  are  implicated  in  immune  suppression  and  
wound   healing.   For   this   reason,   they   are   sometimes   called   wound-­healing  
macrophages.  A  third  phenotype,  regulatory  macrophages,  has  also  been  described.  
Regulatory  macrophages  are  differentiated  in  response  to  anti-­inflammatory  IL-­
10,  and  they  also  produce  it  upon  activation.  They  resemble  the  M2  macrophages  
in  many  ways  (Mosser  and  Edwards  2008).  
Nevertheless,  inflammatory  macrophage  phenotypes  do  not  represent  stably  
differentiated  subsets.  Instead,  they  appear  to  undergo  dynamic  transitions  among  
the  functional  phenotypes  in  response  to  their  microenvironment.  For  example,  
prolonged   exposure   to   LPS   can   lead   to   a   state   of   responsiveness,   known   as  
endotoxin  tolerance,  which  induces  a  switch  of  the  gene  expression  pattern  from  
the   proinf lammatory  M1   phenotype   to   the   anti-­inf lammatory  M2   phenotype  
(Biswas  and  Lopez-­Collazo  2009,  Foster  and  Medzhitov  2009).  Also,  when  M2  
macrophages  loaded  with  oxidized  low-­density  lipoprotein  (oxLDL)  are  exposed  to  
LPS,  they  exhibit  increased  production  of  proinflammatory  cytokines  typical  of  
the  M1  phenotype  (van  Tits  et  al.  2011).  
1.2  The  acute-­phase  response
??????????????????????????????????????????????????? ????????????????????????????????????
of  invading  microbes  and  to  participate  in  the  resolution  of  infection  and  the  repair  
???????????????????? ?????????????????????????????????????????????????????????????
is  an   integral  part  of   the   innate   immune  system  and  observed  across  all  animal  
species  (Cray  et  al.  2009).  It  can  be  described  as  an  immediate  systemic  reaction  
triggered  by  a  local  or  systemic  abnormal  condition  such  as  tissue  injury,  infection  or  
trauma.   The   local   effects   of   the   acute-­phase   response   are   initiated   by   tissue  
macrophages  and  mast  cells  that  recognize  the  disturbance  mainly  via  PRRs.  The  
recognition   leads   to   the  activation  of   additional  macrophages  and  also  of  blood  
monocytes  at  the  site  of  the  stimulus.  When  activated,  macrophages  release  various  
?????????????????????????????????????????????????????????????????????????????
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????????????????????????????????????????????????????????????????????????????????
induce  the  release  of  secondary  cytokines  from  local  stromal  cells,  which  attracts  
neutrophils  to  the  site.  Neutrophils  that  are  normally  restricted  to  the  circulation  are  
now   able   to   enter   the   tissue   via   selective   extravasation   through   the   activated  
endothelium  of   the  blood  vessel   (Pober  and  Sessa  2007).  Secondly,   the  primary  
cytokines  up-­regulate  the  production  and  release  of  neutrophils  and  monocytes  from  
????????? ???????????????????????????????????????????????????????????????????????
effect,  which  is  the  phenomenon  that  best  characterizes  the  systemic  effects  of  the  
APR,  involves  rapid  changes  in  the  hepatic  and  extrahepatic  production  of  acute-­
??????????????????????????????????????????????????????????????????????????????
??????? ?????????? ??? ?????????? ??? ??? ?????? ???????????? ???????????? ??????? ????
Kushner   1999)   and   which   can   function   as   both   mediators   and   inhibitors   of  
??????????????? ???????? ??????????????? ?????????????????????????? ????????????????????
of  different  APPs  facilitates  host  defence  by  improving  the  recognition  of  microbes,  
by  enhancing  the  mobilization  of  leukocytes  into  the  circulation  and  by  increasing  
??????????????????????????????????????????????? ???????? ????????????????????????????????
major,  moderate  or  minor  APPs  depending  on  the  magnitude  of  increase  during  the  
APR.  Traditionally,  major  APPs  increase  10-­  to  100-­fold  (or  more),  moderate  APPs  
2-­  to  10-­fold  and  minor  APPs  only  slightly.  Moderate  and  mild  increases  are  usually  
?????????????????????????????????
The  major  APPs   in   humans   are   serum   amyloid  A   (SAA)   and  C-­reactive  
protein  (CRP).  CRP  was  the  first  identified  APP  (Tillett  and  Francis  1930)  and  it  is  
still  the  most  routinely  used  marker  of  inflammation  in  clinical  work,  despite  the  
fact  that  in  many  conditions  SAA  could  actually  serve  as  a  more  sensitive  indicator  
(Malle  and  De  Beer  1996,  Hartmann  et  al.   1997,  Yamada  et  al.   1999,  Cunnane  
2001).  Positive  APPs  also  include  several  members  of  the  complement  system,  and  
other  APPs,  the  expression  of  which  is  enhanced  by  SAA:  secretory  phospholipase  
A2  (sPLA2)  and  pentraxin  3  (PTX3)  (Gabay  and  Kushner  1999,  Sullivan  et  al.  2010,  
Dong  et  al.  2011a,  Satomura  et  al.  2012).  Importantly,  there  are  also  antiproteases,  
?????????????????????????????????????????????????????????????????????????????????????
fibrinogen,  among  the  positive  APPs.  Their  role  is  to  protect  the  host  tissue  against  
collateral  damage  at  the  affected  site  and  to  limit  local  hemorrhage,  respectively  
(Manley  et  al.  2006).  Such  mechanisms  are  needed  as  some  of  the  APR  effectors,  
such  as   toxic   substances  or  ROS   released  by  neutrophils,   cannot  discriminate  
between  foreign  and  self  (Nathan  2006).  
Normally   the   APR   lasts   only   a   few   days   and   is   ideally   followed   by   the  
?????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????? ???????????????????? ??????????
??????????????? ????????????????et  al.   1998).  This   is  mediated  mainly  by  anti-­
??????????????????????????????????????????????????????????????????????????????????
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neutrophil  recruitment  and  promote  that  of  macrophages  (O’Meara  and  Brady  1997,  
Mitchell  et  al.  2002,  Serhan  and  Savill  2005).  However,  if  phagocytosis  is  delayed,  
apoptotic  neutrophils  may  undergo  secondary  necrosis   triggering  a  new  cycle  of  
??????????????????????????? ???????????????????et  al.  2000).  Furthermore,  SAA  
can  oppose  the  function  of  lipoxins  and  dampen  their  protective  signalling  (Bozinovski  
et  al.????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????
1.3  Pattern  and  danger  recognition
For  years,  innate  immunity  was  regarded  as  a  mechanism  that  simply  discriminates  
“self”  (e.g.  host  proteins)  from  “non-­self”  (e.g.  microorganisms)  and  mediates  the  
responses  accordingly.  However,  a  gradually  increasing  amount  of  data  revealed  
that  the  mechanism  was  probably  much  more  complex  and  that  innate  immunity  
might  be  more  of  a  prerequisite  rather  than  a  mere  addition  to  the  adaptive  immune  
system  (Janeway  1992).  It  was  suggested  that  the  innate  immune  system  recognizes  
substances  in  the  context  of  “danger”  (Matzinger  2002).  These  danger  signals  can  
be  derived  not  only   from  bacterial,   viral   or   fungal   sources  but   also   from  self,  
marking  events  such  as  cellular  stress  or  injury  or  cell  death.  The  signals  fall  into  
two  classes,  pathogen-­associated  molecular  patterns  (PAMPs)  and  non-­microbial,  
danger-­associated  molecular  patterns  (DAMPs)  (Gay  and  Gangloff  2007,  Martinon  
et  al.  2009).  They  are  sensed  by  specific  PRRs,  which  are  expressed  by  cells  at  the  
front   line   of   defence:   macrophages,   monocytes,   dendritic   cells,   neutrophils,  
endothelial  cells  (ECs)  and  mast  cells.  Our  innate  immune  system  consists  of  at  
least  four  cooperating  PRR  families:  (1)  Toll-­like  receptors  (TLRs),  (2)  receptors  
with  nucleotide-­binding  domain  and  leucine-­rich  repeats  (NLRs),  (3)  retinoic  acid  
inducible  gene  I-­like  receptors  and  (4)  C-­type  lectin  receptors.  TLRs  are  located  
either  on  the  outer  cell  surface  or  inside  endosomes  (Barton  and  Medzhitov  2003)  
whereas  the  other  three  reside  in  the  cytoplasm.  NLRs  differ  from  the  other  PRRs  
in   the   sense   that   the   final   outcome   of   the  NLR   stimulation   is   the   proteolytic  
activation   of   proinf lammatory   cytokines   rather   than   the  modulation   of   gene  
expression.  TLRs  and  NLRs  will  be  discussed  in  more  detail  below.
1.3.1  Toll-­like  receptors
TLRs   are   named   for   their   similarity   to  Toll?? ?? ????? ????? ??????????? ????
sequenced  in  Drosophila  melanogaster  (Anderson  et  al.  1985,  Hashimoto  et  al.  
1988).  Soon  after  the  revelation  that  Toll  can  trigger  the  innate  immune  response  
(Lemaitre  et  al.???????????????? ?? ?????? ???????? ?? ???? ??????????????????????????????
These  are  now  known  as  Toll-­like  receptors  (Rock  et  al.  1998).  To  date,  11  human  
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Figure 1. Signalling pathways triggered by Toll-like receptors 2 and 4. Only 
constitutive (and not inducible) TLR heterodimers are presented. Some steps are 
omitted for clarity. Data are derived from Akira 2006, Gay and Gangloff 2007, Kagan 
et al. 2008, Kawai and Akira 2011 and references mentioned in the text. AP-1, 
activating protein 1; CD14, cluster of differentiation 14; IFN, interferon; I?B, inhibitor 
of nuclear factor kappa B; IKK, I?B kinase kinase; IRAK, interleukin-1 receptor-
associated kinase; IRF3, interferon response factor 3; LBP, lipopolysaccharide-binding 
protein; LPS, lipopolysaccharide; MAPK, mitogen activated protein kinase; MD-2, a 
secreted glycoprotein; MyD88, myeloid differentiation primary response protein 88; 
NF-?B, nuclear factor kappa B; P, phosphorylation; TAB, TAK-binding protein; TAK1, 
transforming growth factor-b-activated protein kinase 1; TBK, TRAF family member-
associated NF-?B activator-binding kinase; TIRAP, Toll/IL-1R domain-containing 
adaptor protein; TRAF, tumor necrosis factor receptor-associated factor; TRAM, TRIF-
related adaptor protein; TRIF, TLR/IL-1 receptor domain-containing adaptor protein 
inducing interferon-ß; Ub, ubiquitination
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TLRs  have  been  characterized  (Hanke  and  Kielian  2011).  TLRs  1,  2,  4-­6,  10  and  11  
are  expressed  and  localized  at  the  cell  surface  and  TLRs  3  and  7-­9  in  intracellular  
vesicles,  although  cell  type-­specific  variation  has  been  detected  (Kawai  and  Akira  
2011).  All  TLRs  are  type  I  transmembrane  receptors  that  together  with  IL-­1  and  
IL-­18  receptors  belong  to  the  TLR/IL-­1  receptor  superfamily  (Akira  2006).  All  
members  of  this  family  contain  a  C-­terminal  cytoplasmic  TLR/IL-­1  receptor  (TIR)  
homology  domain  that  is  essential  for  signalling  (Bowie  and  O’Neill  2000).  Besides  
this,  TLRs  are   typified  by  extracellular  N-­terminal   leucine-­rich  repeats  (LRR)  
implicated  in  ligand  recognition.  
Upon  stimulation,  TLRs  interact  with  specific  adaptor  proteins  that  also  
contain  a  TIR  domain.  To  date,   five  adaptor  proteins  have  been   identified:   (1)  
myeloid   differentiation   factor   88   (MyD88),   (2)   Toll/IL-­1R  domain-­containing  
adaptor   protein   (TIRAP;;   known   also   as  MyD88   adaptor-­like,  MAL),   (3)   TIR-­
?????????????????? ???????? ????????? ????????????? ???????? ???? ?????????????
adaptor  molecule  (TRAM)  and  (5)  SAM  and  ARM-­containing  protein  (SARM)  
(McGettrick   and   O’Neill   2004).   Different   TLRs   utilize   different   adaptor  
combinations  to  trigger  the  subsequent  signalling  pathways.  MyD88  mediates  the  
signalling  from  most  TLRs,  with  the  exception  of  TLR3  (Jiang  et  al.  2003),  and  
???????????????????????????????????????????????????????????????????????????????
mitogen-­activated  protein  kinases  (MAPKs)  leading  to  the  activation  of  the  nuclear  
??????????????????????????????????????????? ??????????????????????????????????????
1),   respectively   (Janeway   and  Medzhitov  2002,  O’Neill   and  Bowie  2007).  The  
activation   of   these   transcription   factors   induces   the   expression   of   numerous  
inflammatory  mediators  such  as  cytokines,  chemokines  and  adhesion  molecules.  
TLR2  and  TLR4  require  both  TIRAP  and  MyD88  (Vogel  et  al.  2003)  to  transduce  
?????????????????????????????????????????????????????????????????????????????????
Rab11a-­positive   endosomes   and   further   to   bacteria-­containing   phagosomes  
(Husebye  et  al.  2010)  where  it  employs  TRAM  and  TRIF  to  activate  a  special  TRIF-­
dependent  pathway.  This  results  in  the  activation  of  interferon  response  factor  3  
(IRF3)  (Kagan  et  al.  2008),  which  regulates  the  expression  of  type  I  interferons  
and  chemokines  such  as  interferon    gamma-­induced  protein  (IP-­10),  RANTES  
and   IFN-­inducible  T-­cell  a-­chemoattractant   (Hacker  et  al.  2006).   In  addition,  
inflammatory  monocytes  exhibit  a  unique  MyD88-­dependent  activation  of  type  I  
IFN  that  requires  internalization  of  TLR2  (Kawai  and  Akira  2011).
To  date,  the  most  profoundly  characterized  TLRs  are  TLR2  and  TLR4.  TLR2  
possesses  the  widest  ligand  repertoire  of  all  TLRs,  including  bacterial  lipoproteins  
and  lipopeptides,  fungal  wall  components  and  viral  products.  It  associates  with  a  
co-­receptor  CD14  (Cleveland  et  al.  1996),  besides  which  it  forms  a  heterodimer  with  
either  TLR1  or  TLR6,  which  further  widens  its  ligand  repertoire  (Ozinsky  et  al.  2000,  
????????????et  al.  2006).  In  particular,  TLR2-­TLR6  recognizes  mycoplasmic  diacyl  
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lipopeptides  and  TLR2-­TLR1  triacyl  lipopeptides  (Gay  and  Gangloff  2007).  TLR2-­
???????????????????????????????????? ??????????????????????????? ?????????????????
et   al.   2006).   TLR4   recognizes   LPS,   a   gram-­negative   cell   wall   component,   and  
bacterial   toxins   as   well   as   viral   glycoproteins   (Gay   and   Gangloff   2007).   LPS  
recognition  by  TLR4  is  accomplished  in  concert  with  the  circulating  LPS-­binding  
protein  (LBP)  and  the  CD14  receptor  (Wright  et  al.  1990),  besides  which  constitutive  
interaction  with  the  co-­receptor  MD-­2  is  required  (Schromm  et  al.  2001,  Re  and  
Strominger  2002).  There  is  evidence  that  TLR4  forms  a  heterodimer  with  TLR6,  
which  further  associates  with  CD36  upon  CD36  stimulation  (Stewart  et  al.  2010).  
Interestingly,  both  TLR2  and  TLR4  interact  not  only  with  pathogen-­derived  particles  
but  also  with  the  large  group  of  endogenous  ligands  that  are  likely  to  be  found  at  sites  
????????????????????????????????????????????????????????????????????????????
??????????????????????????????? ???????????? ??????????????????????????????????
apoCIII   (TLR2),   minimally   modified   LDL   (mmLDL)   (TLR2   and   4),   oxidized  
phospholipids  (TLR2  and  4),  stress-­inducible  heat  shock  proteins  (TLR2  and  4)  and  
??????????????????????????????????????et  al.  2003,  Chavez-­Sanchez  et  al.  2010,  
Lundberg  and  Hansson  2010).  The  signalling  pathways  induced  by  TLR2  and  TLR4  
are  illustrated  in  Figure  1.
1.3.2  Nucleotide-­binding  domain  leucine-­rich  repeat  containing  
receptors
????????????????????????????????? ?????????????????? ??????????????? ???????????
structure   containing   a   C-­terminal   LRR   domain,   a   central   nucleotide-­binding  
domain   (NBD)   and   a   variable   N-­terminal   effector   domain.   LRR   domains   are  
believed  to  function  as  ligand  recognizers,  similar  to  the  LRRs  in  TLRs,  but  no  clear  
ligand-­binding  has  been  demonstrated  for  NLRs  yet.  The  NBD  domain  consists  of  
NACHT  (domain  present  in  NAIP,  CIITA,  HET-­E,  and  TP-­1),  the  domain  that  is  
common  to  all  NLRs,  and  often  of  an  additional  NAD  domain  (NACHT-­associated  
domain).  The  effector  domains  are  required  for  signal  transduction.  There  are  
four  different  types  of  these  domains:  acidic  transactivation  domain,  pyrin  domain,  
caspase  recruitment  domain  (CARD)  and  baculoviral  inhibitory  repeat  (BIR)-­like  
domains.  They  have  been  used  as  determinants  by  which  NLRs  are  distinguished  
into  the  following  subfamilies:  NLRA  (NLRs  with  an  acidic  activation  domain),  
NLRB   (NLR  with   a  BIR  domain),  NLRC   (NLRs  with   a  CARD  domain),  NLRP  
(NLRs  with  a  pyrin  domain),  and  NLRX  (NLR  family  with  no  strong  homology  to  
the  N-­terminal   domain   of   any   other  NLR   subfamily  member),   as   per   updated  
nomenclature  by  Ting  et  al  (Ting  et  al.  2008).  The  NLRP  subfamily  is  the  largest  
one  containing  14  members,  whereas  NLRC  contains  5  and  all  the  rest  only  one  
each  (Ting  et  al.  2008,  Tschopp  et  al.  2003).  Most  NLRCs  and  all  members  of  the  
?????????????????????????????????????????????????????????????????????????????????
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caspases  and  the  subsequent  activation  of  cytokines  from  the  IL-­1  family.  This  is  
??????????????????????????????????????????????????????????????????? ?????????
weight   self-­oligomerizing   multiprotein   complexes   that   reside   in   the   cytosol  
(Martinon  et  al.??????????????????????????? ???????????????????????????????
NLRP3,  IPAF  (or  NLRC4)  and  AIM2  (Faustin  et  al.  2007,  Bauernfeind  et  al.  2009,  
Franchi  et  al.  2009,  Franchi  and  Nunez  2010).  NLRP3   (see  below)   is   the  most  
intensively  studied,  and  it  is  also  the  most  important  in  the  scope  of  this  study.  
????????????????????????
1.4.1  Interleukin  1ß
The  IL-­1  family  (IL-­1F)  of  cytokines  plays  a  critical  role  in  the  host  response  
to  infection,  mediating  a  variety  of  functions  from  the  induction  of  APPs  to  the  
alteration  of  metabolism  and  the  regulation  of  fever  and  lymphocyte  activation  
(Glaccum  et  al.  1997).  The  family  consists  of  11  members  with  three  major  forms  of  
?????????????????????????????????????????????????????????????? ????????????????????
separate  but  related  genes  (Rock  et  al.??????????????????????????????????????????????
terms  of  biological  activity  and  receptor  specificity  (Dinarello  et  al.  1986,  Dower  et  
al.  1986,  Arend  et  al.  2008);;  they  stimulate  the  same  receptor  IL-­1R,  while  IL-­1Ra  
????? ??? ???? ???????????? ???????????? ????? ?????? ???? ?????? ???? ?????????? ??? ????
?????????????????????????????????????????????????????????????????????????????????
constitutive  in  primary  cells  and  many  cell  lines,  and  it  is  also  biologically  active  
(Hacham  et  al.  2002,  Hurgin  et  al.???????????????????????????????????????????
????????????????????????????????? ???????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????
nucleus  and  act  as  an  autocrine  growth  factor  (Arend  et  al.  2008).
????????? ? ????????????????????????????????????????????????????? ??????????????




AP-­1  pathways  (Mariathasan  and  Monack  2007,  Franchi  et  al.???????????????????????????
can  induce  its  own  expression  via  the  activation  of  IL-­1R  and  MyD88  (Dinarello  et  al.  
????????????????? ???????????????? ?????????????? ????????????? ?????????????????????? ???
?????????????????????? ??????????????????????????????????????????????????????????????
ICE)  (Thornberry  et  al.??????? ???????????????????????????????????????????????????????
?????????? ??????????????????????????????????????????????????????????????????????????
and  cleaved  by  extracellular  proteases  (Fantuzzi  et  al.  1997,  Coeshott  et  al.  1999).  
?????? ????? ???? ???????? ?? ?????????? ??????? ?????????? ???????? ??? ??????
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transported   through   the   classical   endoplasmic   reticulum/Golgi   pathway,   it   is  
processed  and  secreted  via  a  non-­classical  secretory  system,  i.e.  unconventional  
secretion.  To  date,  four  detailed  models  for  this  secretion  have  been  proposed.  The  
????? ???? ??????? ?????2+? ?????? ????? ??? ???????? ??? ???? ???????????? ??? ????????
receptor  P2X7  (Di  Virgilio  et  al.  2001).  In  the  model  proposed  originally  by  Andrei  
et  al.??????????????????????????????????????????????????????????????????????????????
?????? ??????????????????????????????????????????????????????et  al.  1999,  Andrei  et  
al.  2004).  The  second  model,  also  Ca2+???????????????????????????????? ??????????
and  release  proceed  within  microvesicles  that  are  derived  from  blebs  of  the  plasma  
membrane  (MacKenzie  et  al.???????? ?????????????????????????????2+?????????????
???????????????????????????????????????????????????????????????????et  al.  2000,  Qu  
et  al.  2007).  Indeed,  Qu  et  al.  have  described  a  Ca2+-­independent  model  in  which  
????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????
and  the  formation  of  multivesicular  bodies  (Qu  et  al.  2007).  Besides  these,  there  is  
also  preliminary  evidence   for  a  direct,  yet  uncharacterized,  mechanism  that   is  
????????????????????????????????????????????????????????????????????????????
through  the  cell  membrane  (Brough  and  Rothwell  2007).
?????????? ????????????????
???????????????????? ???????????????????????????????????????????????????
of  its  components;;  the  induction  of  both  NLRP3  and  IL1B  is  a  prerequisite  for  the  
?????????????? ????????????????????????????????????????et  al.  2003,  Mariathasan  et  
al.  2007,  Bauernfeind  et  al.  2009,  Bauernfeind  et  al.  2011).  Upon  activation,  NLRP3  
receptors  oligomerize  and  bind   to  ASC,  apoptosis-­associated  speck-­like  protein  
containing   a   CARD   (caspase   activation   and   recruitment   domain).   NLRP3  
oligomerization  proceeds  via  NACHT  domains  and  requires  the  binding  of  ATP  
(Duncan  et  al.  2007).  ASC  acts  as  a  bridging  molecule  between  NLRP3  and  pro-­
caspase-­1;;  ASC  contains  an  N-­terminal  pyrin  domain,  which   interacts  with   the  
pyrin  domain  of  NLRP3,  and  a  C-­terminal  CARD  that  binds  pro-­caspase-­1.  The  
structure   of  NLRP3   is   presented   in   Figure   2.   Caspases   are   cysteine   proteases  
?????????????????????????????????????????????????????? ???????????????????????????????
??????????????????????????????????????????????????????????????????????????????????
caspases,  caspase-­1  is  synthesized  as  an  inactive  zymogen  (pro-­caspase-­1)  that  is  
?????????????????????????????????????? ??????????????????????????????????????????
??????????????????????????????????????????????? ?????????????????????et  al.  2002).  
Caspase-­1  can  also  activate  other  IL-­1  family  members,  such  as  IL-­18  and  IL-­33  
(Keller  et  al.  2008).  
?????????? ???????????? ??? ????????????? ???????????? ??????????? ????
?????????????????????????????????????????????????????????????? ????????????????
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associated  with  danger  of  some  type,  such  as  cell  damage  or  cell  death.  They  include  
ATP  (Pelegrin  et  al.  2006,  Mariathasan  et  al.  2006),  monosodium  uric  acid  crystals  
(MSU),  calcium  pyrophosphate  dihydrate  (Martinon  et  al.??????????????????????????
islet  amyloid  polypeptide  oligomers  and  mutated  superoxide  dismutase-­1  (Halle  et  
al.  2008,  Masters  et  al.  2010,  Meissner  et  al.  2010),  cholesterol  crystals  (Duewell  et  
al.  2010,  Rajamäki  et  al.  2010)  and  ECM  components  hyaluronan  (Yamasaki  et  al.  
2009)  and  biglycan  (Babelova  et  al.  2009).  Currently,  there  is  no  evidence  for  direct  
ligand  binding  to  NLRP3.  Instead,  NLRP3  appears  to  act  as  a  sensor  of  intracellular  
???????????? ????????????????????????????????????????????????????? ???? ????????
extracellular  particles,  such  as  crystals  or  protein  aggregates,  are  sensed  intracellularly  
or  when  intracellular  components,  such  as  ATP,  are  released  into  the  extracellular  
????????????????????????????????????????????????????????????????????????????????????
known  to  date  include  different  kinds  of  crystalline  or  particulate  material,  such  as  
silica  (Hornung  et  al.  2008,  Dostert  et  al.  2008),  asbestos  (Dostert  et  al.  2008),  metal  
alloy  particles  (Caicedo  et  al.  2009),  alum  and  particulate  vaccine  adjuvants  (Li  et  al.  
2008,  Sharp  et  al.  2009),  as  well  as  UV  radiation  (Feldmeyer  et  al.  2007,  Watanabe  et  
al.  2007)  and  certain  antibiotics  (Allam  et  al.  2011).  
As  for  non-­sterile  inf lammation,  several  bacteria,  viruses  and  fungi  have  
been  implicated  in  the  activation  of  NLRP3  (Davis  et  al.  2011,  Menu  and  Vince  
2011).  Of  special  interest  and  the  most  characterized  in  terms  of  their  mechanism  
are  probably  the  bacteria-­derived  pore-­forming  toxins,  such  as  hemolysins  from  
Staphylococcus  aureus  (Munoz-­Planillo  et  al.  2009),  listerialysin  O  from  Listeria  
Figure 2. The structure of the NLRP3 inflammasome. The unoligomerized NLRP3 complex 
is depicted on the left. NLRP3 oligomerization is driven by the NACHT domains and results 
in the clustering of the caspase-1 domains. Caspase-1 activation is achieved by the 
removal of CARD and the autocleavage at CARD/p20 and p20/p10, leading to the formation 
of the active caspase-1 p10/p20 tetramer. CARD, caspase recruitment domain; LRR, leucine-
rich repeat; NACHT, nucleotide-binding and oligomerization domain; PYD, pyrin domain.
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monocytogenes   (Meixenberger   et   al.   2010),   nigericin   from   Streptomyces  
hygroscopicus   (Mariathasan   et   al.   2006),   pneumolysin   from   Streptococcus  
pneumoniae  (McNeela  et  al.  2010),  toxin  A  from  Clostridium  difficile  (Ng  et  al.  
2010),  tetanolysin  O  from  Clostridium  tetani  (Chu  et  al.  2009)  and  aerolysin  from  
Aeromonas   hydrophila   (Gurcel   et   al.   2006).   Various   roles   have   also   been  
demonstrated   for   f lagellin   from  Salmonella   typhimurium,  malarial   hemozoin  
????????????????????????Candida  albicans  as  well  as  adenoviral  DNA  and  RNA  
from   inf luenza  virus   (Muruve  et  al.  2008,  Allen  et  al.  2009,  Shio  et  al.  2009,  
Kumar  et  al.  2009,  Broz  et  al.  2010).
To   date,   three   distinct   models,   which   may   not   be   exclusive,   have   been  
????????????????????????????????????????????????????????????????????????????????
lysosomal  disintegration  pathway  and  the  ROS  pathway  (outlined  in  Figure  3).  The  
????? ????????????????????????????????????????????????????????????????????????????
including  trauma,  oxidants  and  pathogens  (Burnstock  et  al.  2006).  Also,  LPS  and  
other  PRR  agonists  have  been  shown  to  trigger  the  release  of  ATP  from  mononuclear  
phagocytes  (Ferrari  et  al.  1997,  Piccini  et  al.  2008).  Extracellular  ATP  stimulates  the  
ATP-­gated  ion  channel  P2X7?? ???????????????????????????????????????????????????????
recruitment  of  the  pannexin-­1  membrane  pore  and  results  in  the  activation  of  NLRP3  
(Pelegrin  et  al.  2006,  Mariathasan  et  al.  2006,  Petrilli  et  al.  2007,  Kanneganti  et  al.  
2007).  The  role  of  pannexin-­1  has  since  been  questioned,  however  (Qu  et  al.  2011).  
Decreased   intracellular  K+  has  been  shown  to  promote   the  assembly  of  NLRP3,  
whereas  high   extracellular  K+? ????????? ???? ?????????? ????????? ???? ??????????????
NLRP3  in  response  to  numerous  NLRP3  activators  (Franchi  et  al.  2007,  Dostert  
et   al.   2008,  Rajamäki  et   al.   2010).  Also,   in   an   experimental   setting  where   cell  
integrity  was   distrupted,   inf lammasome   assembly   could   be   inhibited   by   K+  
levels  that  mimicked  the  normal  K+  level  in  the  cytosol  (Kahlenberg  and  Dubyak  
2004,  Petrilli  et  al.  2007).  However,  the  exact  mechanism  by  which  the  intracellular  
K+   concentration   regulates  NLRP3   is  not   clear.   It   is   also  possible   that   the  pore  
formation  allows   small  DAMPs  and  PAMPs   to   enter   the   cytosol   and   to  activate  
NLRP3  directly  (Kanneganti  et  al.  2007).  
The   second   model   implicates   phagocytosed   material,   e.g.   crystals,  
crystalline  material,  particles  and  protein  aggregates,  in  the  activation  of  NLRP3.  
Internalization  of  these  activators  by  phagocytic  cells  initiates  a  cascade  in  which  
lysosomal  swelling  or  destabilization  results  in  the  leakage  of  lysosomal  contents  
into  the  cytoplasm.  The  released  material  appears  to  mediate  the  activation  of  
NLRP3  and  this  activation  is  induced  especially  by  cathepsin  B,  which  is  activated  
by  the  acidification  of  phagosomes  (Hornung  et  al.  2008,  Sharp  et  al.  2009).  The  
mechanism  behind  this  activation  is  not  known,  but  it  has  been  suggested  that  
cathepsin  B  might  generate  a  ligand  for  NLRP3  (Rock  et  al.  2010).  Another  possibility  
is  that  NLRP3  somehow  senses  the  lysosome  rupture  itself  as  NLRP3-­dependent  
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??????????????????????????????????????????????????????????????????????????????????
et  al.  2008).  In  addition,  the  potassium  ionophore  nigericin,  a  potent  activator  of  
caspase-­1,  has  been  shown  to  promote  the  release  of  cathepsin  B  from  the  lysosomes  
(Hentze  et  al.  2003,  Dostert  et  al.  2008).
The  third  model  depicts  a  common  pathway  for  the  NLRP3  activators:  the  
generation  of  ROS.  All  DAMPs  and  PAMPs  tested,  including  ATP  and  phagocytosed  
material,  induce  ROS  production  directly  or  indirectly  and  the  blocking  of  ROS  
diminishes   inf lammasome  activation  (Cruz  et  al.  2007,  Schröder  and  Tschopp  
2010).  ROS  production  can  also  be  triggered  by  so-­called  frustrated  phagocytosis  
in  which  a  particle  is  too  large  for  endocytosis  and  remains  trapped  on  the  cell  
surface   (Dostert  et  al.   2008,  O’Neill   2008).  ROS  may  also  promote   lysosomal  
Figure 3. Proposed models for the activation of NLRP3. Three major models have 
been proposed for the activation of the NLRP3 inflammasome. For clarity, only the 
unoligomerized NLRP3 inflammasome complex is depicted. (1) Extracellular ATP 
stimulates the ATP-gated ion channel P2X7, which then triggers the efflux of potassium 
and induces the recruitment of the pannexin-1 membrane pore. A decreased intracellular 
K+ concentration or extracellular NLRP3 agonists entering the cytosol via pannexin-1 
may activate the NLRP3 inflammasome. (2) Internalization of crystalline or particulate 
material initiates a cascade in which lysosomal swelling or destabilization results in 
the leakage of lysosomal contents into the cytoplasm. The released material, especially 
cathepsin B, mediates the activation of NLRP3, possibly by generating a direct NLRP3 
ligand. (3) All DAMPs and PAMPs, including those implicated in the other activation 
models, induce ROS production directly or indirectly. ROS is presumed to originate from 
the activity of one or several NADPH oxidases or from mitochondria, and it triggers the 
assembly and activation of NLRP3. Data are derived from the references in the text. ATP, 
adenosine triphosphate; CARD, caspase recruitment domain; CatB, cathepsin B; DAMP, 
danger-associated molecular pattern; IL, interleukin; LRR, leucine-rich repeat; NACHT, 
nucleotide-binding and oligomerization domain; PYD, pyrin domain.
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rupture   or,   in   turn,   the   production   of   ROS   could   be   affected   by   the   released  
lysosomal  proteases.  ROS   is  presumed   to  originate   from  the  activity  of  one  or  
several  NADPH  oxidases  (Dostert  et  al.  2008)  or  from  mitochondria  (Zhou  et  al.  
2011).  However,  some  controversy  regarding  the  ROS  model  does  exist:  LPS  alone  
can  induce  ROS  (Emre  et  al.  2007)  but  is  not  able  to  activate  the  inflammasome  in  
macrophages  (Ferrari  et  al.  2006).  Also,  cells  collected  from  patients  with  defective  
NADPH  activity  and  thus  an  inability  to  produce  ROS  via  NADPH  still  demonstrated  
??????????????????????????????????????????????????????????????????et  al.  2010).  
Furthermore,  in  superoxide  dismutase  deficiency,  the  caspase-­1  activity  decreases  
despite  the  increasing  ROS  levels  (Meissner  et  al.  2008).  
1.5  Clinical  implications  of  the  activation  of  NLRP3
?????? ?????? ??? ?????????? ????? ??? ????? ???????? ??? ????? ??? ???? ??????? ???????
response.  However,   its   dysregulation   and   excess   activity   underlies   a   growing  
??????????????????????????????????????????????????????????????????????????????
include   several   types   of   conditions:   autoinf lammatory   diseases,   autoimmune  
diseases  and  other  diseases  with  an  inflammatory  component  and/or  linkage  to  
inflammasomes,  either  direct  or  indirect  (Stojanov  and  Kastner  2005,  Menu  and  
Vince  2011,  Shaw  et  al.  2011).  
Inherited   cryopyrin-­associated   periodic   syndromes   (CAPS),   cryopyrin  
being  an  earlier  name  for  NLRP3,  include  three  chronic  inf lammatory  diseases:  
familial  cold  autoinflammatory  syndrome,  Muckle–Wells  syndrome  and  neonatal  
onset  multi-­systemic   inf lammatory   disease   /   chronic   infantile   neurological  
cutaneous   articular   syndrome   (NOMID/CINCA).   These   syndromes   are  most  
typically  caused  by  gain-­of-­function  -­mutations  in  the  NACHT  domain  of  NLRP3  
(Aganna  et  al.  2002,  Agostini  et  al.  2004,  Shinkai  et  al.  2008),  and  they  exhibit  
??????????????? ??? ?????? ???? ????????????? ??? ??????? ??????? ?????????????
include  recurrent  rash  and  fevers,  joint  pain,  fatigue,  deafness,  disabilities  of  the  
central  nervous  system,  vision  loss  and  joint  and  bone  deformation  (Shaw  et  al.  
2011).   Furthermore,   one   fourth   of   the  MWS   patients   and   up   to   50%   of   the  
NOMID/CINCA  patients  develop  AA  amyloidosis  in  concert  with  elevated  SAA  
levels  and  renal  impairment  (Aganna  et  al.  2002,  Menu  and  Vince  2011  ).  CAPS  
??????????????????????????????? ????????????????????????????????????et  al.  2004,  
Lachmann  et   al.   2009).  Besides  CAPS,   the  dysregulation  of  NLRP3  due   to   a  
mutation   in   the   inf lammasome-­related   genes   has   been   demonstrated   in   the  
pathogenesis  of  familial  Mediterranean  fever  (FMF)  and  the  pyogenic  arthritis,  
pyoderma  gangrenosum  and  acne  syndrome  (Chae  et  al.  2003,  Shoham  et  al.  
2003,  Chae  et  al.  2006).  Complex   inf lammatory  conditions  such  as  gout  and  
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pseudogout,  type  II  diabetes  and  occupation-­related  disorders,  such  as  silicosis  
and  asbestosis  (Maedler  et  al.  2002,  Martinon  et  al.  2006,  Dostert  et  al.  2008,  
Masters  et  al.  2010),  on  the  other  hand,  show  abnormal  inflammasome  activation,  
which  is  not  due  to  genetic  mutations  but  to  a  chronic  exposure  to  particulate  
activators  (McDermott  and  Tschopp  2007,  Ng  et  al.  2010).  Atherosclerosis  and  
Alzheimer’s  disease  can  also  be  included  in  this  group  as  cholesterol  crystals  and  
?????????????????????????????????????????????????????????????????????????????????
et  al.  2008,  Duewell  et  al.  2010,  Rajamäki  et  al.  2010).  Gout  and  type  II  diabetes  
also  respond  to  IL-­1  blocking  therapy  (Larsen  et  al.  2007,  So  et  al.  2007)  and  so  
??????????????????????????????????????????????????????????????????????????????
and  hyper  IgD  syndrome,  in  which,  however,  the  involvement  of  NLRP3  has  not  
yet  been  demonstrated  (Masters  et  al.  2009).
???????????????????????????????????????????????????????????????????????
still  unclear.  This  group  includes  different  types  of  complex  diseases,  such  as  RA,  
multiple   sclerosis   (the   autoimmune   status   of   which,   however,   has   also   been  
questioned;;  Corthals  2011),   type  I  diabetes,  systemic   lupus  erythematosus  and  
????????????????????????????????????????????????????????????????????????????????
several  ways  (Sims  and  Smith  2010),  and  at  least  one  of  these  cytokines  contributes  
to  the  pathogenesis  of  each  of  the  above-­mentioned  autoimmune  diseases,  excluding  
type  I  diabetes  (Calvani  et  al.  2005,  Voronov  et  al.  2006,  Lotito  et  al.  2007,  Acosta-­
Rodriguez  et  al.  2007,  Garrote  et  al.  2008,  Goldbach-­Mansky  2009).  Thus,  it  is  
?????????????????????????????????????????????????????????????????????????????
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2. Serum amyloid A (SAA)
Serum amyloid A (SAA) is a plasma protein that was first identified as a component 
of systemic amyloid deposits detected in patients with persistent inflammation 
(Benditt et al. 1971, Levin et al. 1973). Later it was found to function as an 
apolipoprotein of HDL, the concentration of which can increase up to 1000-fold 
in response to inflammation or injury as a part of the acute-phase response (APR) 
(Benditt and Eriksen 1977). SAA in mice was identified in 1971 (Isersky et al. 1971). 
SAA genes fall into two groups: those induced during the APR by proinflammatory 
mediators (A-SAA) and those expressed constitutively (C-SAA) (Whitehead et al. 
1992). While the expression of C-SAA has been documented only in humans and mice 
(Whitehead et al. 1992, De Beer et al. 1994), the A-SAA genes are highly conserved 
throughout evolution, found not only in eutherian mammals (Uhlar et al. 1994) and 
marsupials (Uhlar et al. 1996) but also in other vertebrates, such as birds (Guo et al. 
1996, Kovacs et al. 2005) and fish (Jensen et al. 1997). The current nomenclature of 
SAA genes and proteins is as suggested in 1999 by Sipe (Sipe 1999).
2.1  The  SAA  gene  family
The  human  SAA  gene  family  comprises  four  genes,  SAA1-­4,  that  
are  all   located   in   the  chromosome  11p15.1   (Sellar  et  al.   1994a,  
Sellar   et   al.   1994b)   and   share   a   four-­exon   three-­intron  
organization   typical   of   apolipoproteins   (Steel   and  Whitehead  
1994).  SAA1  and  SAA2  encode  the  acute-­phase  proteins  SAA1  and  
SAA2  (A-­SAA),  respectively,  and  SAA4  encodes  a  constitutional  
protein  of  HDL  (C-­SAA)  (Steel  et  al.  1993).  SAA3  is  a  pseudogene  
with  no  corresponding  protein  product  (Kluve-­Beckerman  et  al.  
1991,  Sellar  and  Whitehead  1993).  Due  to  allele  polymorphism,  
there   are   five   isoforms   of   SAA1   (SAA1.1,   SAA1.2,   SAA1.3,  
SAA1.4   and   SAA1.5)   and   two   of   SAA2   (SAA2.1   and   SAA2.2)  
(Uhlar  and  Whitehead  1999).  In  mice,  five  SAA  genes,  located  in  
chromosome  7p,  have  been  described  (Lowell  et  al.  1986,  De  Beer  
et  al.  1994,  Butler  and  Whitehead  1996).  Mouse  Saa1.1  and  Saa2.1  
encode  A-­SAA  proteins,  and  they  are  evolutionary  homologs  to  
human  SAA1  and  SAA2.  Mouse  Saa3,  unlike  human  SAA3,  is  an  
expressed  A-­SAA  gene,  but  it  differs  from  Saa1  and  Saa2  both  in  
terms   of   sequence   and   the   location   of   expression   (Meek   and  
Benditt  1986,  Meek  et  al.  1989).  Mouse  Saa4  is  a  constitutively  
expressed  homolog  to  human  SAA4,  and  Saa-­ps1  is  a  pseudogene  
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like  SAA3  (Lowell  et  al.  1986,  De  Beer  et  al.  1994).  Besides  these,  the  inbred  CE/J  
mice,  a  mouse  strain  reported  to  be  unusually  resistant  to  amyloidosis,  expresses  
a  single  isoform,  Saa2.2  (De  Beer  et  al.  1993,  Sipe  et  al.  1993).  In  this  review,  
mouse  SAA  genes  and  proteins  are  referred  to  as  Saa  and  Saa,  respectively,  to  
distinguish  them  from  their  human  counterparts,  SAA  and  SAA.
The  amino  acid  similarities  are  relatively  low,  ~50%,  between  A-­SAA  and  
C-­SAA  proteins  in  both  humans  and  mice  (De  Beer  et  al.  1994,  Whitehead  et  al.  
1992),  implying  that  the  constitutive  SAA  represents  a  separate  branch  in  the  SAA  
family  (Uhlar  and  Whitehead  1999).  Among  the  A-­SAA  proteins  the  amino  acid  
sequence  differences  are  minimal;;  SAA1  and  SAA2  share  a  92%  homology   in  
humans  and  a  91%  homology  in  mice  (Yamamoto  and  Migita  1985,  Uhlar  et  al.  
1994).  However,   these   differences   seem   to  have   an   impact   on   the   function   and  
pathogenicity  of  the  proteins  as  will  be  discussed  later.
2.2  The  expression  of  SAA
During  the  APR  the  serum  level  of  circulating  SAA  protein  can  increase  1000-­fold  
compared  with  the  baseline  (Benditt  and  Eriksen  1977),  reaching  concentrations  
??? ????? ??? ????????? ???? ?????? ???? ?????? ???????? ?? ??????????? ??????????? ??? ????
biosynthetic  capability  into  producing  SAA;;  in  mice  up  to  2.5%  of  the  total  hepatic  
protein  synthesis  may  be  comprised  of  SAA  production  during  the  APR  (Morrow  
et   al.   1981).   The   SAA   concentration   starts   to   increase   3-­6   hours   after   the  
???????????????????????????????????????????????????????????????????????????????????
day  4  (Malle  and  De  Beer  1996,  Yamada  et  al.  1999).  SAA  has  a  relatively  short  half-­
life  of  one  day  (Tape  and  Kisilevsky  1990)  but  the  capacity  of  the  liver  to  catabolize  
SAA  has  been  shown  to  decrease  during  the  APR  (Gollaher  and  Bausserman  1990).  
???? ??????????????????????????????????????????????????????????????????
bind  to  their  designated  hepatic  receptors.  The  role  of  IL-­6  seems  to  be  the  
most   critical   because   it   functions   in   synergy   with   the   other   SAA-­inducing  
???????????????????????????????????? ??????????????? ????????et  al.  2004).  The  
?????????????????????????????????????????? ?????? ???????????????????????? ??????
(also  known  as  CCAAT/enhancer-­binding  protein,  C/EBP)  pathway  (Jensen  and  
Whitehead  1998).  The  transcription  factor  SAA-­activating  factor  1  (SAF-­1)  is  also  
involved  (Ray  et  al.  2006).  In  addition  to  cytokines,  LPS  and  oxLDL  have  been  
shown  to  induce  SAA  expression  in  human  hepatocytes  and  in  the  human  THP-­1  
monocytic  cell   line  as  well  as  in  vivo   in  mice  (Liao  et  al.  1994,  Ray  et  al.  1999,  
Migita  et  al.  2004).
Besides  the  liver,  both  SAA  mRNA  and  SAA  protein  have  been  detected  in  
the  epithelial  components  of  a  wide  array  of  other  tissues,  such  as  the  tissues  of  the  
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intestine,  lung,  kidney,  skin,  tonsil,  prostate,  breast,  thyroid  and  pancreas  (Urieli-­
Shoval  et  al.  1998,  Vreugdenhil  et  al.???????? ???????????????????????????????????????
source  of  SAA  under  non-­acute-­phase  conditions  (Sjöholm  et  al.  2005,  Yang  et  al.  
2006).   SAA   mRNA   and/or   protein   have   also   been   detected   in   histologically  
abnormal  tissues  including  atherosclerotic  lesions  (Meek  et  al.  1994,  Yamada  et  al.  
1996),  Alzheimer’s  disease  brain  (Liang  et  al.???????????????????????????????????
(Kumon   et   al.   1999,  O’Hara   et   al.   2000,  O’Hara   et   al.   2004),   irradiated   bone  
marrow  (Goltry  et  al.  1998)  and  cancer  cell  lines  of  hepatic  and  non-­hepatic  origin  
(Thorn  et  al.  2003,  Gutfeld  et  al.  2006,  Kovacevic  et  al.  2006,  Kovacevic  et  al.  
2008,  Malle   et   al.   2009)   as  well   as   in   tumours   (Urieli-­Shoval   et   al.   2010).   In  
addition,   various   cell   types   have   been   implicated   in   the   expression   of   SAA,  
?????????????????????????????????????????????????????????? ??????????????????????
smooth  muscle  cells  (SMCs)  and  adipocytes  (Meek  et  al.  1994,  Steel  and  Whitehead  
1994,  Urieli-­Shoval  et  al.  1998,  Kumon  et  al.  2002a,  Yang  et  al.  2006).  It  should  also  
be  noted  that  the  regulation  of  SAA  transcription  outside  the  liver  varies  depending  
on  the  cell  type.  In  SMCs,  for  example,  SAA  expression  is  induced  by  glucocorticoids  
???????????????????????????????????????????et  al.  2002a).
2.3  The  molecular  characteristics  of  SAA  proteins  
Human  SAA  proteins  consist  of  104  (SAA1  and  SAA2)  or  112  (SAA4)  amino  acids  
(aa),  which  are  preceeded  by  18-­aa  signal  peptides  in  primary  translation  products.  
SAA  proteins  are  12-­14  kDa  in  size.  The  AA  fragments  most  typically  deposited  in  
????????????????????????????????????????????????????????????????????et  al.  1983),  
although  variations  have  been  documented  (Levin  et  al.  1973,  Westermark  1982,  
Westermark  et  al.   1987).  Despite   the   important  physiological   and  pathological  
implications  proposed  for  SAA,  there  is  relatively  little  data  on  its  structure,  which  
is  mostly  due  to  the  low  solubility  of  the  native  lipid-­free  isoforms.  Early  secondary  
structure  predictions  suggested  that  SAA  is  a  typical  globular  protein,  the  structure  
???????????????????????????????????????????????????????????????????????????????
calcium  and  lipid-­binding  sites  (Turnell  et  al.  1986).  There  are  three  hydrophobic  
regions  spanning  amino  acids  1-­27,  40-­63  and  79-­94  on  SAA  (Turnell  et  al.  1986).  
It  has  been  estimated  that  at  least  one  third  of  SAA  is  helical  (McCubbin  et  al.  1988,  
Meeker  and  Sack  1998)  and  that  it  forms  a  helical  bundle  (Stevens  2004).  Lipid-­free  
SAA  has  also  been  reported   to  aggregate   in  solutions  and   to   form  a  hexameric  
channel  in  lipid  bilayers  (Hirakura  et  al.  2002,  Kinkley  et  al.  2006).
Besides  the  calcium  binding  site  (aa  48-­51),  several  other  binding  regions  on  
SAA  have  been  identified.  The  hydrophobic,  amphipathic  N-­terminus  (aa  1-­11)  has  
been  implicated  in  lipid  binding  (Turnell  et  al.  1986),  based  on  data  achieved  by  
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degradation  studies,  mutagenesis  or  usage  of  SAA  fragments  or  antibodies  against  
different  epitopes  (Husebekk  et  al.  1987,  Malle  et  al.  1995,  Patel  et  al.  1996,  Malle  
et  al.  1998,  Ohta  et  al.???????????????????????????????????????????????????????
suggested  to  be  a  general  requirement  for  the  binding  of  apolipoproteins  to  lipids  
(Segrest  et  al.  1992).  The  N-­terminus,  and  the  first  10-­15  aa  in  particular,  has  also  
been  shown  to  be  the  major  determinant  for  amyloid  formation  (Patel  et  al.  1996,  
Westermark   et   al.   1992,   see   also   chapter   3.1.3).   The   area   spanning   aa   24-­42  
contains  elements   that  resemble   the  cell-­binding  domains  of   two  cell  adhesive  
glycoproteins   of   the   ECM:   laminin   and   fibronectin   (Kawahara   et   al.   1989,  
Preciado-­Patt  et  al.  1994,  Preciado-­Patt  et  al.  1996a,  Ancsin  and  Kisilevsky  1997).  
Besides  this,  a  binding  site  for  another  ECM  component,  heparan  sulfate  (HS)  as  
well  as  for  its  structural  derivative,  heparin,  has  been  located  at  the  C-­terminus  
between  aa  77  and  103   (Ancsin  and  Kisilevsky  1999).  However,   this  applies   to  
neutral  pH  only  as  in  acidic  pH  HS/heparin  binds  to  aa  17-­49  (Elimova  et  al.  2009).  
The  functional  domains  of  SAA  are  summarized  in  Table  1.
SAA residues Binding site/motif Proposed functions References
1-11/18 binding site for HDL/lipid/
cholesterol
cholesterol transport and 
metabolism, foam cell forma-
tion
Turnell et al. 1986, Kisilevsky & 
Subrahmanyan 1992, Liang et 
al. 1995
1-15 amyloidogenic determinant amyloid formation Westermark et al. 1992
1-20 (1 ACAT-inhibiting region cholesterol efflux Kisilevsky & Tam et al. 2003
17-49 HS/heparin binding site 
(low pH)
HDL-SAA remodeling, amyloid 
formation
Elimova et al. 2009
24-76 laminin binding site amyloid formation Ancsin & Kisilevsky 1997 
29-42 YIGSR and RGD-like adhe-
sion motifs
cell adhesion Linke et al. 1991, Preciado-Patt 
et al. 1994
48-51 calcium binding sequence 
GPGG
amyloid formation? Turnell et al. 1986 
74-103 (1 CEH-activating region cholesterol efflux Kisilevsky & Tam et al. 2003




Preciado-Patt et al. 1996a, 
Ancsin & Kisilevsky 1999
  
Table 1. The functional domains in human SAA protein 
ACAT, acyl-CoA cholesterol acyl-transferase; HS, heparan sulfate; CEH, cholesterol ester hydrolase.
(1 study conducted using mouse SAA2.1, more details in chapter 2.5.1
2.4  The  functions  of  SAA
To  date,   SAA  has   been   linked   to   several   physiological   functions,   along  with   the  
?????????????????????????????????????????????????????????????????????????????? ??????
accepted  (Kisilevsky  and  Manley  2012).  The  majority  of  SAA  associates  and  circulates  
with  HDL3  (Benditt  and  Eriksen  1977,  Skogen  et  al.  1979,  Bausserman  et  al.  1980),  
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replacing  apolipoprotein  A-­I  (apoA-­I),  the  normal  HDL  apolipoprotein,  during  the  APR  
(Coetzee  et  al.  1986).  This  applies  to  A-­SAA  only  as  C-­SAA,  which  is  only  minimally  
induced  during  the  APR,  associates  with  both  normal  HDL  and  acute-­phase-­HDL,  AP-­
HDL  (Whitehead  et  al.  1992).  Current  evidence  implicates  SAA  as  an  apolipoprotein  
and  an  acute-­phase  reactant  with  various  immune-­  and  lipid-­related  functions.
2.4.1  Receptors  for  SAA
???????????????????????????????????????????????????????????????????????????
sites  for  SAA  on  macrophages  (Kisilevsky  and  Subrahmanyan  1992),  the  number  of  
which  increases  during  the  APR.  This  interaction  leads  to  endocytosis  of  SAA,  and  
???????????????????????????? ????????????????????????????? ??????????????????????
(Röcken  and  Kisilevsky  1998,  Ancsin  and  Kisilevsky  1999).  HS  as  well  as  a  low  
pH  and  physiological  calcium  concentrations  have  been  suggested  to  promote  
the  dissociation  of  SAA  from  HDL  and  the  subsequent  cellular  uptake  of  SAA  
(Tam  et  al.  2008),  although  the  whole  complex  can  be  internalized  as  well.  In  terms  
of  the  mechanism,  HDL  and  SAA-­containing  acute-­phase  (AP-­)  HDL  appear  to  be  
taken  up  in  a  similar  manner  (Röcken  and  Kisilevsky  1998).  Also,  when  mouse  
??????????????????????????????????????????????????????????????????????????????????
via   clathrin-­mediated   endocytosis,   and   directed   to   the   endosomal-­lysosomal  
pathway  for  degradation  (Kluve-­Beckerman  et  al.  1999,  Kluve-­Beckerman  et  al.  
2001).   More   recent   studies   have   suggested   that   only   the   SAA   2.1   isoform   is  
internalized,  and,  when  it  is  presented  as  a  SAA-­HDL  complex,  SAA,  or  fragments  
thereof,  it  may  actually  proceed  to  the  nucleus,  after  which  it  is  promptly  returned  
to  the  cytoplasm  and  exocytosed  (Kinkley  et  al.  2006).  
As  for  signal  transduction,  several  cell-­surface  receptors  on  different  cell  
types  have  been  identified  as  potential  SAA  receptors.  The  fact  that  SAA  can  bind  
to  more  than  one  receptor  and  induce  the  activation  of  several  signalling  pathways  
makes  it  a  powerful  proinflammatory  mediator.  However,  it  is  intriguing  and  not  
yet  understood  on  a  detailed  molecular  level  how  SAA  can  interact  with  such  a  
variety   of   structurally   diverse   receptors.   The   receptors   implicated   in   SAA  
signalling  and/or  uptake  are  reviewed  below  and  illustrated  in  Figure  4.
FPRL1 
N-­formyl  peptide  receptor  2  (FPR2),  also  known  as  formyl  peptide  receptor-­
like   1   (FPRL1)   or   lipoxin  A4   receptor   (LXA4R),   is   a   seven-­transmembrane  Gi  
protein-­coupled  receptor  encoded  by  the  FPR2  gene.  The  expression  of  FPRL1  has  
been  documented   in   a  wide   range  of   cell   types,   and   several   ligands,   including  
bacterial  and  mitochondrial  peptides,  the  lipid  metabolite  lipoxin  A4,  chemokine  
variants  and  amyloidogenic  proteins,  have  been  suggested  (Migeotte  et  al.  2006).  
The   physiological   functions   of   FRPL1   include   chemotaxis   that   results   in   the  
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migration  and  accumulation  of  neutrophils  and  monocytes  in  vivo  and,  depending  
??????????????????? ???????????????????????????????????????????????????????????????
has  been  shown  to  act  as  a  chemotactic  ligand  for  FPRL1  and  to  induce  phagocyte  
migration   (Su   et   al.   1999)   as  well   as   the   release   of   chemokine  MCP-­1   and   the  
induction  of  matrix  metalloproteinase  (MMP-­)  9  in  human  monocytes  and  human  
umbilical  cord  endothelial  cells  (Lee  et  al.  2005,  2008,  2009,  2010).  In  neutrophils,  
???? ???????? ?????????????????? ???????????????? ???? ?????????????????????????
MAPKs  and  AP-­1,  leading  to  the  secretion  of  IL-­8    (He  et  al.  2003).  In  monocytes,  it  
?????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????et  al.  2006).  
RAGE 
The   receptor   for   advanced   glycation   end-­products   (RAGE)   has   a   single  
transmembrane  domain  and  it  belongs  to  the  immunoglobulin  superfamily  that  has  
been  connected  to  diverse  pathologies  from  atherosclerosis  to  Alzheimer’s  disease.  
Rather  than  single  polypeptides,  RAGE  recognizes  families  of  ligands,  including  
Figure 4. Proposed SAA receptors and subsequent signalling pathways. The data are 
derived from the references mentioned in the text. AP-1, activating protein 1; CD36, cluster 
of differentiation 36; ERK, extracellular signal-regulated kinase; FPRL1, formyl peptide 
receptor-like 1; G-CSF, granulocyte colony-stimulating factor; HO-1, heme oxygenase 1; IL, 
interleukin; JNK, c-Jun N-terminal kinase; MCP-1, monocyte chemoattractant protein 1; MMP, 
matrix metalloproteinase; NF-?B, nuclear factor kappa B; NO, nitric oxide; RAGE, receptor for 
advanced glycation end-products; TLR, Toll-like receptor; TNF, tumor necrosis factor.
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????????? ?????????? ???? ????????? ???????? ???????? ??????? ??? ?????????? ?????????
amphoterins  and  S100/calgranulins,  implying  that  the  interaction  is  dependent  on  
conformational   determinants.   The   expression   of   RAGE   is   up-­regulated   by   its  
ligands,  which  are  present  in  the  diseased  tissues,  and  the  RAGE-­ligand  interaction  
has  been  indicated  as  a  propagation  factor  for  the  cellular  perturbation  in  chronic  
disorders  (Schmidt  et  al.???????? ??????????????????????????????????????????????????
in  RAGE  activation  (Yan  et  al.  2000,  Okamoto  et  al.  2008).  RAGE  expressed  on  
BV-­2   transformed  mononuclear  phagocytes  has  been  shown  to  bind  amyloid  A  
????????????????????????????????? ???????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????
(HO-­1)  and  M-­CSF  (Yan  et  al.  2000).  SAA  induces  IL-­6  and  IL-­8  via  RAGE  as  well  
????????????????????? ??????????????????????????????????????????et  al.  2008).
Class B scavenger receptors 
Class  B  scavenger  receptors  are  a  group  of  receptors  implicated  mainly  in  
lipid  transport  and  pattern  recognition  in  innate  immunity.  The  family  consists  
of   CD36,   first   indentified   as   a   receptor   for   oxLDL   (Endemann   et   al.   1993),  
scavenger  receptor  class  B  type  I  (SR-­BI)  (Acton  et  al.  1994),  LIMP  II  (Vega  et  al.  
1991)  and  the  human  homologue  CD36-­LIMPII  analogous  1  (CLA-­1)  (Calvo  and  
Vega  1993).  CLA-­1  and  SR-­BI  were  originally  indicated  as  HDL  receptors  but  have  
later  also  been  shown  to  bind  to  native  and  modified  LDL  (Acton  et  al.  1994),  
native   VLDL   (Krieger   1999),   LPS   (Vishnyakova   et   al.   2003),   amyloid   fibrils  
(Husemann   et   al.   2001),   and   amphipathic   peptides   possessing   one   or   more  
????????????????????????????????et  al.  2004,  Baranova  et  al.  2005).  CLA-­1/SR-­BI  
expression  has  been  detected  in  the  liver,  ovary  and  adrenal  gland  (Landschulz  et  
al.  1996)  as  well  as  in  atherosclerotic  lesions  (Chinetti  et  al.  2000).  CD36  has  a  
ligand  repertoire  somewhat  similar  to  that  of  CLA-­1/SR-­BI,  except  that  it  does  
not   bind   acetylated   or   extensively   oxidized  LDL  but   rather   binds  moderately  
oxidized  LDL,  i.e.  mmLDL  (Endemann  et  al.  1993).  Besides  this,  CD36  participates  
in   signal   transduction   by   associating  with   a   heterodimer   formed   either   by  
TLRs  2  and  6  (Triantafilou  et  al.  2006)  or  TLRs  4  and  6  (Stewart  et  al.  2010)  or  
by  regulating  JNK  signalling  and  the  cascade  of  foam  cell  formation  (Rahaman  
et  al.  2006).  SR-­B1,  CLA-­1  and  CD36  have  all  been  suggested  to  participate  in  the  
internalization  of  SAA  (Baranova  et  al.  2005,  Cai  et  al.  2005,  Baranova  et  al.  
2010).  For  example,  both  lipid-­free  SAA  and  SAA-­HDL  are  bound  and  internalized  
by  SR-­BI  on  hepatocytes,  while  the  uptake  of  HDL  is  inhibited  (Cai  et  al.  2005).  
CLA-­1  and  CD36  also  participate  in  downstream  SAA  signalling  resulting  in  the  
activation  of  AP-­1  and  the  production  of  IL-­6  and  IL-­8  (Baranova  et  al.  2005,  
Baranova  et  al.  2010).  




the  functions  of  SAA,  signalling  via  both  TLR2  and  TLR4  has  been  demonstrated.  
?????????????????????????????????? ??????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????? ?????
?????????????????????????????????? ??????????????????????????? ????? ???????????
derived   from  patients  with   sarcoidosis   (He  et  al.   2009,  Chen  et  al.   2010).  SAA  
signalling  through  TLR4  causes  an  ERK1/2  and  p38  MAPK-­mediated  induction  of  
NO  synthase,  which  leads  to  an  increased  production  of  NO  (Sandri  et  al.  2008).
2.4.2  The  immune-­related  functions  of  SAA
SAA  possesses   various   cytokine-­like   and  proinf lammatory  properties.  
????????????????????? ??????????????????????????????????????????????????????????
??????? ??? ????????? ??? ??????? ??????????? ???? ??? ?????????? ???? ???? ?????
documented  in  different  cell  types.  These  include  monocytes  (Patel  et  al.  1998,  
Lee  et  al.  2006,  Franco  et  al.  2011),  macrophages  (Song  et  al.  2009,  Baranova  et  
al.  2010,  Ather  et  al.  2011),  neutrophils  (Furlaneto  and  Campa  2000,  He  et  al.  
2003),   lymphocytes  (Song  et  al.  2009),  fibroblasts  (Okamoto  et  al.  2008)  and  
adipocytes  (Faty  et  al.  2012).  Besides  cytokines,  SAA  induces  the  production  of  
G-­CSF  in  mouse  macrophages  and  the  release  of  chemokines,  such  as  MCP-­1,  
from  monocytes,  peripheral  blood  mononuclear  cells  (PBMCs),  human  umbilical  
cord  endothelial  cells  and  adipocytes  (Lee  et  al.  2008,  Lee  et  al.  2009,  Song  et  al.  
2009,  He  et  al.  2009,  Lee  et  al.  2010,  Faty  et  al.  2012)  and  the  release  of  liver  
activation  regulated  chemokine  (LARC,  CCL20)  from  synoviacytes  and  mononuclear  
cells  (Sandri  et  al.  2008,  Migita  et  al.  2009).  In  addition,  SAA  in  its  lipid-­free  
form  possesses  chemoattractant  properties  and  is  able  to  induce  the  migration,  
adhesion   and   tissue   filtration   of   inf lammatory   cells   (Badolato   et   al.   1994,  
Badolato  et  al.  1995,  Xu  et  al.  1995,  Preciado-­Patt  et  al.  1996a,  Olsson  et  al.  1999,  
Su  et  al.  1999,  Dong  et  al.  2011b).  This  can  accelerate  local  inf lammation  and  may  
also  play  a  role  in  chronic  inf lammatory  diseases,  such  as  atherosclerosis  (see  
chapter   3.2).   Furthermore,   SAA   can   contribute   to   inf lammation-­associated  
thrombosis  by  inducing  the  expression  of  tissue  factor  (TF)  in  PBMCs  (Cai  et  al.  
2007).  Also,  ROS  production   in  neutrophils   is   increased   in   response   to   SAA  
(Björkman  et  al.  2008).  During  the  APR,  SAA  enhances  the  expression  of  other  
APPs,  such  as  sPLA2  and  pentraxin  3  (PTX3)  (Sullivan  et  al.  2010,  Dong  et  al.  
2011a),  although  contradictory  data  do  exist  (Tietge  et  al.  2002).  In  addition,  SAA  
participates  in  host  defence  by  aiding  in  the  clearance  of  microbes;;  SAA  binds  to  
Gram-­negative  bacteria  via  outer  membrane  protein  A  (OmpA)  and  can  act  as  an  
opsonin   for  macrophages  and  neutrophils   (Hari-­Dass  et  al.  2005,  Shah  et  al.  
2006).  Indeed,  it  has  been  suggested  that  the  epithelial  expression  of  SAA  in  the  
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intestine  reduces  the  bacterial  load  and  functions  as  a  protective  factor  against  
colitis  (Eckhardt  et  al.  2010).
??????????????? ???????????? ?????????????????? ??????????????????????????????
activities   as   well.   SAA   induces   the   release   of   anti-­inf lammatory   cytokines,  
particularly  IL-­10,  from  monocytes  and  PBMCs  (Lee  et  al.  2006,  Song  et  al.  2009)  
and  inhibits  platelet  aggregation  (Zimlichman  et  al.  1990).  Furthermore,  SAA  has  
??????????????????????????????????????????????????????????????????????Acinetobacter  
baumannii  pneumonia  in  mice  (Renckens  et  al.  2006).  The  reason  for  this  effect  is  
not  clear,  but  it  is  speculated  that  preceeding  high  levels  of  SAA  may  down-­regulate  
?????????????????????????????????????????????????????????????????????et  al.  2006).  
There  is  also  evidence  that  SAA  binds  to  neutrophils  via  its  C-­terminal  binding  site  
and  inhibits  the  respiratory  burst  (Linke  et  al.  1991,  Preciado-­Patt  et  al.  1996b).  More  
recently,  SAA  has  been  shown  to   induce  a  microenvironment   that  promotes   the  
expansion  of  regulatory  T  cells  (Treg)  at  sites  of  infection  or  injury  (Nguyen  et  al.  
2011).  This  property  also  connects  SAA  to  the  regulation  of  the  adaptive  immune  
response.  In  addition,  SAA  has  been  shown  to  promote  the  development  of  the  Th17  
type  of  immune  response  in  a  mouse  model  of  asthma  in  an  indirect  way  by  increasing  
???????????????????????????????et  al.  2011),  which  has  been  implicated  in  the  conversion  
of  Treg  into  IL-­17-­producing  Th17  cells  (Chung  et  al.  2009).  
2.5  SAA  in  association  with  lipoproteins
Lipoproteins,  the  transporters  of  lipids  in  the  blood,  can  be  divided  into  different  
classes  according  to  their  density.  In  principle,  dense  particles  have  a  high  protein  
content,  whereas  less  dense  particles  contain  more  triglycerides.  The  four  classes  
from   the  most   dense   to   the   least   dense   are   HDL,   LDL,   intermediate   density  
lipoprotein  (IDL),  and  VLDL.  The  ApoB-­100-­containing  lipoproteins  LDL,  IDL  and  
VLDL  are  considered  atherogenic,  while  HDL  and  its  major  apolipoprotein  apoA-­I  
appear  to  play  a  protective  role  against  atherosclerosis  (Barter  et  al.  2004,  Lewis  
and   Rader   2005).   This   is   mostly   due   to   the   involvement   of   HDL   in   reverse  
cholesterol  transport  (RCT),  the  process  in  which  excess  cholesterol  from  peripheral  
tissues  and  cells  is  transported  to  the  liver  for  excretion  (Lewis  and  Rader  2005).  
In  addition,  HDL  particles  possess  antioxidant  properties,  which  have  a  direct  
impact  on  LDL  oxidation;;  apoA-­I  is  capable  of  removing  hydroperoxides  from  LDL  
(Navab  et  al.  2000a,  Navab  et  al.  2000b),  besides  which  HDL  carries  enzymes,  such  
as  paraoxonase-­1,  which  can  destroy  such  oxidant  molecules  (Navab  et  al.  2001,  
Mackness  et  al.???????? ?????????????????????????????????????????????????????????
inhibiting  the  oxLDL-­stimulated  MCP-­1  and  the  cytokine-­induced  expression  of  
adhesion  molecules  (Barter  et  al.  2004,  Calabresi  et  al.  1997).
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SAA  associates  and  circulates  normally  with  HDL3,  utilizing  its  N-­terminal  
lipid  binding  site  (Turnell  et  al.????????????????????????????????????????????????????
cytokine  induction,  have  been  shown  to  decrease  in  the  presence  of  HDL  or  when  SAA  
is  bound  to  HDL  (Furlaneto  and  Campa  2000,  Baranova  et  al.  2010  Franco  et  al.  
2011).   The   baseline   level   of   lipid-­free   SAA   is   relatively   low.   Nevertheless,   the  
distribution  of  SAA  among  different  lipoprotein  classes  and  the  lipid-­free  fraction  is  
not  constant  (Marhaug  et  al.  1982,  Cabana  et  al.  2004).  In  human  patients  with  stable  
coronary  artery  disease,  almost  one  fourth  of  the  circulating  SAA  is  associated  with  
LDL  or  VLDL,  and  the  LDL-­SAA  complex  has  been  indicated  as  a  potent  marker  
associated  with  an  increased  risk  of  a  future  cardiac  event,  its  sensitivity  exceeding  
that  of  SAA  or  CRP  alone  (Ogasawara  et  al.  2004).  More  recently,  the  biomarker  value  
of  the  complex  was  also  implicated  in  the  metabolic  syndrome  (Kotani  et  al.  2009).  
Studies  on  several  mouse  models  of  obesity  and/or  atherosclerosis  actually  suggest  
that  a  high-­fat  diet  may  promote  the  redistribution  of  SAA  to  the  apoB-­100-­containing  
lipoproteins  (Lewis  et  al.  2004,  Subramanian  et  al.  2008,  King  et  al.  2010).  It  has  also  
been  speculated  that  SAA  binds  to  non-­HDL  lipoproteins  or  remains  lipid-­free  when  
the  serum  level  of  SAA  exceeds  the  capacity  of  HDL  to  bind  SAA  (Cabana  et  al.  2004,  
Bausserman  et  al.  1987).  This  could  indeed  be  the  case  during  a  strong  APR  when  the  
?????????????????????????????????????????????????????????????????????????????????
the  liver.  SAA  can  also  bind  cholesterol  directly,  and  it  has  been  suggested  that  SAA  
???? ?????????????????????????????????????????????????????????????????????????????
(Liang  and  Sipe  1995,  Liang  et  al.  1996).  
2.5.1  Reverse  cholesterol  transport  
In   macrophages,   any   internalized   cholesterol   that   is   not   utilized   for  
membrane   homeostasis   or   other   cellular   functions   is   esterified   by   acyl-­CoA  
cholesterol  acyl-­transferase  (ACAT).  Cholesteryl  esters  (CEs)  are  the  predominant  
form  of   intracellular  storage  of  cholesterol,  although  a  continuous  cycle  of  de-­
esterification  by  neutral  cholesterol  ester  hydrolase  (nCEH)  and  re-­esterification  
by  ACAT  does  take  place.  Under  normal  conditions  apoA-­I  constitutes  70-­100%  of  
the  apolipoprotein  content  of  HDL  and  it  also  represents  the  starting  material  for  
HDL  synthesis  and  maturation.  ApoA-­I  is  secreted  by  the  liver  or  the  intestine  as  a  
lipid-­poor  apoA-­I,  which  then  obtains  phospholipids  and  cholesterol  via  eff lux  
from  the  liver,  or  from  chylomicrons  or  VLDL  in  a   lipoprotein  lipase-­mediated  
process.  The  end  product  is  a  nascent  phospholipid-­rich,  cholesterol-­poor  HDL  
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and  key  acceptors  of  cellular  cholesterol  (Lewis  and  Rader  2005).  
In   the   reverse   cholesterol   transport   (RCT)   pathway,   the   CEs   stored   in  
peripheral  cells  are  first  de-­esterified  by  nCEH,  after  which  the  free  cholesterol,  
accompanied  by  phospholipids,  is  transferred  to  extracellular  lipid-­poor  apoA-­I  or  
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cellular  cholesterol  leading  to  the  cholesterol  eff lux  is  mediated  by  ATP-­binding  
cassette  transporter  proteins,  such  as  ABCA1,  also  known  as  cholesterol  eff lux  
regulatory  protein,   and  ABCG1   (Denis  et  al.   2004,  Vedhachalam  et  al.   2007).  
Cholesterol  eff lux  can  also  proceed  via  SR-­B1  (De  la  Llera-­Moya  et  al.  1999).  In  the  
????????????? ???? ????????? ???????????? ??? ????????? ??? ??????????? ??? ?????????
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with  a  CE-­rich  core  (Daniels  et  al.?????????????????????????????????????????????????
differentiated  by  density  and  size,  the  smaller  and  denser  HDL3  and  the  bigger  
HDL2,  the  latter  of  which  is  formed  as  a  result  of  the  continuous  accumulation  of  
CEs.  In  the  end,  HDL2  binds  to  SR-­B1  on  hepatocytes,  while  CEs  are  selectively  
taken   up   by   the   liver   or   alternatively,   the  whole  HDL   particle   is   internalized  
(Tulenko  and  Sumner  2002,  Robichaud  et  al.  2009).  The  hepatic  uptake  can  also  
be   indirect  and  proceed  via   the  CE   transfer  protein   (CETP)   that  promotes   the  
transfer  of  CEs  to  LDL,  IDL,  VLDL  and  chylomicrons  in  exchange  for  triglycerides  
(Stein  and  Stein  2005).  
Reverse cholesterol transport during the APR
During  the  APR,  the  HDL  particle  faces  many  changes.  Firstly,  the  plasma  
concentrations  of  HDL  cholesterol  and  apoA-­I  decrease  rapidly  (Coetzee  et  al.  1986,  
Khovidhunkit  et  al.  2004),  the  reason  behind  which  is  not,  however,  completely  
understood.  SAA-­containing  AP-­HDL  is  cleared  faster  than  normal  HDL  (Salazar  
et  al.  2000),  but  it  is  unlikely  that  the  mere  presence  of  SAA  on  HDL  is  the  cause  as  
HDL  levels  seem  to  decrease  before  the  increase  in  the  concentration  of  SAA  (Ly  et  
al.   1995).   Secondly,   the   composition   and   physico-­chemical   properties   of  HDL  
change  dramatically  (Pruzanski  et  al.  2000,  Cabana  et  al.  1999,  Abe-­Dohmae  et  al.  
2006,  Hu  et  al.  2008).  SAA  becomes  the  major  apolipoprotein  on  HDL,  comprising  
up  to  80%  of  its  apolipoprotein  content  (Marhaug  and  Husby  1982,  Coetzee  et  al.  
1986,  Husebekk  et  al.  1987).  The  newly-­formed  AP-­HDL  has  a  higher  density  and  
larger  particle  size  than  normal  HDL  (Clifton  et  al.  1985,  Coetzee  et  al.  1986,  Abe-­
Dohmae  et  al.  2006),  although  at  least  in  mice  the  increase  in  size  is  not  related  to  
the  presence  of  SAA  but  rather  to  an  increase  in  surface  phospholipids  (De  Beer  et  
al.  2010).  SAA-­containing  AP-­HDL  can  form  via  two  pathways:  the  displacement  of  
apoA-­I  by  SAA  from  the  HDL  particles  or  the  biogenesis  of  HDL  driven  by  SAA.  
ApoA-­I  displacement  by  SAA,  as  demonstrated  in  vitro,  can  reach  a  displacement  
rate  as  high  as  87%  (Coetzee  et  al.  1986).  The  de  novo  synthesis  of  AP-­HDL  seems  
to  resemble  the  synthesis  initiated  by  apoA-­I;;  both  syntheses  depend  on  ABCA1  
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Dohmae  et  al.  2006,  Hu  et  al.  2008).  However,  it  is  still  unclear  how  similar  the  
SAA-­HDL   generated   by   apoA-­I   displacement   and   the   SAA-­HDL   obtained   via  
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biogenesis  are  in  terms  of  function,  if  at  all.  Also,  the  proportions  of  these  two  types  
in  plasma  are  currently  unknown  (Cabana  et  al.  1999,  Abe-­Dohmae  et  al.  2006).
Lipid  metabolism  and  the  properties  of  HDL  are  also  affected  during  the  
APR  and  inf lammation.  Proinflammatory  cytokines  have  been  shown  to  inhibit  
LCAT   in   the   circulation   (Ly   et   al.   1995,   Skretting   et   al.   1995)   and   also   the  
expression  of  ABCA1  (Yin  et  al.  2010).  Furthermore,  during  systemic  inflammation  
the  anti-­inf lammatory  and  antioxidant  properties  of  HDL  may  be  overcome  
by   an   excess   of   accumulated   oxidants.   In   that   case,   HDL   can   turn   into  
‘proinflammatory  HDL’,  HDL  particles  with  limited  capabilities  to  promote  RCT  
and   to   inhibit   the  oxidation  of  LDL  (Navab  et  al.  2006,  McMahon  et  al.  2006,  
Skaggs  et  al.   2012).  The   impairment   of  RCT   in   response   to   inf lammation  has  
indeed  been  demonstrated   in  vivo   in  mice  and  in  humans  (McGillicuddy  et  al.  
2009,  Malik  et  al.  2011,  De  la  Llera  Moya  et  al.  2012).  Furthermore,  a  recent  study  
reported  an  inverse  correlation  between  SAA  enrichment  on  HDL  and  the  anti-­
inf lammatory  capacities  of  HDL  (Tölle  et  al.  2012).  This  is  supported  by  earlier  
findings  suggesting  that  SAA  promotes  the  selective  CE  uptake  by  peripheral  cells  
(Artl  et  al.  2000)  and  the  reduction  of  cholesterol  eff lux  and  RCT  (Banka  et  al.  
1995,  Artl  et  al.  2000,  Cai  et  al.  2005,  Annema  et  al.  2010),  under  the  condition  
that  SAA  consititutes  more   than  50%  of   the  HDL  protein   (Banka  et  al.   1995).  
However,  there  is  a  fair  amount  of  controversy  regarding  the  impact  of  SAA  on  
lipid  metabolism.  It  has  been  shown  that  the  presence  of  SAA  on  HDL  reduces  the  
affinity   of  HDL   for   normal   hepatocytes   and   increases   that   for  macrophages,  
PBMCs  and  ECs  (Kisilevsky  and  Subrahmanyan  1992,  Hayat  and  Raynes  2000).  
Accordingly,  the  number  of  AP-­HDL  binding  sites  increases  on  macrophages  and  
decreases  on  hepatocytes  (Kisilevsky  and  Subrahmanyan  1992),  suggesting  that  
the   net   effect   is   a   shift   in   HDL   cholesterol   carrying   capacity   towards   the  
macrophage.  Later  on,  the  presence  of  SAA  in  AP-­HDL  was  shown  to  enhance  the  
mobilization  and  eff lux  of  intracellular  cholesterol  both  in  tissue  cultures  (Tam  et  
al.  2002,  Stonik  et  al.  2004,  van  der  Westhuyzen  et  al.  2005)  and  in  vivo  (Tam  et  
al.  2002,  Kisilevsky  and  Tam  2003).  Furthermore,  mouse  Saa2.1  can  modulate  the  
intracellular  cholesterol  balance  so  that  it  shifts  from  CEs  to  free  cholesterol.  This  
is  mediated  via  two  specific  regions  identified  on  Saa2.1;;  the  N-­terminal  region  
acts  as  an  inhibitor  for  ACAT  and  the  C-­terminus  as  an  enhancer  for  nCEH.  It  has  
been  demonstrated  that  liposomal  formulations  containing  either  the  whole  Saa2.1  
protein  or  peptides  spanning  the  above-­mentioned  activities  enhance  RCT  from  
cholesterol-­laden  macrophages   (Tam   et   al.   2002,   Kisilevsky   and   Tam   2003).  
Importantly,   these   peptides   have   been   shown   to   reverse   the   development   of  
atherosclerotic  lesions  in  hyperlipidemic  mice  (Tam  et  al.  2005).  Also,  HS,  bound  
by  SAA,  has  been   implicated   in  AP-­HDL  remodeling   that   results   in   increased  
cholesterol  eff lux  from  macrophages  (Tam  et  al.  2008).  In  summary,  Kisilevsky  et  
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al.  have  proposed  that  the  role  of  SAA  during  acute  inflammation  may  in  fact  be  to  
recycle  cholesterol  from  damaged  cells  and  tissues;;  SAA  would  first  target  the  
HDL-­SAA  complex  to  macrophages,  detach  from  HDL  and  enter  the  cell,  inside  
which  it  would  promote  the  efflux  of  cholesterol  to  HDL  by  regulating  the  activities  
of  ACAT  and  nCEH  (Kisilevsky  and  Manley  2012).  
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3. SAA in pathological conditions
The involvement of SAA has been established in several pathologies. The prime 
example is AA amyloidosis, a systemic protein misfolding disease that develops 
secondary to a prolonged inflammatory condition, most commonly RA (Hazenberg et 
al. 2004). In the pathogenesis of RA, SAA has been shown to induce the expression 
of adhesion molecules, angiogenesis and matrix degradation via the activation of 
NF-?B (Mullan et al. 2006). Another example is the group of cardiovascular diseases, 
in which SAA can potentially function as an independent risk predictor (Jousilahti et 
al. 2001, Johnson et al. 2004) or as an active mediator in their pathogenesis (Lewis 
et al. 2004, Dong et al. 2011b). SAA has also been implicated in many conditions 
associated with cardiovascular diseases, or their risk, such as obesity, insulin 
resistance, type 2 diabetes and the metabolic syndrome (Faty et al. 2012, Zhao et al. 
2010, Yang et al. 2006, Herder et al. 2006, Karlsson et al. 2004, Kotani et al. 2009). 
Furthermore, it has been proposed that SAA may function as a direct link between 
obesity and atherosclerosis (Yang et al. 2006). The role of SAA in AA amyloidosis and 
atherosclerosis will be discussed below.
Growing evidence also indicates a connection between SAA and cancer. There 
is a close association between malignant transformations and chronic inflammation, 
particularly via the synthesis and secretion of proinflammatory cytokines; tumour 
promotion and progression involve several signal transduction pathways that are 
activated by proinflammatory cytokines (Malle et al. 2009). The expression of SAA 
has been detected in cancer cell lines and also in different types of tumours (Thorn 
et al. 2003, Gutfeld et al. 2006, Kovacevic et al. 2006, Kovacevic et al. 2008, Urieli-
Shoval et al. 2010, Cocco et al. 2010). Elevated SAA levels correlate with tumour 
grading (Weinstein et al. 1984, Liu et al. 2007) and many studies indicate SAA as 
a potential serum biomarker in the monitoring of the recurrence or status of the 
disease or treatment response (Howard et al. 2003, Cocco et al. 2009, Fischer et al. 
2012). Several proinflammatory properties of SAA, such as the ability to induce cell 
adhesion/migration and the production of matrix metalloproteinases (MMPs), are 
also compatible with the mechanisms related to tumour invasion and metastasis and 
suggest that SAA could be involved in tumour pathogenesis (Gutfeld et al. 2006).
3.1  AA  amyloidosis
The  German  pathologist  Rudolph  Virchow,  who   conducted   his  
studies   in   the   1850s,   is   widely   considered   to   have   discovered  
amyloid   and   invented   the   name,   although   a   number   of   other  
scientists  were  most  likely  also  involved  (Aterman  1976).  Based  on  
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it  was  named  amyloid  after  the  Greek  word  ‘amylon’,  which  means  starch  or  cellulose.  
Amyloidosis  is  a  clinical  disorder  caused  by  the  extracellular  deposition  of  
insoluble  fibrils  in  tissues  and/or  organs.  These  fibrils  originate  from  aggregations  
of   misfolded   proteins   that   are   normally   soluble.   Amyloid   fibril   formation   in  
humans  has  been  demonstrated  for  27  different  proteins  and  9  of  them  have  also  
been  studied  in  animals  (Sipe  et  al.  2010).  Local  amyloidoses,  such  as  certain  forms  
of  AL  (amyloid   light  chain)  amyloidosis  or  Alzheimer’s  disease,  affect  only  one  
organ  or  tissue,  whereas  in  systemic  amyloidoses,  such  as  AA  amyloidosis  or  AGel  
amyloidosis  (Finnish-­type  amyloidosis),  the  deposits  can  be  found  in  any  internal  
organ,  or   in  all  of  them,  as  well  as   in  connective  tissue  and  blood  vessel  walls.  
Amyloidoses  can  be  further  divided  into  hereditary  and  acquired  forms.
3.1.1  The  prevalence  and  clinical  characteristics  of  AA  amyloidosis
AA   amyloidosis   or   secondary   amyloidosis   is   the  most   common   form   of  
systemic  amyloidosis  (Buxbaum  1996),  except  in  the  US  where  the  frequency  of  AL  
amyloidosis  is  higher.  AA  amyloidosis  occurs  secondary  to  chronic  inflammation,  
the  origin  of  which  can  be   infectious  or  non-­infectious,  or  to  other  conditions,  
including  hereditary  periodic  fever  or  neoplasms,  such  as  Hodgkin’s  disease  and  
renal  cell  carcinoma.  The  disease  is  characterized  by  the  systemic  deposition  of  
extracellular  SAA-­derived  fibrils  in  tissues  and  organs.  The  spleen  and  the  liver  are  
the  first  organs  to  be  affected  but  even  a  remarkable  amyloid  load  in  these  organs  
can  remain  asymptomatic   (Hazenberg  and  van  Rijswijk  1994,  Hawkins  2002).  
Next,  the  deposits  start  to  appear  in  the  kidneys,  the  adrenal  gland,  the  liver,  the  
gastrointestinal  tract,  the  intestine,  the  peripheral  nervous  system,  the  skin  and  
the  respiratory  system  (Lachmann  et  al.  2007).  The  only  exception  is  the  brain,  
which  remains  mainly  unaffected,  although  cerebrovascular  involvement  has  been  
reported  (Schroder  and  Linke  1999).  Cardiac  involvement  is  also  rare  (Lachmann  
et  al.  2007).  The  renal  deposition  of  AA  fibrils  causes  proteinuria  in  up  to  95%  of  
cases  (Hazenberg  and  van  Rijswijk  1994,  Dember  2006,  Ferrario  and  Rastaldi  
2006a,  Ferrario  and  Rastaldi  2006b,  Pinney  and  Hawkins  2012),  and  the  diagnosis  
is  typically  made  after  the  appearance  of  the  renal  symptoms.  From  the  viewpoint  
of  prognosis,  this  is  often  too  late  as  around  10%  of  patients  have  already  reached  
end-­stage  renal  failure  at  the  time  of  diagnosis  (Pinney  and  Hawkins  2012).  If  the  
inf lammatory  conditions  persist,  renal  dysfunction  and  renal  failure,  requiring  
dialysis  and  renal  transplantation,  will  follow.  
The  absolute  prevalence  of  AA  amyloidosis   is  difficult   to  confirm  as   the  
disease  occurs  secondary  to  other  diseases  and  as  there   is  also  great  variation  
among  individuals  regarding  the  extent  of  amyloid  deposition  and  the  severity  of  
the  disease.  In  some  patients  AA  amyloidosis  can  remain  asymptomatic  and  thus  
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also  undiagnosed  unless  an  autopsy  is  performed.  Recent  studies  have  estimated  
that   only   25-­50%   of   the   patients   with   histological   findings   of   amyloid   have  
clinically   apparent   amyloidosis   (Wakhlu   et   al.   2003,   Sanmarti   et   al.   2004,  
Koivuniemi  et  al.  2008).  An  early  autopsy  study  conducted  in  the  Netherlands  
estimated   the   total  prevalence  of  AA  amyloidosis   to  be  as   low  as  1   in  100  000  
(Janssen   et   al.   1986).   Later   on,   estimations   have   mainly   been   based   on   the  
prevalence  of  the  primary  diseases  and  the  portion  of  these  patients  also  affected  
by  AA  amyloidosis.  It  should  also  be  noted  that  patients  with  the  same  primary  
disease  can  be  affected  at  different  rates.  The  most  common  underlying  disease  for  
AA  amyloidosis   in   industrialized  countries   is  RA,  which   is  proposed   to  be   the  
primary  disease  in  56%  of  cases  of  AA  amyloidosis  (Hazenberg  and  van  Rijswijk  
1994).  On  the  other  hand,  the  prevalence  of  AA  amyloidosis  in  RA  varies  greatly  
depending  on  the  country,  and  estimates  between  3  and  30%  have  been  suggested  
(Kobayashi  et  al.  1996,  Gomez-­Casanovas  et  al.  2001,  El  Mansoury  et  al.  2002,  
Wakhlu  et  al.  2003,  Koivuniemi  et  al.  2008).  Generally,  environmental  factors,  
such  as   food  and   lifestyle,   as  well   as  drug   treatment,   the   type  of   the  primary  
disease  and  also  genetic  factors  most  likely  play  a  role  in  the  pathogenesis  of  AA  
amyloidosis  and  might  explain  the  differences.
When  the  amyloid  deposition  develops  into  renal  amyloidosis,  the  prognosis  
for   both   the   patient   and   renal   survival   becomes   poor.   In   one   study   the   renal  
survival  rate  after  5  years  was  30%  and  the  patient  survival  rate  after  10  years  20%  
(Sasatomi  et  al.  2007).  In  another  study,  which  followed  the  clinical  outcome  of  
patients  with  RA  and  AA  amyloidosis  receiving  hemodialysis,  50%  of  the  patients  
died  within  less  than  a  year  (Kuroda  et  al.  2006).  The  typical  causes  of  death  for  
patients   with   RA   and   renal   AA   amyloidosis   are   infections,   renal   failure   and  
cardiovascular  disease  (David  et  al.  1993,  Sasatomi  et  al.  2007).  
3.1.2  The  pathological  and  physical  characteristics  of  AA  amyloidosis
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structures.  This  conformation  is  stabilized  by  intermolecular  interactions,  leading  
to  the  formation  of  different  amyloid  species,  such  as  oligomers,  protofibrils  and  
fibrils,   which   in   the   end   accumulate   as   amyloid   deposits   in   affected   tissues.  
Amyloid   is  primarily  recognized  by  staining  with  a  dye  called  Congo  Red,  and  
Congo  Red  positive  amyloid  exhibits  a  distinctive  apple-­green  birefringence  when  
examined  under  polarized  light.  In  addition,  amyloid  deposits  from  diverse  origins  
share   a   strikingly   similar   fibrillar   ultrastructure.   On   electron   microscopy,  
individual  amyloid  fibrils  are  typically  straight,  unbranched  filament  bundles,  
which  have  a  diameter  of  10  nm  and  a  length  of  several  micrometers.  On  X-­ray  
?????????????????????? ????? ??????? ???????? ???????? ??????????????? ???????????????
????????????????????????????????????????????????????????????????????????????????
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axis  (Pauling  and  Corey  1951,  Sunde  et  al.  1997).  The  mature  amyloid  fibrils  in  AA  
amyloidosis  also  contain  a  serum  amyloid  P  (SAP)  component  and  glycosaminoglycans  
(GAGs),  such  as  chondroitin  sulfate,  dermatan  sulfate,  HS  and  heparin  (Magnus  et  
al.  1994,  Inoue  et  al.  1998,  Inoue  and  Kisilevsky  1999),  as  presented  in  Figure  5.  
The  mature  fibril  is  fairly  resistant  to  proteolysis  (Tennent  et  al.  1995).
Amyloid  fibril  formation  follows  a  nucleated  growth  mechanism,  which  is  a  
two-­step  reaction  consisting  of  a  slow  nucleation  step,  the  so-­called  lag  phase,  and  
of  a  subsequent  rapid  exponential  growth  phase  (Naiki  and  Nakakuki  1996,  Serio  
et  al.  2000).  It  is  assumed  that  the  lag  phase  is  the  time  required  for  the  formation  
of  the  “nucleus”  or  “seed”.  After  this,  monomers  or  oligomers  associate  with  the  
????????? ???????????????????????????????????????????? ????????????????????????????
step  seems  to  play  a  key  role  in  determining  the  kinetics  of  the  fibril  formation  and  
it  can  be  shortened  by  several  substances,  including  preformed  fibrils  and  amyloid-­
enhancing  factor  (AEF,  see  below),  or  by  introducing  mutations  (Uversky  and  Fink  
2002).  The  different  amyloid  species  are  illustrated  in  Figure  6.
The  proposed  nucleated   growth  mechanism   is   crucial   in   light   of  what   is  
currently  understood  about  the  toxicity  and  function  of  amyloid  preforms.  Although  
it   is   clear   that   the  physical   disruption   in   the   tissue   architecture   caused  by   the  
amyloid   deposits   can   be   detrimental   (Pepys   2001),   more   recent   data   indicate  
??????????????????????????????????????????????????????????????????????????????????
aggregates   as   the  most   potent  mediators   of   cell   damage   and   cell   toxicity.   This  
“corrected”  amyloid  hypothesis  shows  an  analogue  to  prion  proteins;;  it  has  been  
???????????????????????????????????????????????????????????????????????????????????
species  most   damaging   to   neurons   (Fontaine   and   Brown   2009).  However,   the  
Figure 5. A schematic drawing of an AA amyloid fibril. Modified from Inoue and 
Kisilevsky 1999. AA, amyloid A; AP, amyloid P; CSPG, chondroitin sulfate proteoglycan; 
HSPG, heparan sulfate proteoglycan.




their  effects  (Kagan  and  Thundimadathil  2010).  This  is  outlined  in  the  amyloid  pore  
???????????? ?????? ????????? ????? ???????????? ???? ???????? ?????????? ??????? ?????
membranes   (Lashuel   et   al.   2002,  Hirakura   et   al.   2002)   and   that   the  membrane  
permeabilization  by  these  species   is  a  common  component  of  the  toxicity  (Lashuel  
2005).  Toxicity  can  also  be  at  least  to  some  extent  due  to  the  misfolded  state  of  the  
?????????????????????????????????????????????????????????????????????????????????
systems,  causing  oxidative  stress  or  sequestration  of  some  essential  proteins,  which  
could  then  lead  to  apoptosis  or  other  forms  of  cell  death  (Chiti  and  Dobson  2006).  
???????? ??????????????????????????????????????????????????????????????????????
O’Neill   2011).   Three   types   of   amyloidogenic   or   misfolded   proteins   have   been  
suggested   to   activate   the   NLRP3   inf lammasome,   leading   to   the   secretion   of  
???????????????????????????????????????????????????????????????????????????????????
soluble  islet  amyloid  polypeptide  oligomers  in  macrophages  in  type  2  diabetes  and  
the  mutated,  misfolded  superoxide  dismutase  1  in  microglia  in  amyotrophic  lateral  
sclerosis  (Halle  et  al.  2008,  Masters  et  al.  2010,  Meissner  et  al.  2010).  Also,  it  has  
been  proposed  that  the  lipid  composition  of  the  cell  membrane  can  modulate  the  
toxicity  of  oligomers  (Evangelisti  2012).
????????????????????????? ?????????????????
SAA   is   the   precursor   protein   for   the   AA   protein   present   in   the   amyloid  
deposits  in  AA  amyloidosis.  Two  steps  are  required  for  the  transformation  from  SAA  
???????????????????????????????????????????????????????????????????????????????
mechanism  and  order  of  the  events  leading  to  the  transformation  are  still  not  fully  
the structure of various amyloid proteins and found
divergence between the basic arrangements of steric
zippers in amyloid fibrils. He categorized the amyloid
proteins into eight classes, depending on three struc-
tural principles: first, whether their !-strands were
antiparallel or parallel; second, whether the !-sheets
were packed “face-to-face” or “face-to-back”; and third,
whether the orientation of the !-sheets was “up-up” or
“up-down” with respect to each other (Fig. 4C) (26).
Most of the eight variations of steric zippers that were
described have been observed in amyloid proteins such
as tau, prion, amyloid-!, and insulin, which are associ-
ated with protein misfolding diseases.
PROTEIN MISFOLDING DISEASES
Protein misfolding diseases represent a group of disor-
ders that have protein aggregation and plaque forma-
tion in comm n. Here, we provide an overview of the
current understanding of protein misfolding diseases
by describing the most studied diseases of the main
categories (Table 2) and illustrating the common
mechanisms of protein misfolding in protein misfold-
ing diseases.
Amyloidosis
Amyloidosis is a group of protein misfolding diseases,
in which protein aggregates accumulate either system-
ically or locally in certain organs or tissues (Table 2).
Amyloidosis can be either hereditary or acquired (52).
The hereditary forms are caused by mutations in the
genes of (mostly) plasma proteins. Little is known
about the precise conditions that lead to the develop-
ment of the other, acquired, forms. In patients with
amyloidosis, various symptoms can arise, depending on
which protein is involved and at what site the aggrega-
tion occurs. Most patients have gastrointestinal abnor-
malities, kidney insufficiencies, or heart problems, and
the affected organs are characteristically e larged, rub-
bery, and firm.
The most common form of amyloidosis is primary
systemic amyloidosis, in which immunoglobulin light
chains or fragments thereof that are produced by
plasma cell clones form amyl id. The diseas typically
develops in individuals after the age of 40 and can
affect both genders. The amyloid deposits occur in
basically all organs of the body, inducing various com-
plications including congestive cardiac and renal fail-
ure; hepatosplenomegaly, neuropathy, and skin lesions
(53). The diagnosis of the disorder is rather difficult; it
requires histologica nalysis, definiti n of the correct
amyloidosis, and characterization of the underlying
plasma cell clone (54). Unfortunately, efficient therapy
is not available for most forms of amyloidosis. The aim
of current treatment is to reduce the supply of the
monoclonal light chain through suppression of the
underlying plasma clone by autologous stem cell trans-
plantation and chemotherapy. This is an aspecific ap-
proach with high potential risk (55).
Alzheimer’s disease
Neurodegenerative diseases were the first described
protein misfolding diseases. Alzheimer’s disease is one
of the most studied conformational diseases. The small,
40- to 42-amino acid long (39- and 43-aa peptides have
also been described) amyloid-! peptide aggregates
accumulate and form senile plaques in the brain of
patients with Alzheimer’s disease. Amyloid-! is cleaved
off from its amyloid precursor protein (APP) by !- and
Figure 3. Protein misfolding and aggregation. Under certain circumstances such as pH or temperature change, mechanical
stress, glycation, or oxidation, proteins undergo conformational changes that result in unfolding and partial misfolding that is
associated with the tendency to aggregate. During aggregation, proteins can obtain a range of different structural appearances,
which are generally enriched in cross-! structure, including intermediates varying from unordered amorphous aggregates to
ordered fibrils that are called amyloid.
4 Vol. 22 July 2008 HERCZENIK AND GEBBINKThe FASEB Journal
Figure 6. Protein misfolding and aggregation. Printed from Herczenik & Gebbink 2008 
with permission.
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be  shorter  or  longer  (21-­89  aa)  or  sometimes  span  the  whole  protein  (Levin  et  al.  
1973,  Westermark  1982,  Westermark  et  al.  1987,  Prelli  et  al.  1991,  Kisilevsky  and  
Young  1994).  The  N-­terminus  usually  remains  intact  or  lacks  at  most  one  or  two  aa  
(Röcken  and  Shakespeare  2002).  It  is  not  completely  clear  whether  SAA  dissociates  
??????????????????????????????????????????????????????????????????????????????
????????????????????? ???????????????????????????????????????????????????????????????
and  also  the  fact  that  degradation  of  SAA  in  vivo  is  hindered  in  the  presence  of  HDL  
(Bausserman  and  Herbert  1984),  suggest  that  the  dissociation  from  HDL  takes  place  
?????????????????????? ?????????????????????????????????????????????in  vitro,  it  may  
????????????????????????????????????????????????????????????????????????et  al.  2002).  
In  addition  to  the  experimental  and  transgenic  mouse  models  of  AA  amyloidosis  
(Kindy  and  De  Beer  1999,  Solomon  et  al.  1999),  AA  amyloidosis  has  been  induced  in  
several  cell  types  including  mouse  and  human  peritoneal  cells,  human  peripheral  
blood  monocytes  and  J774  macrophages  (Kluve-­Beckerman  et  al.  1999,  Kisilevsky  
et  al.  2004,  Magy  et  al.  2007).
???????????????????????????????????????????????????????????????????????
determinant  of  amyloid  formation.  Either  the  replacement  of  a  single  amino  acid  
(Gly8-­>Asp8)  or  the  deletion  of  the  whole  stretch  diminishes  or  inhibits  amyloid  
????????????????in  vitro  (Westermark  et  al.  1992,  Patel  et  al.  1996).  Consistent  with  
this,  the  constitutively  expressed  and  non-­amyloid-­related  C-­SAA  as  well  as  mouse  
Saa  isotypes  Saa2.1  and  Saa2.2  lack  glycine  at  the  corresponding  position  (Watson  
et  al.  1992).  In  mice,  only  Saa1.1  can  be  found  in  amyloid  deposits  (Yamamoto  and  
Migita  1985;;  note:  Saa1.1  was  called  Saa2  at  the  time  of  this  publication),  while  
Saa2.1   is  principally  absent.  Saa2.2,  on  the  other  hand,   is   the  sole  Saa   isoform  
expressed  in  the  amyloid-­resistant  CE/J  mouse  (De  Beer  et  al.  1993,  Sipe  et  al.  1993).  
It  is  not  clear,  though,  whether  the  absence  of  Saa2.2  in  the  deposits  is  due  to  the  
???????????????????????????????????????????????????????????????et  al.  2002,  Patke  et  
al.  2012).  The  central  region  of  SAA  may  also  play  a  role  in  amyloid  formation  since  
SAA1  and  its  isoforms  are  predominantly  found  in  AA  deposits  even  though  the  
N-­termini  of  human  SAA1  and  SAA2  are  identical  (Liepnieks  et  al.  1995).
The involvement of macrophages
According  to  the  current  understanding,  the  impaired  proteolytic  digestion  
of   SAA  may   be   the  major   contributor   to   the   development   of   AA   amyloidosis.  
Macrophages  that  promptly  internalize  SAA  have  been  implicated  in  the  process  
(Magy  et  al.  2007,  Kluve-­Beckerman  et  al.  2001,  Kluve-­Beckerman  et  al.  2002).  
Under  normal  conditions  SAA  is  directed  to  the  endosomal-­lysosomal  pathway  and  
degraded.  However,  as  studies  conducted  in  the  mouse  macrophage  cell  culture  
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model  of  AA  amyloidosis  suggest,   in  the  presence  of  consistently  elevated  SAA  
concentrations  the  degradation  is  incomplete  and  SAA  intermediates  can  aggregate  
into   fibrils.   Amyloid   is   detected   first   in   intracellular   vesicles   and   later   also  
extracellularly.  Changes  in  lysomal  morphology  can  be  seen,  which  implies  that  the  
exocytosis  is  mediated  by  lysosome-­derived  vesicles  (Kluve-­Beckerman  et  al.  2001,  
Kluve-­Beckerman  et  al.  2002,  Magy  et  al.  2007).  SAA  has  also  been  shown  to  
colocalize  with  lysosomal  cysteine  proteases,  called  cathepsins,  in  the  intracellular  
milieu  (Röcken  et  al.  2006).   Indeed,  several  macrophage  or  monocyte-­derived  
enzymes  have  been  reported  to  degrade  SAA  in  vitro.  These  include  serum  serine  
proteases  such  as  thrombin,  kallikrein  and  plasmin;;  metalloproteinases  such  as  
collagenase,  stromelysin  and  elastase  (Uhlar  and  Whitehead  1999);;  and  several  
cathepsins  (B,  D,  G,  K  and  L)  (Yamada  et  al.  1995a,  Yamada  et  al.  1995b,  Elliott-­
Bryant  et   al.   1998,  Röcken  et   al.   2005,  Röcken  et   al.   2006).  Cathepsin  B   can  
produce  the  76-­aa  AA  protein  most  commonly  found  in  AA  deposits  (Yamada  et  al.  
1995b)   as  well   as   a   significant   portion   of   other   AA   proteins   reported   to   date  
(Röcken  et  al.  2005).  However,  since  the  inhibition,  or  knock-­out,  of  cathepsin  B  
does  not  inhibit  the  amyloid  formation  in  human  cell  cultures  or  in  vivo  in  mice  
(Röcken  et  al.  2006,  van  der  Hilst  et  al.  2009),  it  may  be  that  cathepsin  B  only  
mediates   AA   peptide   formation   without   affecting   the   actual   amyloid   load.  
Cathepsin   L,   on   the   other   hand,   has   been   identified   as   a   potential   amyloid-­
promoting  protease.  Furthermore,  it  has  been  suggested  to  function  as  a  proteolytic  
activator  of  SAA  as  it  releases  the  C-­terminal  region  of  SAA  implicated  in  the  nCEH  
enhancement   (Röcken  et  al.  2006,  Kisilevsky  and  Tam  2003,   see  also  chapter  
2.5.1).  Elastase  and  cathepsins  D  and  K  digest  SAA  mainly  in  its  amyloidogenic  
N-­terminus  and  do  not  form  AA  proteins  (Westermark  et  al.  1992,  Yamada  et  al.  
1995a,  Yamada  et  al.  1995b,  Patel  et  al.  1996,  Röcken  et  al.  2005,  Röcken  et  al.  
2006,   van  der  Hilst  et  al.   2009).  Thus,   they   are   likely   to  have   a  protective   or  
retarding  role  in  amyloidogenesis.  Indeed,  inhibiting  cathepsin  D  in  the  mouse  
model   of   amyloidosis   has   been   shown   to   significantly   increase   the   amyloid  
deposition  (van  der  Hilst  2011).  MMPs  1-­3  are  capable  of  degrading  both  SAA  and  
AA  fibrils  (Stix  et  al.  2001).  The  MMP  digestion  of  SAA  leaves  the  N-­terminus  
intact  and  although  AA  proteins  corresponding  to  those  generated  by  MMPs  have  
not  yet  been  detected  in  amyloid  deposits  (Röcken  et  al.  2005),  MMPs  are  thought  
to  contribute   to   the  pathogenesis  of  AA  amyloidosis.  MMPs  are  present   in  AA  
amyloid  deposits   and  SAA1   itself   can   induce   their   expression   in  mononuclear  
phagocytes  and  synovial  fibroblasts  (Migita  et  al.  1998,  O'Hara  et  al.  2004,  Lee  
et  al.  2005).  Furthermore,   there  are  differences  among  SAA   isoforms   in   their  
susceptibility  to  proteolysis  by  MMPs  (see  below).  
As   for   receptor-­linked   factors,   RAGE   has   been   implicated   in   amyloid  
accumulation  in  tissues.  The  expression  of  RAGE  is  increased  in  AA  amyloidosis,  
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mouse  Saa1.1  in  cells  originating  from  monocytes  (Yan  et  al.  2000).  Importantly,  
in  the  mouse  model  of  AA  amyloidosis  the  blockage  of  RAGE  decreases  cellular  
stress  and  splenic  accumulation  of  amyloid  (Yan  et  al.  2000).  The  activation  of  
inf lammatory  cells  by  amyloid   fibrils   can  also   represent  a  general  pathway   in  
which  induced  proinflammatory  mediators  function  as  a  source  of  the  toxic  effects  
observed  in  amyloidosis.
Genetic factors
Polymorphisms  in  the  SAA1  genes  have  been  identified  as  risk  factors  for  AA  
amyloidosis.  Both  SAA1  and  SAA2  can  be  found  in  amyloid  deposits,  but  SAA1  
clearly   predominates   (Liepnieks   et   al.   1995,   Yamada   et   al.   1999).   Two   single  
nucleotide  polymorphisms   (SNPs)   at   exon  3   create   three  different   isotypes   of  
SAA1:  SAA  1.1  (Val52-­Ala57),  SAA  1.3  (Ala52-­Ala57)  and  SAA  1.5  (Ala52-­Val57)  
(Moriguchi  et  al.  2001).  The  frequencies  of  these  genotypes  vary  remarkably  among  
different  countries  and/or  races,  and  both  SAA1.1  and  SAA1.3  have  been  found  to  
increase  the  risk  for  AA  amyloidosis.  Caucasians  have  a  76%  frequency  for  SAA1.1  
(Moriguchi  et   al.   1999),   and  Caucasian  patients  with  FMF  and   the  SAA1.1/1.1  
genotype   carry   a   3-­   to   7-­fold   risk   for  AA  amyloidosis   (Cazeneuve  et  al.   2000,  
Gershoni-­Baruch  et  al.  2003,  Altiok  et  al.  2003,  Yilmaz  et  al.  2003).  In  contrast,  in  
the  Japanese  population  the  combination  of  RA  and  the  SAA1.3  allele  (frequency  
40%),  but  not  SAA1.1,  constitutes  a  risk  factor  of  amyloidosis  (Moriguchi  et  al.  
1999,  Baba  et  al.  1995).  RA  patients  with  the  1.3/1.3  genotype  have  been  estimated  
to  have  a  risk  8  times  higher  than  the  control  group,  and  they  also  seem  to  develop  
AA  amyloidosis  sooner  after  the  onset  of  RA  (Moriguchi  et  al.  2001).  In  addition,  
SAA1.4,  another  SAA1   isoform,  has  been  proposed  to  be  linked  to  the  uniquely  
high  prevalence  of  AA  amyloidosis  in  some  areas  of  Papua  New  Guinea  (Westermark  
et  al.  1996,  Westermark  and  Westermark  2008).  However,  the  differences  among  
the  various  alleles  and/or  ethnic  groups  and  their  vulnerabilities  to  AA  amyloidosis  
are  still  mainly  unexplained.  Differences  in  protein  secondary  structure  are  hardly  
the  cause  considering  that  SAA1.1  and  SAA1.3,  for  example,  diverge  in  one  single  
amino   acid   only   (Val52-­Ala52).   Indeed,   SNP   -­13T/C,   which   is   located   in   the  
5’-­f lanking  region  of  SAA1  and  associated  with  increased  transcriptional  activity,  
has  been  suggested  to  serve  as  a  link  among  the  different  alleles;;  the  SAA1  -­13T  
allele   is   tightly   associated  with  SAA1.1   in  Caucasians   and  with  SAA1.3   in   the  
Japanese  population  (Moriguchi  et  al.  2001,  Moriguchi  et  al.  2005),  thus  indicating  
-­13T   positivity   as   a   connecting   factor.   Another   explanation   for   the   differing  
vulnerabilities   to   AA   amyloidosis   arises   from   the   studies   in  which   SAA1.1   in  
comparison  with  SAA1.5  has  been  shown  to  be  more  susceptible  to  proteolysis  by  
MMP-­1  (van  der  Hilst  et  al.  2008).  
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Transmission and amyloid-enhancing factors in AA amyloidosis
Amyloid-­enhancing   factor   (AEF)   can   be   described   as   transferable  
amyloidogenic  activity  present  in  the  splenic  extracts  prepared  from  amyloidogenic  
mice  (Werdelin  and  Ranlov  1966,  Axelrad  et  al.  1982).  AEF  has  been  shown  to  contain  
?????? ?????????? ???? ?????????????????????? ????????????? ???????????????????
????????????????????????????????????????????????????????????????????????????????????
amyloidoisis  can  be  dramatically  shortened  from  one  month  to  one  week  (Werdelin  
and  Ranlov  1966,  Lundmark  et  al.  2002).  Similarly,  transferring  peripheral  blood  
monocytes  from  amyloidotic  mice  into  healthy  ones  induces  extensive  amyloidosis  
in  the  recipients  (Sponarova  et  al.  2008).  AEF  speeds  up  the  amyloid  deposition  also  
in  the  cell  culture  models  of  AA  amyloidosis  (Kluve-­Beckerman  et  al.  2001,  Magy  et  
al.?????????????????????????????????????????????????????????????????????????????????
and  other  amyloid  proteins  have  been  shown  to  function  in  a  similar  way  (Brissette  
et  al.  1989,  Ganowiak  et  al.  1994,  Johan  et  al.  1998,  Larsson  et  al.  2011),  indicating  
????????????????????????????????????????????????????????????????????????????????????
such  as  Escherichia  coli????????????????????????????????????????????????????????????????
AA  amyloid   formation   in   the  mouse  model  of  AA  amyloidosis   (Lundmark  et  al.  
??????? ???? ?????? ?????????????? ???????? ???? ?????????????? ??? ???????? ????????
?????????????????????????????????????????????????????????????????????????????????????
AA  amyloidosis,  at  least  in  mice,  is  considered  a  transmissible  disease  that  shows  
clear   analogy   to   prions.   In   prion   diseases   the   normal   prion   protein   PrPC   is  
transformed  into  an  abnormal,  “infectous”  PrPSc,  which  in  turn  starts  to  induce  a  
similar  transformation  in  other  PrPC  proteins  (Prusiner  1982).  Prions  are  transmitted  
by  different  routes.  As  for  the  experiments  on  the  mouse  models  of  AA  amyloidosis,  
??????????????????????????????????????????? ????????????????? ???????????????????
However,  oral  transmission  via  drinking  water  as  well  as  goose-­derived  foie  gras,  
has  also  been  reported  (Lundmark  et  al.  2002,  Solomon  et  al.  2007).
Another  group  of  potent  amyloid-­enhancing  factors  consists  of  HS  and  its  
derivative  heparin,  which  are  found  in  mature  amyloid  fibrils,  in  the  ECM  and  on  
cell  surfaces  (Bellotti  and  Chiti  2008,  Motamedi-­Shad  et  al.  2012).  HS  has  been  
shown  to  bind  Saa1.1  in  vitro  and  to  accelerate  AA  fibril  formation  by  increasing  
?????????????????????????????????????et  al.  1988).  In  terms  of  the  mechanism,  it  
has  been  shown  that  GAGs  have  a  higher  affinity  for  oligomeric  amyloidogenic  
proteins  than  for  their  monomeric  forms.  Binding  increases  the  density  of  negative  
charges  on  the  GAG  surface,  which  in  turn  promotes  protein  aggregation  (Castillo  
et  al.  1998,  Suk  et  al.  2006).  Besides  SAA  and  HS,  a  similar  effect  has  also  been  
reported  for  the  interaction  between  HS/heparin  and  several  other  amyloidogenic  
proteins  (McLaurin  et  al.  1999,  McLaughlin  et  al.  2006,  Suk  et  al.  2006).  
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3.2  SAA  and  atherosclerosis
SAA  has  been  implicated  in  several  stages  of  atherosclerosis  (King  et  al.  2011).  The  
plasma  levels  of  SAA,  and  also  of  the  SAA-­LDL  complex,  correlate  with  the  risk  of  
cardiovascular  disease  (Jousilahti  et  al.  2001,  Johnson  et  al.  2004,  Ogasawara  et  
al.  2004).  Furthermore,  in  hyperlipidemic  mice,  the  SAA  concentration  correlates  
directly  with  the  size  of  atherosclerotic   lesions,   independent  of   the  cholesterol  
concentration  in  plasma  (Lewis  et  al.  2004,  Dong  et  al.  2011b).  SAA  protein  can  be  
found  in  atherosclerotic  lesions,  resulting  from  infiltration  or  local  expression  by  
ECs,  foam  cells,  SMCs,  adventitial  macrophages  and  adipocytes  (Meek  et  al.  1994).  
In  the  lesions,  SAA  colocalizes  with  apo  B,  apoA-­I  and  proteoglycans  (Lewis  et  al.  
2004,  Yamada  et  al.  1996,  O’Brien  et  al.  2005).  SAA  can  accelerate  inflammation  
in  the  arterial  wall  by  attracting  inflammatory  cells  to  the  site  and  by  inducing  the  
expression  of  cytokines,  chemokines  and  other  mediators.  In  addition,  SAA  might  
contribute   to   lipid   accumulation  by  promoting  both   lipoprotein   retention   and  
internalization  as  well  as  to  lesion  destabilization  by  inducing  the  expression  of  ECM  
degrading  enzymes.  These  features  are  discussed  in  more  detail  in  the  next  three  
sections  and  summarized  in  Figure  7.
3.2.1  The  clinical  and  pathological  characteristics  of  atherosclerosis
Atherosclerosis  is  the  most  common  form  of  cardiovascular  disease  (CVD).  
With  its  variable  clinical  manifestations,  CVD  is  the  principal  cause  of  death  in  the  
US,  Europe  and  most  of  Asia,  killing  nearly  20  million  people  in  the  world  annually.  
In  Europe,  CVD  accounts  for  over  4.3  million  deaths  per  year  and  represents  48%  
of  all  deaths  (Lopez  et  al.  2006).  Despite  the  available  drug  therapies,  such  as  statin  
treatment  (Baigent  et  al.  2005),  70%  of  the  clinical  events  cannot  be  prevented,  and  
10%  of  them  occur  in  seemingly  healthy  individuals  (Greenland  et  al.  2003).  
????????????????????????????????????????? ????????????????????????????????????
layer  of  the  arterial  wall.  It  can  be  characterized  by  a  progressive  accumulation  of  
???????????????????????????????????????????????????????????????????????????????
within  the  intima  and  by  the  subsequent  formation  of  atherosclerotic  lesions.  The  
lesions  mainly  affect  large  and  medium-­sized  muscular  arteries  (Fuster  et  al.  2005).  
??????????????????????????????????????????????????????????????????????????????????
formation  of  so-­called  fatty  streaks,  the  earliest  type  of  lesions  (Stary  et  al.  1994,  
Napoli  et  al.  1997).  The  fatty  streaks  are  composed  of  macrophage-­derived  foam  cells  
(see  below)  and  T  cells,  and  they  generally  contain  very  little  extracellular  lipid.  At  
this  stage,  the  disease  is  asymptomatic  and  will  not  become  clinically  overt  for  many  
years.  If  a  consistent  accumulation  of  lipids  continues,  it  will  lead  to  the  thickening  
of  the  intima  and  the  formation  of  a  lesion.  An  advanced  atherosclerotic  lesion  is  
???????????? ??????????????? ??????????????????????????????????????????????????????????
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???????????????????????????? ?????????????????????????????????????????????????????????
SMCs,  which  have  migrated  from  the  media  (the  middle  layer  of  the  arterial  wall),  
and  of  components  of  the  ECM,  such  as  collagen  and  proteoglycans.  Depending  on  
the  vulnerability  of  the  lesion,  which  is  principally  determined  by  the  thickness  of  
???????????????????????????????????????????????????????????????????????????????????
to  acute  occlusion,  which  is  caused  by  a  lesion  rupture  and/or  thrombus,  and  can  
lead  to  myocardial  infarction  or  stroke  (Lusis  2000).  Besides  the  architecture  of  the  
plaque,  ECM  degradation  by  macrophage-­  or  mast  cell-­derived  proteases  as  well  as  
????????????????????????????????????????????????????
3.2.2  Lipid  accumulation  in  atherosclerosis
In  advanced  atherosclerotic  lesions,  lipids  can  be  found  in  two  forms:  either  
as  intracellular  lipid  droplets  inside  foam  cells  or  as  extracellular  lipid  deposits  
that  form  the  lipid  core  of  the  lesion.
Lipoprotein retention 
The   extracellular   lipid   in   the   lesions   is   generated   via   the   retention   of  
lipoproteins  from  the  circulation  or  via  lipid  release  from  dying  foam  cells,  and  it  is  
mainly   stored   as   lipid   droplets   (Kruth   1997),   besides   which   the   crystal-­form  
cholesterol  may  also  be  present  (Abela  et  al.  2009,  Duewell  et  al.  2010).  The  retention  
?????????????????????????????????????????????????????????????????????????????????????
(Steinberg   et   al.   1985).   This   occurs   via   transcytosis,   which   is   a   non-­selective  
endocytic  pathway  utilizing  pinocytic  vesicles,  or  by  passing  between  the  ECs  (Kao  
et  al.   1995).  Once   in   the   intima,   the   lipoproteins  are  bound  and   trapped  by   the  
????????????????????????????????????????????????????????????????????????????????
fractions   of   the   lipoproteins   (Hurt-­Camejo   et   al.   1990).   Then,   the   trapped  
?????????????? ???????????? ????? ???? ?????????? ??? ?????????????????????? ????? ???
proteolytic  or  lipolytic  processing  or  oxidation  (Öörni  et  al.  2000).  The  members  of  
the   sPLA2   family,   which   exhibit   variable   lipolytic   activities,   contribute   to   the  
????????????????????????????????? ?????????????? ??????????????????et  al.  2008,  
????????????????????????????? ???????????????????????????????????????????????
???????????? ???? ?????? ???????????? ??????? ???????????????????????????????????
become  prone  to  aggregation  and  fusion,  contributing  to  the  formation  of  the  lipid  
core  (Pentikäinen  et  al.  2000,  Hakala  et  al.  2001,  Öörni  et  al.  2005).  This  cascade,  
outlined   in   the   response-­to-­retention   hypothesis   (Williams   and   Tabas   1995,  
Williams   and   Tabas   1998),   indicates   the   proteoglycan-­mediated   lipoprotein  
retention  as  one  of  the  initial  stages  of  atherosclerosis.  
Nearly  all  lipoproteins  that  are  small  enough  (less  than  70  nm  in  diameter)  
to  be  transported  inside  the  pinocytic  vesicles  can  enter  the  intima  via  the  same  
transcytotic  pathway  as  LDL  (Kruth  2001).  Due  to  the  lack  of  apoB  and  low  amounts  
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of  apoE,  however,  HDL  particles  are  not  retained  in  the  ECM  as  efficiently.  Instead,  
they  move  through  the  intima,  acquire  cholesterol  from  foam  cells,  and  enter  the  
lymphatic   system  within   the  media   (Nanjee   et   al.   2001).   In   the   intima,  HDL  
particles  can  also  inhibit  the  oxidation  of  the  proteoglycan-­bound  LDL  (Barter  et  
al.  2004).  However,  apoA-­I  can  be  found  in  atherosclerotic  lesions,  colocalized  
with   apoB   and   proteoglycans   in   both   humans   and  mice   (O’Brien   et   al.   1998,  
Kunjathoor  et  al.  2002,  O’Brien  et  al.  2005),   indicating  retention.  SAA  carries  
binding  sites  for  proteoglycans  (Ancsin  and  Kisilevsky  1999,  Elimova  et  al.  2009)  
and  could,  thus,  promote  the  retention  of  AP-­HDL.  Indeed,  the  role  of  SAA  as  a  
mediator  of  the  HDL-­proteoglycan  interaction  is  supported  by  a  number  of  studies  
(O’Brien  et  al.  2005,  Wilson  et  al.  2008,  Chiba  et  al.  2011).  Similarly,  the  presence  
of  SAA  on  LDL  (Ogasawara  et  al.  2004)  can  promote  LDL  retention  by  increasing  
the  number  of  proteoglycan  binding  sites  on  the  particle.  SAA  also  induces  the  
synthesis  of  proteoglycans  in  SMCs,  biglycan  in  particular,  via  the  induction  of  
??????????? ?????? ???????? et   al.   2002,   Wilson   et   al.   2008).   Although   all  
proteoglycans   can   bind   LDL   and   many   of   them   have   been   implicated   in  
atherogenesis,  biglycan  is  the  proteoglycan  most  often  found  to  be  colocalized  with  
apoB  (O’Brien  et  al.  1998,  Nakashima  et  al.  2007).  In  addition,  SAA  can  modulate  
the  expression  and  release  of  sPLA2-­IIA  from  SMCs  and  also  the  enzyme  activity  
of  sPLA2  (Pruzanski  et  al.  1995,  Sullivan  et  al.  2010).  
Pathways for LDL internalization and foam cell formation 
The  filtration  of  inflammatory  cells  into  the  intima  is  another  key  event  in  
the  initiation  of  atherosclerosis.  Once  inside  the  intima,  monocytes  differentiate  
into  tissue  macrophages  in  response  to  the  local  cytokine  environment  and  start  to  
express  scavenger  receptors  that  enable  them  to  internalize  modified  lipoproteins.  
The  expression  of  TLRs  also  changes;;  an  increased  expression  of  TLR1,  TLR2  and  
TLR4  on  macrophages  and  ECs  can  be  detected  in  atherosclerotic  intima  compared  
with  normal  intima  (Xu  et  al.  2001,  Edfeldt  et  al.  2002).
Macrophages  acquire  intracellular  lipid  via  two  kinds  of  pathways:  receptor-­
mediated  and  receptor-­independent  pathways.  The  uptake  of  native  LDL  proceeds  
mainly  via  the  LDL-­receptor  (LDLR).  However,  due  to  the  downregulation  of  LDLR  
in  the  presence  of  excess  cholesterol  (the  LDL  concentration  in  the  intima  can  be  
two  times  higher  than  in  the  circulation),  differentiated  macrophages  in  the  intima  
express  LDLR  very  poorly  (Hoff  et  al.  1978,  Brown  and  Goldstein  1986).  Oxidized  
and  acetylated  LDL  particles,  on  the  other  hand,  are  internalized  via  scavenger  
receptors   (SRs),   the   expression   of   which   is   not   regulated   by   the   cholesterol  
concentration  (Goldstein  et  al.  1979,  Hoff  et  al.  1990,  Steinberg  1997,  Schrijvers  et  
al.  2007).  For  this  reason,  modified  LDL  has  for  long  been  considered  the  main  
source  of  the  lipid  in  foam  cells  (Kruth  2001),  and  the  scavenger  receptor  class  AI/
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II  (SR-­AI/II)  and  CD36  (from  the  SR-­B  family)  have  been  indicated  as  the  principal  
receptors   in   foam   cell   formation   (Suzuki   et   al.   1997,   Kunjathoor   et   al.   2002,  
Rahaman  et  al.  2006).  Recent  data,  however,  underscore   the   role  of   receptor-­
independent  and  non-­selective  pathways,  such  as  f luid-­phase  pinocytosis,  in  lipid  
accumulation  and  suggest  that  native  LDL  may  similarly  serve  as  source  material  
for  foam  cells  (Kruth  2011).  
Medial  SMCs  that  have  migrated  into  the  intima  can  also  internalize  lipids  and  
become  foam  cells  (Llorente-­Cortes  et  al.  1998).  As  in  macrophages,  the  expression  
of  LDLR  is  downregulated  by  excess  LDL,  and,  thus,  the  contribution  of  native  LDL  
to   foam  cell   formation   is  minimal.   Instead,   lipids   in  SMC  foam  cells  are  mainly  
derived  from  aggregated  LDL  that  is  taken  up  by  LDLR-­related  protein  1  (Llorente-­
Cortes  et  al.  2000).  Curiously,  SAA  has  been  shown  to  be  chemotactic  for  aortic  SMCs  
(Kumon  et  al.  2002b)  and  also  to  increase  the  uptake  of  cholesterol  into  these  cells  in  
vitro  (Liang  et  al.  1996),  suggesting  a  direct  role  for  SAA  in  foam  cell  formation.
Under  normal  conditions  the  internalized  lipoproteins  are  degraded  by  
lysosomal   enzymes,   such   as   cathepsins   and   lipases,   inside   the   lysosomes.  
OxLDL,  though,  is  partly  resistant  to  lysosomal  enzymes  (Jessup  and  Kritharides  
2000)  and  can  also  reduce  their  activity  (Hoppe  et  al.  1994,  O’Neil  et  al.  2003).  
Subsequently  the  protein  fractions  are  secreted  out  of  the  cell,  and  the  cholesterol,  
if   not   directed   to   cellular  membranes,   is   re-­esterified   by  ACAT   and   stored   in  
cytosolic  lipid  droplets  (Brown  and  Goldstein  1986),  as  mentioned  in  chapter  2.5.1.  
If  the  uptake  of  large  amounts  of  lipoproteins  continues,  exceeding  the  limits  the  
RCT  pathway,  macrophages  turn  into  foam  cells;;  the  lipid  droplets  can  occupy  most  
of  the  cytoplasm,  and  the  cells  have  a  foamy  appearance  (Pasquinelli  et  al.  1989).  
Foam  cells  eventually  die  by  apoptosis  (Akishima  et  al.  2005),  contributing  to  the  
formation  of  the  lipid  core.  
????????????????????????????????????????????
Despite   the   wide   acceptance   of   the   response-­to-­retention   hypothesis  
(Williams  and  Tabas  1995,  Williams  and  Tabas  1998)  and  the  causative  role  of  
cholesterol   in  atherosclerosis,  many  factors  also  challenge  this  paradigm.  
One   half   of   all   heart   attacks   and   strokes   occur   among   individuals   without  
hypercholesterolemia,   and   extensive   experimental   evidence   suggests   that  
inflammation  is  actually  a  key  contributor  to  all  stages  of  the  disease  (Libby  et  al.  
2009,  Libby  2012).  The  inflammatory  aspect  of  atherosclerosis  has  gained  more  
and  more  attention  during   the   last   10  years,   initiated  by   the   landmark  article  
“Atherosclerosis  –  An  Inflammatory  Disease”  by  Russell  Ross  in  1999  (Ross  1999).  
Prior  to  this,  Ross  and  his  colleagues  had  already  proposed  a  model  stressing  the  
importance  of  endothelial  dysfunction  in  the  development  of  atherosclerosis  (Ross  
1993).   Indeed,   even   in   healthy   arteries   some   regions   are   more   prone   to  
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atherosclerosis   than  others.  These  are   typically  branches  or   curvatures  where  
laminar  blood  f low  might  become  disturbed  or  oscillated.  A  mere  reduction  in  
?????????????????????????????????????????????????????????????????????????????????
(Hajra  et  al.  2000).  Furthermore,  studies  conducted  on  rabbits  and  homozygous  
apoE-­deficient  mice  demonstrate  that  exposure  to  a  hypercholesterolemic  diet  can  
result   in  the  upregulated  expression  of  adhesion  molecules   in  the   lesion-­prone  
areas   prior   to   any   detectable   lesion   formation   or   overlying   very   early   lesions  
(Cybulsky  and  Gimbrone  1991,  Li  et  al.  1993,  Nakashima  et  al.  1998,  Iiyama  et  al.  
1999).   The   role   of   proinf lammatory   cytokines   and   other   mediators   in  
??????????????????????????????????????????????????????? ???????????????????????????
???????????? ???????? ????????????????????????????????????????????????et  al.  1995,  
Gu  et  al.  1998,  Kirii  et  al.  2003,  Ohta  et  al.  2005,  Smith  et  al.  2010).  Importantly,  
several  PRRs,  particularly  TLR1,  TLR2  and  TLR4,  are  expressed  at  higher  levels  in  
ECs,  macrophages  and  SMCs  in  the  atherosclerotic  intima  than  in  normal  intima  
(Xu  et  al.  2001,  Edfeldt  et  al.  2002,  Vink  et  al.  2002,  Otsui  et  al.  2007).
??????????????????? ?????????????? ???????????????????????????????????????????
can   have   an   impact   on   the   endothelium   and   disturb   its   normal   homeostatic  
functions   (Sattar   et   al.   2003).   This   partly   explains   why   chronic   systemic  
?????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????
(Myasoedova  and  Gabriel  2010,  Skaggs  et  al.  2012).  In  fact,  cardiovascular  disease  
is  the  major  cause  of  death  in  RA  (Avina-­Zubieta  et  al.?????????????????????????????
can  promote  the  development  of  atherosclerosis  also  by  inducing  changes  in  the  size  
and  density  of  LDL  (Khovidhunkit  et  al.  2004)  and  by  enhancing  the  oxidation  of  
LDL  by  macrophages  and  ECs  (Maziere  et  al.  1994).  The  involvement  of  the  innate  
immune  system  is  further  highlighted  by  the  fact  that  APPs,  such  as  CRP  and  other  
pentraxins  as  well  as  SAA,  have  been  indicated  as  both  risk  predictors  (Morrow  et  
al.  2000,  Jousilahti  et  al.  2001,  Johnson  et  al.  2004,  Tsimikas  et  al.  2006)  and  
active  mediators  of  atherosclerosis  (Ridker  et  al.  2002).  In  hyperlipidemic  mice,  the  
SAA   concentration   has   been   shown   to   correlate   directly   with   the   size   of  
atherosclerotic   lesions,   independent  of   the  cholesterol   concentration   in  plasma  
(Lewis  et  al.  2004,  Dong  et  al.  2011b),  indicating  SAA  as  an  atherosclerotic  factor.
Cell recruitment and inflammatory cascades in atherosclerosis
Inf lammation   in   atherosclerotic   lesions   represents   a   complex   set   of  
interactions  between  inf lammatory  cells,  ECs  and  SMCs,  connected  by  a  number  
of   mediators   and   inducers   at   different   levels.   The   inf lammatory   cascade   is  
initiated  by  endothelial  dysfunction  (Gimbrone  et  al.  2000),  a  condition  involving  
oxidative   stress,   the   generation   of   ROS   and   a   subsequent   reduction   in   the  
endothelial  production  of  NO.  NO   is  an   important   regulator  of  vascular   tone,  
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platelet  and  leukocyte  interactions  and  vascular  SMC  proliferation  (Ignarro  et  al.  
1987,  Azuma  et  al.  1986,  Kubes  et  al.  1991,  Tanner  et  al.  2000).  Oxidative  stress  
and  endothelial  dysfunction  can  result  from  several  factors  including  high  levels  
of  LDL,  free  radicals  caused  by  smoking,  hypertension,  disturbed  blood  f low  and  
infectious  agents  (Ross  1999,  Libby  et  al.  2009).  In  chronic  systemic  inflammatory  
???????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????et  al.???????????????
for   example,   reduces   the   bioavailability   of   NO   (Yoshizumi   et   al.   1993)   and  
increases  endothelial  permeability  (Petrache  et  al.  2003).  Upon  activation,  ECs  
start  to  produce  adhesion  molecules  that  promote  the  adhesion  of  monocytes,  T  
cells  and  mast  cells  to  the  endothelium.  The  deposition  and  oxidation  of  LDL  in  
the  subendothelial  space  can  also  promote  the  expression  of  adhesion  molecules  
(Kume  et  al.  1992,  Watson  et  al.  1997)  and  proinf lammatory  cytokines  in  ECs  
(Leitinger  2003,  Matsuura  et  al.  2006).
The   adhesion   of   monocytes,   the   most   abundant   inf lammatory   cells   in  
atherosclerorotic  lesions,  is  mainly  mediated  by  vascular  cell  adhesion  molecule  1  
(VCAM-­1).  Adherent  monocytes  then  enter  the  intima  via  diapedesis  following  a  
chemoattractant  gradient  formed  by  EC-­derived  chemotactic  proteins  such  as  MCP-­
1  and  IL-­8  (Libby  2002).  Within  the  intima,  monocytes  differentiate  into  tissue  
macrophages  in  response  to  M-­CSF  and  GM-­CSF,  which  are  also  produced  by  
the  activated  ECs,  or  their  combination  (Rajavashisth  et  al.  1990).  Macrophages  
replicate  in  the  intima  and  can  become  foam  cells  following  a  continuous  uptake  of  
?????????????????? ????????????????????????????????????????????????????????????
?????????????????????????????? ?????? ?????????????????????????????????????????????
as  well  as  ROS,  growth  factors  and  MMPs  (Østerud  and  Bjørklid  2003).  The  secreted  
cytokines  and  other  mediators  stimulate  the  migration  of  medial  SMCs  into  the  
intima  and  the  subsequent  production  of  ECM  proteoglycans  (Lusis  2000).
T   cells,   like  monocytes,   enter   the   intima  mainly   via   VCAM-­1-­mediated  
?????????????????????????????????????????????????????????????????????????????????
??????????? ??? ???? ???? ???????? ???????????????? ???????? ??? ?????? ???? ????
???????????????????????????????????????????????????????????????????????????????????
such  as  oxLDL,  heat-­shock  proteins  and  microbial  surface  proteins  (Rocha  and  
Libby  2009).  Upon  activation,  T  cells  can  polarize  into  two  subtypes  of  secretory  
??????????????????????? ??????????????????????????????????????????????????????????
????????h1  cells),  or  those  secreting  mainly  anti-­inflammatory  cytokines,  such  as  
IL-­10  and  IL-­4  (Th2  cells)  (Libby  2002).  These  cytokines  may  modify  the  expression  
patterns  of  other  cell  types,  such  as  macrophages,  if  present.  Besides  Th1  and  Th2  
cells,  Th17  and  Treg  subtypes  have  been  identified  (Rocha  and  Libby  2009,  Chen  
and  Nunez  2010).  
Mast  cell  progenitors  are  recruited  from  the  circulation  by  eotaxin  and  stem  
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cell  factor  (SCF)  (Miyamoto  et  al.  1997,  Haley  et  al.  2000),  the  latter  of  which  also  
mediates   their   differentiation   into   tissue   mast   cells   (Galli   et   al.   2011).   The  
preformed  as  well  as  de  novo  synthesized  proinflammatory  cytokines  and  growth  
factors  (chapter  1.1.1)  released  from  mast  cells  amplify  the  inf lammation  in  the  
intima.  In  addition,  released  histamine  can  enhance  the  permeability  of  the  ECs  
and  thus  promote  an  easier  entry  for  more  lipoproteins  (Ma  and  Kovanen  1997).
SAA  is  potentially  involved  in  nearly  all  stages  of  arterial   inf lammation.  
Starting   from   the   endothelial   level,   SAA   has   been   shown   to   increase   ROS  
????????????????????????????????????????????????????????????????????????in  vitro,  
and  it  could,  thus,  induce  endothelial  dysfunction  (Björkman  et  al.  2008,  Wang  et  
al.  2008,  Witting  et  al.  2011).  The  chemoattractant  properties  of  SAA  may  enable  
it  to  mediate  the  migration  of  phagocytes,  T  cells,  mast  cells  and  monocytes  and  to  
promote  their  adhesion  to  the  endothelium  and  their  infiltration  into  the  intima  
(Dong   et   al.   2011b,   Badolato   et   al.   1994,   Badolato   et   al.   1995,  Xu   et   al.   1995,  
Preciado-­Patt  et  al.  1996a,  Olsson  et  al.  1999,  Su  et  al.  1999).  In  addition,  SAA  
promotes  the  release  of  MCP-­1  from  both  PBMCs  and  ECs  (Song  et  al.  2009,  Lee  et  
al.  2010),  which  would  further  increase  the  recruitment  of  inflammatory  cells.  In  
????????????????????????????????????????????????????????????????????????????????
?????????????????????? ??????????? ???????????????????????????????????????? ??????????
macrophages  and  neutrophils  (see  chapter  2.4.2  for  more  details).  Besides  this,  
foam  cells  have  been  reported  to  secrete  SAA  (Meek  et  al.  1994).  The  mechanisms  
by  which  SAA  has  been  suggested  to  affect  the  development  of  atherosclerosis  are  
summarized  and  illustrated  in  Figure  7.
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Figure 7. The involvement of SAA in the development of an atherosclerotic lesion. 
SAA is potentially involved in several steps in the formation of an atherosclerotic lesion. 
On the endothelial level, SAA promotes endothelial dysfunction and the secretion of 
MCP-1 and acts as a chemoattractant for leukocytes. In the intima, SAA-associated 
LDL and also HDL are more efficiently trapped by proteoglycans. SAA activates resident 
macrophages, which leads to the secretion of proinflammatory cytokines and further 
local inflammation. SAA also induces the synthesis of biglycan and sPLA2 by SMCs, 
enhancing lipoprotein retention and modification, and promotes the migration of SMCs 
and their lipid uptake, which may promote SMC foam cell formation. SAA also induces 
the production of MMPs and might, thus, contribute to the destabilization of the lesion. 
The data are derived from King et al. 2011 and from the references mentioned in the 
text. GM-CSF, granulocyte-macrophage colony-stimulating factor; HDL, high-density 
lipoprotein; IFN, interferon; IL, interleukin; LDL, low-density lipoprotein; MCP-1, 
monocyte chemoattractant protein 1; M-CSF, macrophage colony-stimulating factor; 
MMP, matrix metalloproteinase; NO, nitric oxide; ROS, reactive oxygen species; SAA, 
serum amyloid A; SMC, smooth muscle cell; sPLA2, secretory phospholipase A2; TNF, 
tumor necrosis factor; VCAM, vascular cell adhesion molecule.
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III Aims of this Study
The aim of this study was to elucidate the interaction between Serum amyloid A 
(SAA) and cells of the innate immune system, to study the consequences of this 
interaction in terms of AA amyloidosis and atherosclerosis, and to explore the 
regulation of the proinflammatory activity of SAA in inflammation.
The specific aims can be outlined as follows:
1) to study whether SAA can induce the activation and degranulation of mast cells 
and to research the consequences of this activation, with an emphasis on amyloid 
formation
2) to elucidate whether SAA is able to activate human macrophages and to 
investigate the mechanisms underlying this activation, with an emphasis on the 
inflammasome function, and
3) to explore the impact of native and oxidized lipoproteins on the proinflammatory 
activity of SAA.
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IV Materials and Methods
The methods used in this study are summarized in Table 2. Detailed descriptions can 
be found in the original publications and/or reference material, as indicated. Only 




Cell cultures and cell stimulation
Isolation, maturation, culture and stimulation of human mast cells I Saito et al. 2006
Culture and stimulation of the HMC-1 cell line I Butterfield et al. 1988
Isolation, differentiation, culture and stimulation of human 
macrophages II & III
Nakanishi et al. 
2009
Isolation and stimulation of mouse peritoneal macrophages from wild-
type and ASC-deficient mice II
Isolation, differentiation and stimulation of mouse bone marrow-
derived macrophages from wild-type and ASC-deficient mice II
Culture, differentiation and stimulation of THP-1 cells II & III
Fluorescence imaging of cathepsin B and lysosomes in THP-1 cells II BIOMOL
Small interfering RNA (siRNA) experiments II Qiagen
Animals
Induction of sterile peritonitis in C57BL/6J mice III
Enzyme-linked immunosorbent assay (ELISA) for human IL-1ß, TNF-? and 
histamine and for mouse IL-1ß I, II & III
R&D Systems, IBL, 
BioLegend
Quantitative real time reverse transcriptase polymerase chain reaction 
(qRT-PCR) II & III
Western blotting II
Gel electrophoresis
   Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) II Laemmli et al. 1970
   Tricine-SDS-PAGE I Schagger and von Jagow 1987
High-performance liquid chromatography with tandem mass spectrometry 
(HPLC-MS/MS) I
Degradation/digestion of SAA in vitro I
Transmission electron microscopy (TEM) I
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Lipoprotein preparations
Isolation of LDL and HDL3 from plasma III
Havel et al. 
1955
Copper oxidation of LDL and HDL3 III
Lipid extraction from LDL III Folch et al. 1957
Preparation of lipid microemulsions III Ginsburg et al. 1982
TBARS analysis III Hessler et al. 1983
Lowry assay III Lowry et al. 1951
SAA-lipoprotein complex formation III
Thin layer chromatography (TLC) III
Statistical analyses (one-way ANOVA with post tests) I, II & III
Table 2 Methods used in the present study
The assessment of the distribution of SAA in lipoprotein classes 
???????????????? ??? ????? ?????????????????????????????????????????????????????
and  incubated  for  2  hours  at  +37°C.  After  this,   lipoproteins  were  fractioned  by  
sequential  ultracentrifugation  (Havel  et  al.  1955)  and  the  amount  of  SAA  in  each  
fraction  was  determined  by  a  commercial  enzyme-­linked  immunosorbent  assay  
(ELISA)  kit  for  human  SAA  (Invitrogen).
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V Results and Discussion
1. SAA activates cells of the innate immune system 
(Studies I & II)
Experiments in the present study were mostly conducted using a recombinant human 
SAA protein, the amino acid sequence of which corresponds to the sequence of SAA 
1.1 except for the addition of Met at the N-terminus, the substitution of Asp for Asn 
at position 60 and the substitution of His to Arg at position 71. In addition, human 
SAA derived from plasma was used. 
1.1  SAA  activates  HMC-­1  cells  and  human  mast  cells
The  induction  of  cytokine  production  by  SAA  was  studied  using  
the  human  mast  cell  line  (HMC-­1),  the  only  established  cell  line  
that   resembles   human   mast   cells   in   terms   of   phenotype  
(Butterfield   et   al.   1988,  Nilsson   et   al.   1994).   SAA   induced   a  
????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????
strong  as  or  even  higher  than  what  was  achieved  by  chemical  
activation   with   a   combination   of   phorbol-­12-­myristate-­13-­
acetate  (PMA),  which  is  a  protein  kinase  C  (PKC)  activator,  and  a  
Ca2+  ionophore.  Interestingly,  using  a  combination  of  chemical  
activation  and  SAA  stimulation  resulted  in  further  stimulation  
??????????????????????????????????????????????????????????????
not   mediated   via   the   same   pathway,   i.e.   G   protein   or   PKC  
signalling.  Human  albumin  and  heat-­inactivated  SAA  failed  to  
reproduce  the  induction,  implying  that  the  effect  is  specific  for  
and   dependent   on   the   native   conformation   of   SAA   (Study   I,  
figure  1).  Although  HMC-­1  cells  resemble  human  mast  cells  in  
????? ?????????? ????? ??? ???? ???????? ??????? ?????? ???????????
Thus,   the   effect   of   SAA   on   IgE-­induced   degranulation   was  
studied  in  human  mast  cells  (huMCs)  that  were  derived  from  
cord   or   peripheral   blood   CD34+   progenitor   cells.   A   low   but  
dose-­dependent   release  of  histamine   in   the  presence  of  SAA  
was  observed  (Study  I,  figure  2),  confirming  the  degranulation  
in  response  to  SAA.  
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Despite  the  common  factors,  such  as  RA,  there  is  still  very  little  data  on  
the  direct  interaction  between  SAA  and  mast  cells.  The  SAA-­induced  adhesion  
of   mouse   mast   cells   to   ECM   components   (Hershkoviz   et   al.   1997)   and   the  
chemotaxis  of  HMC-­1  cells  and  huMCs  (Olsson  et  al.  1999)  have  been  described.  
The  SAA  chemotaxis  appears  to  depend  on  the  Gi  class  G  proteins  as  the  effect  is  
sensitive  to  pertussis-­toxin  (PTX)  as  well  as  to  inhibitors  of  tyrosine  kinase  and  
PKC  (Olsson  et  al.???????????????????????????????????????????? ???????????????
the  release  of  histamine  from  huMCs  described  here  are  novel  findings  as  no  MC  
mediator   release   in   response   to   SAA  has   been   reported   before.   In   contrast,  
Hershkowiz  et  al.  concluded  that  SAA  is,  in  fact,  unable  to  activate  mouse  mast  
cells   (Hershkoviz   et   al.   1997).   This   controversy,   however,   might   be   due   to  
species-­related  differences.  Furthermore,  the  involvement  of  G  proteins  and/or  
tyrosine  kinases  seems  to  characterize  the  SAA-­induced  mast  cell  adhesion  and  
chemotaxis   (Hershkoviz   et   al.   1997,   Olsson   et   al.   1999),   whereas   our   data  
suggests  that  the  activation  of  mast  cells  by  SAA  is  not  dependent  on  G  protein  
signalling.  Thus,  the  two  different  types  of  activities  would  also  be  mediated  via  
separate  pathways.  
The  molecular  mechanisms  involved  in  the  effect  of  SAA  on  mast  cells  were  
not  elucidated  further  in  Study  I.  Interestingly,  NLRP3,  although  predominantly  
expressed  in  monocytes,  granulocytes  and  chondrocytes  (Feldmann  et  al.  2002,  
Manji  et  al.???????????? ????????????????????????????????????????????????????????
by  the  mast  cells  of  CAPS  patients  (Nakamura  et  al.  2009,  Kambe  et  al.  2010).  
Furthermore,   using  mouse   bone  marrow-­derived  mast   cells  Nakamura   et   al.  
demonstrated   that   mast   cells   carrying   a   CAPS-­associated  NLRP3   mutation  
??????????????????????????????????????????????????????????????????????????????
?????????????????????????????? ?????????????????????????? ?????????????????????
et  al.  2009).  Importantly,  the  combination  of  LPS  priming  and  NLRP3  activation  
?????????????????????????????????????????????????????????????????????????et  al.  
??????????????????????????????? ?????????????????????????????????????????????????
in  the  degranulation  are  differentially  regulated,  which  is  logical  considering  that  
?????? ??? ?????????????????????????????? ??????? ???????????????? ???? ???????????
histamine  and  the  presence  of  tryptase-­like  activity  in  the  cell  culture  medium  
(see  chapter  3.1  in  Results  and  discussion)  were  observed  in  the  present  study,  one  
???????????????????????????????????????????????????????????????????????????????????
human  mast   cells.   It   remains   to  be   elucidated  which   signalling  pathways  are  
employed.  Six  members  of  the  TLR  family  are  expressed  in  mast  cells:  TLR  1,  2,  
3,  4,  6  and  9  (Rao  and  Brown  2008),  and,  as  SAA  has  been  shown  to  interact  with  
TLR2  and  TLR4  (Sandri  et  al.  2008,  Chen  et  al.  2010,  He  et  al.  2009)  in  monocytic  
cells,  these  receptors  might  mediate  the  effects  of  SAA  also  in  mast  cells.
64
1.2  SAA  induces  the  release  of  cytokines  from  human  
macrophages
Next,  the  role  of  SAA  in  the  production  of  cytokines  in  human  monocyte-­derived  
macrophages   as  well   as   in  mouse  peritoneal   (PMs)   and  bone  marrow-­derived  
macrophages   (BMMs)  and  monocytic  THP-­1  cells  was  studied.  Monocytes  and  
macrophages  have  differential  requirements  for  inflammasome  activation  and  the  
???????????????????????????????????et  al.???????? ??????????????????????????????
response  to  TLR  ligands  without  additional  stimulation,  most  likely  because  of  
their   autocrine   production   of  ATP   and/or   constitutive   activation   of   caspase-­1  
(Dinarello  et  al.  1987,  Burchett  et  al.  1988,  Ferrari  et  al.  1997).  Macrophages,  on  the  
other  hand,  are  not  capable  of  releasing  substantial  amounts  of  endogenous  ATP  
????????????????????????????????????????????????????????????????et  al.  2009).  THP-­1  
monocytic  cells  also  require  a  priming  step  unless   they  are  differentiated   into  
macrophages   in   the   presence   of   PMA;;   PMA-­differentiated   THP-­1   cells   show  
?????????????????????????????????????????????et  al.  1988).  
We   found   that  SAA  was   able   to   induce   the   gene   expression  of   IL1B   and  
TNFA,  both  of  which  peaked  at  6  hours,   in  human  macrophages  that  had  been  
differentiated  from  monocytes  by  GM-­CSF  (Study  II,  figure  1A).  SAA  also  induced  
a  clear  and  dose-­dependent  secretion  of  these  proteins  in  human  macrophages  
(Study  II,  figure  1B)  as  well  as  in  mouse  PMs  and  BMMs  (Study  II,  figures  5AB)  and  
PMA-­differentiated  THP-­1  macrophages   (Study   II,   figure   6B).  Based   on   these  
observations,  3  mg/ml  was  selected  as  the  standard  concentration  of  SAA  for  the  
???????????????????????????????????????? ????????????????????????????????????
immunoblotting  (Study  II,  figures  1C  and  5B).  To  verify  that  the  observed  effect  
was  not  due  to  the  properties  of  a  recombinant  protein,  plasma-­derived  human  
SAA   (Pussinen  et  al.   2001)  was  also   tested  and   found  capable  of   inducing   the  
????????????????????????????????????????????????????????????????????????????????????
involvement  was   excluded  by   treating   the   recombinant   SAA  preparation  with  
proteinase  K  or  polymyxin  B,  an  inactivator  of  endotoxins,  prior  to  the  experiments  
(Study  II,  figure  2D).
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2. SAA activates inflammasome signalling in human 
macrophages (Study II and unpublished data)
The production of IL-1ß is under strict regulation, exemplified by the fact that 
two separate signals are required for the release of IL-1ß in its mature form; the 
first one induces the expression of NLRP3 and IL1B and the second one induces the 
maturation of pro-IL-1ß via inflammasome activation. Some mediators have been 
shown to provide both of these signals. Live bacteria are the prime example; they 
stimulate the NF-?B pathway via PRRs, while NLRP3 is activated by bacterial toxins 
and/or pore-formation (Bauernfeind et al. 2011). Also, soluble biglycan, which can be 
released from the ECM during tissue injury, has been shown to induce IL-1ß release in 
macrophages without additional stimulants, via the concerted action of TLRs 2 and 4 
and P2X7 in a process that involves ROS generation (Babelova et al. 2009). The above 
results indicated that SAA can also act as such a mediator, capable of providing both 
signals needed for the secretion of IL-1ß.
Results and Discussion
2.1  SAA  primes  human  macrophages  via  TLR2  
and  TLR4
First  we  elucidated  the  signal  transduction  pathways  by  which  
SAA  primes  the  macrophages,  i.e.  induces  the  expression  of  IL1B.  
Previous  reports  suggest  that  SAA  is  involved  in  the  signalling  
pathways  mediated  by  FPRL1,  class  B  scavenger  receptors,  RAGE  
and  TLRs  2  and  4.
In   the   present   study,   we   observed   that   both   TLR2   and  
TLR4   play   a   role   in   the   SAA-­mediated   expression   of   IL1B   in  
?????????????????? ??????? ?????????????????????????????????
??????????????????????????????????????????????????????????????????
???? ???????????? ??? ????? ???? ???????? ???????? ??? ??????????
analysis,   according   to  which   SAA   induced   a   clear   increase   in  
????????????????????????????????????????????????????????
CSF  (unpublished  observations,  data  not  shown).  The  expression  
of   IP-­10   and   RANTES   is   mediated   by   the   TRIF-­dependent  
pathway  and  the  transcription  factor  IRF3  (Hacker  et  al.  2006),  





SAA-­mediated  induction  of  IL1B.  It  should  be  noted,  though,  that  the  expression  of  
CD36  can  vary  markedly  among  different  macrophage  phenotypes   in  vitro,  M1  
(GM-­CSF)  macrophages  showing  a  lower  expression  level  of  CD36  (van  Tits  et  al.  
2011),  and  there  is  also  variation  among  individuals  (Kashiwagi  et  al.  1995).  A  lack  
of  CD36  may  also  be  compensated  by  other  pathways.  As  scavenger   receptors,  
including  CD36,   form  pairs  with  TLRs,   the   impact  of  blocking  a  particular  SR  
might  depend  on  whether  or  not  it  is  associated  with  a  TLR.
???? ??????????????????????????????????????
Inflammasome  activation  results  in  the  recruitment  and  autoproteolytic  activation  
????????????????????????????????????????????????????????????????? ????????????????
the  present  study,  the  involvement  of  caspase-­1  and  the  inflammasome  pathway  in  
?????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????
(Study  II,  figure  3A).  In  addition  to  this,  SAA  induced  the  secretion  of  proteolytically  
processed  caspase-­1  (Study  II,  figure  3B),  which  is  in  keeping  with  previous  studies  
demonstrating   exocytosis   of   caspase-­1  with   other   inf lammasome   components  
(Andrei  et  al.  2004,  Qu  et  al.  2007).  Indeed,  ASC  isoforms  were  also  detected  in  the  
cell  culture  supernatant  subsequent  to  SAA  stimulation  (Study  II,  figure  5C).  The  
role  of  ASC  was  further  confirmed  by  stimulating  PMs  and  BMMs  derived  from  
ASC-­deficient  (Mariathasan  et  al.  2004)  and  wild-­type  mice  with  SAA  (Study  II,  
figures  5AB).  The  most  characterized  inflammasome  so  far,  NLRP3,  requires  ASC  
to  function  as  a  bridge  between  itself  and  caspase-­1.  However,  as  ASC  is  associated  
with  other  inflammasomes  as  well,  we  employed  the  siRNA  technique  to  assess  the  
importance  of  NLRP3.  Silencing  the  gene  encoding  NLRP3  in  PMA-­differentiated  
THP-­1  macrophages  led  to  a  significant  decrease  in  the  SAA-­induced  secretion  of  
???????????? ??????????????????????????????????????????? ??????? ???? ????????????
Lastly,  SAA  also  induced  a  rapid  and  robust  increase  in  the  expression  of  NLRP3  
(Study  II,  figure  6C),  which  has  been  shown,  similarly  to  IL1B  expression,  to  be  a  
prerequisite  for  the  assembly  and  activation  of  NLRP3  (Bauernfeind  et  al.  2009,  
Bauernfeind  et  al.  2011).  SAA  had  no  effect  on  the  expression  of  NLRP1  or  NLRP2  
(Study  II,  figure  6C).  Taken  together,  these  findings  strongly  implicate  NLRP3  as  
the  SAA-­responsive  inflammasome.  
????????????????????????????????????????????????????????????? ???????????????
????????????????????????????????????????????????????????????????????????????????????
monocytes,  macrophages  and  PBMCs  (Song  et  al.  2009,  Ather  et  al.  2011,  Franco  et  




lung   following   the   instillation   of   recombinant   human   SAA.   This   induction  was  
????????????????????????????????????????????????????????????????????????????
receptor  antagonist.  Furthermore,  Ather  et  al.  showed  that  SAA  induced  the  secretion  
???????????????????????????????????????????????????????????????????????????????
cells.  Besides  this,  the  priming  capability  of  SAA  has  been  demonstrated  in  synovial  
??????????????? ??????????????????????????????????????????????????????????????????
cells  for  the  MSU-­induced  activation  of  NLRP3  (Migita  et  al.  2012).
???? ????????????????? ????????????????????????? ??7  receptor
To  date,  numerous  NLRP3  activators  along  with  different  activation  models  have  
been  proposed  (see  chapter  1.4.2  in  Review  of  the  literature).  Extracellular  ATP,  
which  stimulates  the  ATP  receptor  P2X7,  is  one  of  the  main  activators  of  NLRP3  
(Mariathasan  et  al.  2006,  Ferrari  et  al.  2006).  In  the  present  study,  we  used  the  
compound  KN-­62  (Baraldi  et  al.  2003)  as  well  as  oxidized  ATP,  both  of  which  block  
the  P2X7  receptor,  and  observed  that  SAA  mediates  the  activation  of  NLRP3  via  
P2X7R  signalling  (Study  II,  figure  3A).  Whether  or  not  SAA  stimulates  the  receptor  
directly   was   assessed   by   using   apyrase,   an   ATP/ADP-­hydrolyzing   enzyme.  
Macrophages  are  not  capable  of  releasing  substantial  amounts  of  endogenous  ATP  
(Netea  et  al.  2009),  but  it  is  still  theoretically  possible  that  SAA,  similarly  to  LPS,  
induces  the  release  of  ATP  through  TLR4  instead  of  activating  P2X7R  directly.  Also  
????????????????????????????????????????????????????????????????????????????
microglia  (Sanz  et  al.  2009).  However,  apyrase  had  no  effect  on  the  SAA-­mediated  
???????????????????????????????????????????????????????????????????????????????????
response   to  SAA  was  observed  either.  Thus,   the   results   suggest   that   the  SAA-­
mediated  activation  of  the  inf lammasome  is  mediated  by  a  direct  interaction  of  
SAA  with  P2X7R  and  that  it  is  not  associated  with  the  release  of  ATP  or  ADP.  This  
is   an   interesting   finding   considering   that   ATP   is   so   far   the   only   established  
physiological  activator  of  P2X7  (Ferrari  et  al.  2006),  although  the  interaction  with  
soluble  biglycan  has  been  discussed  (Babelova  et  al.  2009).  SAA  has  previously  
been  reported  to  be  involved  in  the  antiapoptotic  effects  of  P2X7  in  neutrophils  but  
the  authors  concluded  that  in  relation  to  these  effects  P2X7  is  not  a  specific  receptor  
for  SAA  (Christenson  et  al.  2008).
2.4  Cathepsin  B  in  the  SAA-­mediated  activation  of  NLRP3
Cathepsin  B  activity  has  been  shown  to  play  an  important  role  in  the  activation  of  
???? ?????????????????? ???????????????????????????????????????????????et  al.  
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2009)  or  upstream  (Hentze  et  al.  2003,  Halle  et  al.  2008,  Hornung  et  al.  2008,  
Terada  et  al.  2009,  Duewell  et  al.  2010)  from  the  inflammasome  assembly.  The  role  
of  cathepsin  B  as  an  activator  of  caspase-­1  is  fairly  established;;  the  inhibition  of  
???????????????????????????????????????????????????????????????? ???????????????????
(Hentze  et  al.  2003).  The  cathepsin  B-­mediated  activation  of  pro-­caspase-­1  has  
been  demonstrated  inside  enlarged  lysosomes  in  microglia  (Terada  et  al.  2009).  
Cathepsin  B  can  also  maturate  pro-­caspase-­1  in  a  cell-­free  system  at  acidic  pH  
(Vancompernolle  et  al.  1998),  confirming  the  physical  importance  of  the  interaction  
between  the  two  enzymes.  Importantly,  phagocytosis  of  particulate  and  fibrillar  
???????????????????????????????????? ??????????????????????????????????????????????
shown  to   induce   lysosomal  destabilization  and   leakage  of  cathepsin  B   into   the  
cytoplasm,  which   then   results   in   the   activation   of   the  NLRP3   inf lammasome  
(Halle  et  al.  2008,  Hornung  et  al.  2008,  Duewell  et  al.  2010,  Rajamaki  et  al.  2010).
In  the  present  study,  we  observed  that  the  activity  of  cathepsin  B  was  also  
?????????????????????????????? ?????????????????????????????????????????????????
3A).  This  was  verified  by  utilizing  an   irreversible,   cell-­permeable   cathepsin  B  
inhibitor,   Ca074Me.   The   finding   may   suggest   the   involvement   of   the   same  
lysosomal   disintegration   pathway   that   has   been   demonstrated   for   the   above-­
mentioned  particulate  material,  especially  as  lysosomes  have  been  implicated  also  
in   intracellular  AA  amyloid  fibrillogenesis  and  in  the  subsequent  exocytosis  of  
amyloid  fibrils  (Kluve-­Beckerman  et  al.  2001,  Kluve-­Beckerman  et  al.  2002,  Magy  
et  al.  2007).  The  SAA  concentration  used  in  the  present  study,  however,  did  not  
induce  lysosomal  destabilization  or  leakage  of  cathepsin  B  into  the  cytosol  (Study  
II,   figure  4A).  Furthermore,  treating  macrophages  with  cytochalasin  D  had  no  
????????????????????????????????????????????????? ???????????????????????????????
clearly   imply   that   intracellular   f ibril   formation   followed   by   lysosomal  
disintegration,  or  phagocytosis  of  SAA-­derived  extracellular  fibrils,  is  hardly  the  
mechanism  inducing  the  activation  of  NLRP3  in  the  present  study.
In  summary,  our  results  suggest  that  the  observed  SAA-­induced  activation  
of   the   inf lammasome  depends  on   the  activity  of   cathepsin  B  but   that   it   is  not  
mediated  through  fibril  formation  or  lysosomal  destabilization.  Instead,  in  the  
present  study,  caspase-­1,  cathepsin  B  and  ASC  were  secreted  to  the  cell  culture  
media   in   response   to   SAA   (Study   II,   figures   3B,   4B   and  5C).  This   is   a   logical  
observation   in   light   of   the   findings   by   others   showing   that   inf lammasome  
components,  including  cathepsin  B,  are  released  in  response  to  P2X7R  stimulation,  
independent  of  cytokine  release  (Lopez-­Castejon  et  al.  2010),  or  as  a  part  of  the  
?????????????????????????????????????????et  al.  2004,  Qu  et  al.  2007).  In  addition,  
the   release   of   cathepsin   B   in   response   to   SAA   has   recently   been   observed   in  
synovial  fibroblasts,  in  which  SAA  induces  the  priming  step  (Migita  et  al.  2012).  
However,  it  is  still  unclear  exactly  how  the  cathepsin  activity  then  contributes  to  
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???? ????????????? ??????????? ??? ?????? ???????????? ????? ???? ????? ??? ?? ????????
secreted  component  or  marker  hardly  supports  the  results  of  the  present  study  
with  a  cathepsin  B  inhibitor.
It  is  also  important  to  note  that  the  cell-­permeable  cathepsin  B  inhibitor  
(Ca-­074Me)  used  in  this  study  has  been  shown  to  inhibit  not  only  cathepsin  B  but  
also  the  closely  related  cathepsin  L  when  tested  on  mouse  fibroblasts  (Montaser  et  
al.  2002).  Thus,  both  cathepsins  could  potentially  contribute  to  the  activation  of  
NLRP3.  In  accordance  with  this,  a  recent  study  utilized  a  similar  non-­specific  
cathepsin  inhibitor  and  reproduced  our  findings,  i.e.  the  attenuation  of  the  SAA-­
???????? ?????????? ??? ?????? ??? ????????? ??? ???? ??????????? ????????? ??????????
peritoneal  macrophages,  but  they  also  reported  that  SAA  could  induce  the  secretion  
??? ?????? ??? ?????????? ???????????? ???????????? ??? ????? ????????? ??????? ??????
although  not  discussed  by  Poynter,  indeed  supports  the  potential  role  of  cathepsin  
L  in  the  activation  of  NLRP3  and  requires  further  study.  
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3. The activation of the innate immune system cells is 
involved in AA amyloid formation (Studies I & II)
Tissues that are either prone to develop amyloid deposits or are already affected 
by them also contain an abundant number of mast cells (Westermark 1971). This 
is particularly exemplified in renal AA or AL amyloidosis, in which the affected 
kidney also shows an increased density of interstitial mast cells (Toth et al. 2000, 
Danilewicz and Wagrowska-Danilewicz 2002). Thus, we hypothesized that mast cell 
mediators might be involved in the extracellular processing of SAA. SAA was found 
to be a strong activator of mast cells based on the induction of the secretion of IL-
1ß and TNF-a and also of histamine (Study I, figures 1 and 2). Tryptase is the major 
protease stored in the granules and it can be found in all human mast cells (Schwartz 
et al. 1987). Tryptase possesses trypsin-like specificity, i.e. it cleaves its substrates 
at the carboxyl side of Arg or Lys residues (Hallgren and Pejler 2006). Chymase, on 
the other hand, resembles chymotrypsin and cleaves its substrates at the carboxyl 
side of aromatic or Leu residues (Powers et al. 1985). HuMCs used in the present 
study were cultured from cord blood or peripheral blood CD34+ progenitor cells as 
per Saito et al. (Saito et al. 2006) with modifications. In short, SCF, IL-4, IL-6 and IL-
10, and/or combinations thereof, were utilized to produce mature mast cell cultures 
expressing both tryptase and chymase.
Results and Discussion
3.1  Mast  cell  proteases  degrade  SAA
First,   the   ability   of  mast   cell   proteases   to   degrade   SAA  was  
studied  using  purified  human  tryptase  and  chymase  (Study  I,  
figure  3).  Tandem  mass  spectrometric  analysis  (MS/MS)  of  the  
digestion   mixture   revealed   that   tryptase   generated   an   SAA  
peptide  whose  mass  corresponded  to  the  N-­terminal  fragment  of  
SAA   (residues   3-­16;;   SFFSFLGEAFDGAR),   which   is   the   area  
implicated  in  amyloid  formation  (Westermark  et  al.  1992,  Patel  
et  al.  1996).  Chymase  and  a  mixture  of  chymase  and  tryptase  
degraded  the  N-­terminus  completely  (Study  I,  figure  3B).  Next,  
the  degradation  was  studied  using  cell  culture  media  collected  
from  immunologically  (IgE-­)activated  huMCs,  which  also  contained  
MC  granules.  The  degradation  pattern  of  SAA   in   the  medium  
was  similar  to  that  achieved  by  purified  tryptase  (Study  I,  figure  
4A)  and  importantly,  the  N-­terminal  SAA  fragment  was  found  
intact.  This  is  surprising  considering  that  the  granules  contain  
both  proteases.  However,   the  explanation  may  arise   from  the  
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fact   that  upon  degranulation   tryptase   is   released   from  the  granules,  whereas  
chymase  remains  bound  to  the  heparin  proteoglycans  of  the  remnants  (Kovanen  
1991,  Lindstedt  et  al.  2001).  SAA,  in  turn,  can  bind  to  the  heparin  proteoglycan  
matrix  via  two  separate  binding  sites  (Ancsin  and  Kisilevsky  1999,  Elimova  et  al.  
2009),  and,  thus,  the  interaction  between  SAA  and  chymase  might  be  sterically  
hindered.  It  should  also  be  noted  that  in  vivo  chymase,  unlike  tryptase,  can  be  
inactivated  by  several  natural  inhibitors  present  in  interstitial  f luids,  principally  
??????????????? ??????????? et   al.   1989,  Kokkonen  et   al.   1997).   Interestingly,   a  
chymotrypsin-­like  mast  cell  protease  purified  from  rat  brain  has  been  shown  to  
proteolyze   the   amyloid  precursor   protein   in   a  manner   that   releases   the   area  
?????????????????????????????????????????et  al.  1993).  This  supports  our  findings  
and   suggests   that   proteases   of   this   type   might   very   well   participate   in   the  
proteolytic  processing  and  activation  of  amyloidogenic  protein  precursors.
We  also  elucidated  whether  SAA  can  induce  the  degranulation  of  mast  cells,  
resulting  in  the  release  of  chymase  and  tryptase  and  the  degradation  of  SAA  itself.  
Indeed,  the  presence  of  SAA  in  the  culture  medium  led  to  a  partial  disappearance  
of   full-­length   SAA,   as   analyzed   by   western   blotting.   The   degradation  was   as  
efficient  as  what  was  observed  after  the  immunological  activation  of  huMCs  (Study  
I,  figure  4BC).  In  summary,  these  findings  demonstrate  that  both  purified  mast  
cell  proteases  and  human  mast  cell-­conditioned  media  can  degrade  SAA  and  that  
SAA  alone  is  sufficient  to  induce  the  degranulation  of  mast  cells  and  the  subsequent  
degradation  of  itself.
3.2  Continuously  elevated  SAA  levels  lead  to  amyloid  
formation  in  mast  cell  cultures
During  prolonged  inflammation  in  vivo,  the  levels  of  SAA  in  serum  are  persistently  
high  due  to  the  hepatic  production  of  SAA  induced  by  proinflammatory  cytokines.  
In  order  to  simulate  this  physiological  condition  in  our  experimental  setting,  we  
set  up  a  7-­day  experiment  where  SAA  was  added  to  the  cell  cultures  in  two-­day  
intervals,  ensuring  an  excess  of  SAA  throughout  the  experiment.  The  cell  culture  
media  were  analysed  by   transmission  electron  microscopy,  which   revealed  an  
extensive  formation  of  fibril-­like  structures  and  aggregates  (Study  I,  figures  5AB).  
This  finding  was  further  supported  by  the  fact  that  the  N-­terminal  fragment  of  
SAA  could  not  be  detected  by  MS  analysis   in   the  cell  culture  medium  samples  
collected  after  day  4,  suggesting  that  the  fragment  was  no  longer  in  a  soluble  form  
(Study  I,  data  not  shown).
In  summary,  we  propose  that  mast  cells  can  contribute  to  the  formation  of  
amyloid  deposits  in  tissues  according  to  the  following  sequence.  High  levels  of  
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SAA  activate  mast  cells,  which  degranulate  and  release  neutral  proteases,  notably  
tryptase.  The  tryptase-­generated  amyloidogenic  SAA  fragment  can  then  function  
as  a  local  amyloid-­enhancing  factor  and  induce  AA  fibrillogenesis.  This  may  be  
further  enhanced  by  heparin,  a  component  of  mast  cell  granules  as  well  as  by  
mature  amyloid  fibrils.  HS  and/or  its  structural  derivative  heparin  have  indeed  
been  implicated  in  the  acceleration  of  AA  amyloidosis  (Bellotti  and  Chiti  2008,  
Motamedi-­Shad  et  al.  2012).  Elimova  et  al.  have  demonstrated  that,  in  an  acidic  
pH,  both  heparin  and  HS  promote  the  aggregation  of  HDL-­Saa  as  well  as  the  
dissociation  of  Saa  from  HDL  (Elimova  et  al.  2009).  The  HS-­binding  regions  on  
SAA,  the  N-­terminal  aa  17-­49  (Elimova  et  al.  2009)  or  the  C-­terminal  aa  77-­103  
(Ancsin  and  Kisilevsky  1999),  could  then  facilitate  the  cell  surface  binding  and  
the  HS-­mediated  aggregation  of  Saa.  In  accordance  with  this,  the  inhibition  of  
the  SAA-­HS  interaction,  either  by  blocking  the  HS  binding  site  (Kisilevsky  et  al.  
1995,  Elimova  et  al.  2004)  or  by  utilizing  heparanase  (Li  et  al.  2005),  decreases  
AA  fibrillogenesis  in  vivo.
3.3  Macrophage-­derived  cathepsin  B  might  contribute  to  
?????????????????????????????
In  addition  to  mast  cells,  macrophages  also  appear  to  accumulate  near  AA  deposits  
in  vivo  (Kuroiwa  et  al.  2003)  and  they  have  been  implicated  in  the  processing  of  
exogenous  SAA  in  the  cell  culture  models  of  AA  amyloidosis.  Amyloid  formation  in  
these  macrophage  models  requires  high  SAA  concentrations  and  most  often  also  
the  presence  of  amyloid-­enhancing  factor  (AEF).  Not  surprisingly,  we  observed  no  
????????? ?????????????????????? ????????????? ??????????????? ?????????????????????
?????????????????????????????????????????????????????????????????? ??????????????????
secretion   of   the   active   form   of   cathepsin   B   into   the   cell   culture  medium  was  
?????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????
the  extracellular  milieu.  This  is  in  accordance  with  a  previous  study  that  compared  
SAA  clearance   in   the  HepG2  cell   line  and   in  hamster  peritoneal  exudate  cells,  
including   macrophages,   and   demonstrated   that   SAA   is   degraded   mostly  
extracellularly   when   incubated   with   peritoneal   cells   (Liang   and   Sipe   1995).  
Furthermore,   a   P2X7?????????? ???? ?????????????????? ???????? ??? ??????????
cathepsins  from  human  and  mouse  macrophages  has  been  reported.  Importantly,  
in  that  study  the  secreted  cathepsins  were  proteolytically  active  as  evidenced  by  the  
degradation  of  ECM  collagen  in  vitro  (Lopez-­Castejon  et  al.  2010).  In  terms  of  pH,  
extracellular  space  is  not  the  optimal  environment  for  lysosomal  proteases  (pH  6.0  
for  cathepsin  B),  but  the  data  from  Lopez-­Castejon  et  al.  as  well  as  others  (Werle  et  
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al.  1997,  Linebaugh  et  al.  1999)  imply  that  residual  or  some  forms  of  cathepsin  B  
activity  exists  also  in  a  neutral  pH.  Furthermore,  local  acidosis  is  a  well-­known  
??????????????????????????????????????????????????????????????????????????????
surroundings  by  different  mechanisms  (Leake  1997).  As  mentioned  earlier  (chapter  
3.1.3  in  Review  of  the  literature),  several  members  of  the  cathepsin  family  have  
been  implicated  in  the  proteolytic  processing  of  SAA.  Cathepsin  B,  the  expression  
????????? ?????????? ??????? ???????????? ????? et   al.   1995),   has   been   shown   to  
degrade  SAA  and  to  release  the  amyloidogenic  N-­terminus  (Yamada  et  al.  1995b,  
Röcken  et  al.?????????????????????????????????????????????????????????????????????????
not  clear,  though,  as  blocking  cathepsin  B  does  not  seem  to  affect  the  amyloid  load  
in  vitro  or  in  vivo  (Röcken  et  al.  2006,  van  der  Hilst  et  al.???????????????????????
?????????????????????????????????????????????????????????????????????????????????
components  of   the  ECM  and  mediators,   such  as  other  proteases   released   from  
resident   cells.   Thus,   the   secretion   of   active   cathepsin  B   from  macrophages   in  
response  to  SAA  and  the  ability  of  cathepsin  B  to  create  the  amyloidogenic  SAA  
fragments  may  well  represent  a  pathway  that  serves  as  a  source  of  seeding  material  
for   amyloidogenesis.  One   can   also   envision   a   cascade   involving   both   resident  
macrophages  and  mast  cells  in  which  cytokines  secreted  from  both  cell  types  as  
well  as  proteases,  including  tryptase  and  cathepsin  B,  would  continuously  activate  
more  cells  and  produce  more  amyloidogenic  AA  fragments,  respectively.
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4. The activity of SAA is regulated by native and 
oxidized lipoproteins (Study III & unpublished data)
The SAA concentration used in the present study was within a normal physiological 
range (1-5 mg/ml). The fact that this concentration induced a strong inflammatory 
response in human macrophages suggests that the findings are relevant also in vivo. 
Considering that during the APR the serum level of SAA can increase up to 1000-fold, 
reaching a concentration of 1 mg/ml or more, it is obvious that strict regulatory 
mechanisms other than merely transcriptional ones must exist. One such mechanism 
has been suggested to be the interaction of SAA with HDL. Indeed, many pathological 
features of SAA, including proinflammatory and also proatherogenic activities 
are associated with the free protein and become blocked or at least altered in the 
presence of HDL. For example, pre-incubation of SAA with HDL inhibits SAA-induced 
events, such as endothelial dysfunction in human aortic ECs (Witting et al. 2011), the 
production of monocyte TF and cytokines in PBMCs (Cai et al. 2007, Song et al. 2009, 
Franco et al. 2011) and the expression of sPLA2 in rat SMCs (Sullivan et al. 2010).
Most in vitro studies concentrating on the interaction between SAA and lipoproteins 
have been conducted using either SAA-rich AP-HDL or preformed complexes of SAA 
and HDL, justified by the fact that HDL is naturally associated with SAA in vivo. 
Depending on the conditions, however, the extrahepatic expression of SAA can lead 
to significant local concentrations of lipid-free SAA. Thus, the utilization of free 
SAA and free lipoproteins, instead of preformed complexes, in the experiments can 
actually better mimic the physiological conditions at the site of inflammation. 
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4.1  The  distribution  of  SAA  among  lipoprotein  
classes
Although  HDL3   is   the  major   carrier   of   SAA   in   the   circulation  
(Benditt  and  Eriksen  1977,  Skogen  et  al.  1979,  Bausserman  et  al.  
1980),  the  distribution  of  SAA  among  the  lipoprotein  classes  is  not  
constant.  In  order  to  verify  that  all  lipoproteins  are  indeed  capable  
of  binding  to  SAA  in  vitro  under  our  experimental  conditions  and  
to  establish  the  binding  ratios  for  the  complexes,  SAA  was  mixed  
with  pooled  plasma,  after  which   the  plasma   lipoproteins  were  
fractioned  and  the  amount  of  SAA  in  each  fraction  was  assessed.  
As  illustrated  in  Figure  8,  approximately  85%  of  SAA  was  found  to  
be  associated  with  HDL  (either  HDL2  or  HDL3)  and  3%  with  LDL.  
The  proportion  of  lipid-­free  SAA  was  11%.  We  observed  that  SAA  
bound  to  HDL3  and  LDL  at  molar  ratios  of  1:1.1  (SAA:HDL3,  mol/
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mol)  and  1:2.7  (SAA:LDL,  mol/mol),  respectively.  This  is  generally  in  keeping  with  
the  reported  in  vivo  observations  during  the  APR  in  humans  (Marhaug  et  al.  1982,  
Marhaug  and  Husby  1982)  and  mice  (Cabana  et  al.  2004)  as  well  as  under  mimicking  
conditions  in  vitro  (Cabana  et  al.  2004).  Variations  in  the  distribution  of  SAA  are  
likely  to  result  from  different  SAA  or  lipoprotein  concentrations  and  from  other  
???????????????????????????????????????????????????????? ??????????in  vitro  seems  
to   decrease   as   a   function   of   SAA   concentration   (Baranova   et   al.   2010).   The  
???????????????????????????????????????????????????????????????????????????????
typically  seen  during  a  medium-­to-­strong  APR.  
Figure 8. The distribution of SAA among lipoprotein classes in vitro. The data are 
means from two independent experiments conducted using a plasma pool of five donors. 
HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density 
lipoprotein; SAA, serum amyloid A; VLDL, very low-density lipoprotein.
4.2  Native  and  oxidized  lipoproteins  decrease  the  SAA-­
induced  secretion  of  cytokines
First,  the  effect  of  native  and  oxidized  lipoproteins  on  the  SAA-­induced  expression  
???????????????????????????????????????? ??????????? ?????????????????????????
were  isolated  from  human  plasma  and  oxidized  by  Cu2+.  The  lipid  peroxidation  was  






























The  analysis  of  mRNA  levels  revealed  that  the  expression  of  IL1B  and  TNFA  




the  lipoproteins,  then  SAA,  or  vice  versa)  or  whether  or  not  SAA  and  the  lipoproteins  
????? ????????????????????????????????????????????????????????????????????
???????????? ????????????????????????????????????????????????????????????
While   the   inhibition   of   SAA   activity   by   HDL3   has   been   demonstrated  
previously,  the  inhibition  of  SAA  by  LDL,  to  our  knowledge,  has  not  been  reported  
before.  In  fact,  a  recent  study  reported  that  LDL  failed  to  inhibit  the  SAA-­mediated  
?????????????????????????et  al.  2011).  However,   that  study  was  conducted  on  
non-­differentiated  THP-­1  cells  and  PBMCs  (vs.  GM-­CSF  macrophages  and  PMA-­
differentiated  THP-­1  macrophages  used  in  our  study)  and  also  with  a  higher  SAA  
concentration,  which  might  explain  the  different  results.  The  in  vivo  formation  and  
presence  of  the  SAA-­LDL  complex  has  been  previously  demonstrated  (Ogasawara  et  
al.  2004,  Kotani  et  al.  2009).  OxLDL  particles  have  been  shown  to  possess  many  
??????????????????????????????????????????????????????????????????????????????? ?????
role  in  the  development  of  atherosclerosis  (Kruth  2001).  Against  this  background,  the  
???????????????????????????????????????????????????????????????????????????????
studies  that  demonstrate  that  oxLDL  may  inhibit  or  delay  the  LPS-­induced  expression  
of  IL1B  (Hamilton  et  al.  1990,  Fong  et  al.  1991,  Hamilton  et  al.  1998,  Mikita  et  al.  2001).  
???????????? ?????????? ??????????????????????????????????????????? ????????? ????
??????????? ???????? ?????????????et  al.  1998,  Ohlsson  et  al.  1996,  Brand  et  al.  1997).  
4.3  The  requirements  for  co-­presence  and  lipoprotein  uptake  
Next  we  elucidated  whether  the  co-­presence  of  SAA  and  the  lipoproteins  is  required  
for   the   inhibitory  effect  of   these   lipoproteins.  When   the   cells  were   thoroughly  
washed  following  the  incubation  with  the  lipoproteins  and  prior  to  the  addition  of  
SAA,  the  ability  of  the  native  lipoproteins  to  inhibit  the  expression  of  IL1B  and  the  
?????????????????????????????????? ??????????????????????????????????????????? ????
inhibitory   effect   of   oxLDL   and   oxHDL3   persisted   even   after   their   removal,  
?????????????????????????????????????????????????????????????????????????????????
lipoproteins  is  mediated  through  a  direct  effect  on  macrophages.  The  inhibitory  
activity  of  native  lipoproteins,  in  contrast,  involves  interaction  with  SAA,  possibly  
resulting  in  an  impairment  of  the  ability  of  SAA  to  interact  with  its  receptor(s),  such  
as  TLR2  and  TLR4.  This  might  be  a  consequence  of  complex  formation  between  
SAA  and  lipoproteins,  which  could  result  in  steric  hindrance.  Recombinant  SAA  
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added  to  a  serum-­containing  cell  culture  medium  has  indeed  been  shown  to  readily  
associate  with  HDL  (Magy  et  al.  2007).  Alternatively,  SAA  could  be  internalized  as  
an  SAA-­lipoprotein   complex  and  become  degraded,   resulting   in   the   loss  of   its  
activity.  The  uptake  of  oxidized  lipoproteins  could,  in  addition,  trigger  intracellular  
?????????????????????????????????????????????????????????????????????????????
be   internalized   via   receptor-­mediated   or   receptor-­independent,   non-­specific  
????????????????????????????????????????????????????????????? ????????????????????
macropinocytosis  (Amyere  et  al.  2002,  Swanson  2008).  These  are  mainly  processes  
requiring  actin  polymerization  (Conner  and  Schmid  2003,  Schrijvers  et  al.  2007,  
Kruth  2011).  Thus,  we  next  utilized  cytochalasin  D  to  explore  whether  the  actin-­
dependent  internalization  of  lipoproteins  is  involved  in  the  inhibitory  effect.  As  
expected,  cytochalasin  D  inhibited  the  uptake  of  LDL  and  also  the  uptake  of  pre-­
made   LDL-­SAA   complexes   based   on   the   decreased   intracellular   content   of  
????????????????????????????????????????????????????????????????????????????? ??????
contrary,   cytochalasin   D   had   no   effect   on   the   ability   of   native   or   oxidized  
???????????????????????????????????????????????????????????????????????????????????
the  online-­only  data  supplement),  suggesting  that  the  internalization  of  lipoproteins  
is  not  required  for  their  inhibitory  effect.
4.4  Oxidized  lipoproteins  and  lipid  particles  inhibit  the  
activation  of  NLRP3
??? ??????? ???????? ???? ?????????? ??? ???? ???????????? ?????????? ??? ?????? ???
lipoproteins  is  a  mere  consequence  of  the  reduced  expression  of  IL1B,  the  above-­
described  experiments  were  repeated  using  PMA-­differentiated  THP-­1  macrophages,  
which  exhibit  constitutive  expression  of  IL1B  (Fenton  1988).  Interestingly,  native  
????????????? ???? ??? ??????? ??? ???? ???????????? ???????? ??? ?????? ??? ??????
macrophages,  while  oxidized  lipoproteins  significantly  inhibited  it  also  in  these  
cells   (Study   III,   figure   4A).   This   implies   that   the   inhibitory   effect   of   native  
lipoproteins  can  be  explained  by  the  reduced  expression  of  IL1B,  whereas  their  
oxidized  forms  also  inhibit  the  inflammasome  cascade  and  the  maturation  of  IL-­
?????????????????????????????????????????????????????????????????????????????????????
NLRP3,  nigericin,  a  bacterial-­derived  pore-­forming  toxin  and  an  activator  of  the  
NLRP3   inf lammasome   (Mariathasan   et   al.   2006),   was   tested.   Indeed,   both  
oxidized   lipoproteins,  but   in  particular  oxLDL,  also  significantly   inhibited  the  
?????????????????????????????????????????????? ???????????????????????????????????
indicating   that   the   ability   of   oxidized   lipoproteins   to   inhibit   the   NLRP3  
inflammasome  is  not  restricted  to  the  SAA-­induced  activation.
In  order  to  study  whether  the  inhibitory  effect  of  oxLDL  was  conferred  by  its  
Results and Discussion
78
lipid  or  protein  fraction,  microemulsion  particles  were  prepared  of  lipids  that  had  
been   extracted   from   oxLDL.   When   introduced   to   human   macrophages,   the  
microemulsion  particles  derived  from  oxLDL  were  equally  efficient  in  inhibiting  
??????????????? ????????????? ????????????????????????? ?????????????????? ???? ??????
fraction  is  the  part  mediating  the  inhibitory  effect.  Oxidized  phospholipids,  such  
as   the   oxidation   products   of   1-­palmitoyl-­2-­arachidonoyl-­sn-­glycero-­3-­
phosphorylcholine  (PAPC),  have  been  proposed  to  act  as  inhibitors  of  signalling  by  
TLR2  and  4  (Bochkov  et  al.  2002,  Walton  et  al.  2003,  Nonas  et  al.  2006).  The  
phospholipid   fraction   of   oxLDL  may   also   inhibit   the   intracellular   activity   of  
cathepsin  B  (Hoppe  et  al.  1994,  O’Neil  et  al.  2003).  As  the  activity  of  cathepsin  B  is  
required  for  the  SAA-­induced  activation  of  NLRP3,  it  can  be  speculated  that  this  




Some   studies   have   demonstrated   that   mmLDL   and   oxLDL   can   induce   the  
expression  of  IL1B  (Masters  et  al.?????????????????????????? ???????????????????????
via  activation  of  NLRP3  (Duewell  et  al.  2010,  Jiang  et  al.  2012).  The  uptake  of  
??????????????????????????????????? ???????? ???????????????????????????????? ??? ???
sensitive  to  cytochalasin  D  (Jiang  et  al.  2012).  In  contrast  to  this,  the  inhibition  of  
the   SAA-­induced   activation   of   NLRP3   observed   in   the   present   study   was  
independent   of   the   oxLDL  uptake   (Study   III,   figure   I   in   the   online-­only   data  
supplement).  This  suggests  that  oxLDL  may  be  involved  in  two  opposite  regulatory  
pathways,  triggered  by  various  mediators  in  the  cellular  microenvironment  and  
perhaps  also  by  the  properties  of  the  oxLDL  particles  themselves.  For  example,  
mmLDL,  once  taken  up  and  directed  to  lysosomes,  can  form  cholesterol  crystals  
that  have  been  indicated  as  NLRP3  activators  (Duewell  et  al.  2010,  Rajamaki  et  al.  
2010).  In  addition,  the  two  pathways  could  be  temporally  separated  and/or  involve  
secondary   signalling   cascades,   such   as   anti-­oxidative   and   anti-­inf lammatory  
responses.  Indeed,  in  the  present  study  oxLDL  and  oxHDL3,  as  well  as  microemulsion  
particles   prepared   from   the   lipids   of   oxLDL,   induced   an   increase   in   the   gene  
expression  of  heme  oxygenase  (HO-­1)  that  was  inversely  proportional  to  the  release  
??????????????????????????????????????? ???????????????????????????????????????????????
(Hsp32),  catalyzes  the  conversion  of  the  heme  group  of  hemoglobin  into  bilirubin,  
biliverdin  and  carbon  monoxide  (Siow  et  al.  1999,  Takahashi  et  al.  2007).  HO-­1  is  
highly  anti-­inflammatory,  and  it  can  be  induced  by  a  number  of  physiological  and  
pathological   stimuli,   including   oxidative   stress   signals,   cytokines,   bacterial  
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compounds  and  growth  factors  (Paine  et  al.  2010).  The  gene  expression  of  HO1  is  
mediated  by   redox-­dependent   transcription   factors,   notably  Nrf2   (Alam  et   al.  
1999),   which   is   translocated   into   the   nucleus   upon   stimulation.   Importantly,  
oxLDL,  mmLDL  as  well  as  oxHDL  have  been  indicated  as  inducers  of  HO1  (Anwar  
et  al.  2005,  Ma  et  al.  2007,  Rossmann  et  al.  2011),  and  HO-­1  has  recently  been  
implicated   in  a  negative   feedback  mechanism   involved   in   the  activation  of   the  
NLRP3  inflammasome  (Nurmi,  K.  et  al.,  unpublished  data).  Thus,  the  induction  of  
HO1  by  oxLDL  could  at  least  partly  explain  the  dampening  of  the  SAA-­induced  
activation  of  NLRP3  observed  in  the  present  study.  Interestingly,  a  similar  feedback  
mechanism  has  been  described  for  oxLDL  and  its  ability  to  induce  oxidative  bursts  
in  macrophages  (Fischer  et  al.  2002).  Fischer  et  al.  observed  that  oxLDL  induced  
ROS  production  upon  first  contact  but  was  also  able  to  reduce  it  via  the  activation  
of  the  insulin-­sensitizing  and  anti-­inflammatory  peroxisome  proliferator-­activated  
???????????????????????????et  al.  2000)  that  led  to  desensitization  of  macrophages.  
4.6  OxLDL  inhibits  the  SAA-­induced  peritonitis
?????????????????????????????????????????????????????????????????????????????????
also  in  vivo.  For  this,  SAA  was  used  to  induce  peritonitis  in  mice.  Previously,  the  
induction  of  sterile  peritonitis  has  been  demonstrated  by  several  substances  including  
thioglycolate  (Gilmour  et  al.  2006),  yeast-­derived  zymosan  (Perretti  et  al.   1992),  
casein  (Iversen  et  al.  2005),  high-­mobility  group  box  1  (HMGB1)  (Orlova  et  al.  2007),  
?????????????????????????????????????????????????????et  al.  2005)  as  well  as  MSU  
and  octacalcium  phosphate  crystals  (Getting  et  al.  1997,  Martinon  et  al.  2006,  Uratsuji  
et  al.  2012,  Narayan  et  al.  2011).  SAA-­induced  peritonitis  has  not  been  described  
???????? ??????????????????????????????????????????????????????????? ??????????????
????????????????????????????????????????????????????????????????????????????????????
SAA  and  oxLDL  were   injected   into   the  peritonea  of  wild-­type  C57BL/6J  
??????????????????????????????????????????????????????????????????????????????????
f luid,  as  determined  4  hrs  after  the  injection.  There  was  also  an  increase  in  the  
neutrophil  count  (Study  III,  figure  6).  OxLDL  alone  did  not  induce  these  effects.  
Importantly,  the  injection  of  oxLDL  one  hour  prior  to  SAA  clearly  diminished  the  
?????????????????????????????????????????????????????? ????????????????????????????
These  findings  strongly  suggest  that  the  inhibitory  effect  of  oxidized  lipoproteins  
that  was  observed  in  the  preceding  cell  culture  experiments  can  also  occur  in  vivo  
and  has  physiological  relevance.  OxLDL  may  represent  a  novel  and  significant  






Native  human  SAA  is  fairly  difficult  and  laborious  to  purify,  and  probably  
for  this  reason  it  is  not  commercially  available.  Thus,  most  SAA  studies  conducted  
so   far,   including   ours,   have   utilized   a   recombinant   form  of   human  SAA,   “the  
consensus  SAA  molecule”,   that   is  a  mixture  of  SAA1  and  SAA2.  Alternatively,  
some   groups   have   decided   to  work  with  mouse   Saa   proteins.   It   is   certainly  
possible  that  recombinant  SAA  differs  from  the  native  SAA,  especially  in  terms  of  
posttranslational  modifications.  However,   native   and   recombinant   SAA  have  
been  used  in  parallel  (Christenson  et  al.  2008,  Linke  et  al.  1991,  and  the  present  
study:   Study   II,   figures   1D   and   2C).   One   study   has   reported   on   functional  
differences  between  the  two,  noting,  though,  that  the  purification  procedure  of  
human  SAA  may  also  affect  its  properties  (Björkman  et  al.  2010).  The  bacterial  
origin  of   the  recombinant  SAA  and  the  possibility  of  endotoxin  contamination  
might  also  be  problematic  issues.  However,  this  is  routinely  controlled  by  including  
polymyxin  B  or  a  similar  LPS  blocker  in  the  experimental  design  (Christenson  et  
al.  2008,  Sandri  et  al.  2008,  Chen  et  al.  2010,  Li  et  al.  2010,  Ather  et  al.  2011).
Another  issue  to  be  considered  arises  from  the  lipidic  state  of  SAA.  In  fact,  
many  of  the  main  findings  presented  in  this  field  over  the  years  have  recently  been  
questioned   (Kisilevsky   and   Manley   2012).   Since   delipidated   SAA   can   form  
aggregates  in  vitro  (Kinkley  et  al.  2006),  Kisilevsky  and  Manley  claim  that  SAA  
hardly   exists   in   a   lipid-­free   form   in   vivo,   or   at   least   not   in   amounts   that   are  
physiologically   relevant.   Thus,   all   the   data   produced   using   lipid-­free   SAA,  
including  the  majority  of  the  data  on  receptor  interactions,  should  be  interpreted  
with  extreme  care.  According  to  Kisilevsky  and  Manley,  receptors  indicated  as  
“SAA  receptors”  (SR-­B1,  TLR2,  TLR4,  FPRL1,  CD36)  may  simply  be  fulfilling  their  
role  as  scavenger  receptors  as  macrophages  most  likely  internalize  aggregated  SAA  
via  phagocytosis.  However,  the  aggregation  data  by  Kinkley  et  al.  as  well  as  the  
experimental  data  employing  HDL-­SAA  (Kisilevsky  and  Manley  2012,  Kinkley  et  
al.   2006)   have   again   been   produced  with   plasma-­purified   SAA   that   has   gone  
through   a   long   purification   and/or   reconstruction   process.   As   a   result,   the  
physiological   relevance   of   the   obtained   product   can   also   be   questioned.  
Furthermore,  the  model  suggested  by  Kisilevsky  and  Manley  fails  to  explain  why,  
then,  the  inhibition  of  actin  polymerization  does  not  affect  SAA  signalling  as  has  
been  demonstrated  (Kluve-­Beckerman  et  al.  2001;;  Study  II,  figure  3A;;  Study  III,  
figure  I  in  online-­only  data  supplement).  Also,  if  we  presume  that  the  aggregated  
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SAA  is  internalized  merely  via  non-­specific  phagocytosis,  then  blocking  one  of  the  
proposed  SAA  receptors,  such  as  TLR2  or  TLR4,  should  have  no  impact  because  
other  scavenging  pathways  could  substitute  for  the  inhibited  ones.  However,  this  is  
not  the  case,  as  has  been  shown  by  using  neutralizing  antibodies  against  TLRs  
(Study  II,  figures  2BC)  or  macrophages  from  TLR2  or  TLR4-­deficient  mice  (Cheng  
et  al.  2008,  Sandri  et  al.  2008,  He  et  al.  2009,  Chen  et  al.  2010,  Ather  et  al.  2011).  
Importantly,  epitope  mapping  studies  have  suggested  that  the  lipidic  state  of  
SAA  does  not  affect  its  conformation  or  oligomeric  form  (Malle  et  al.  1995,  Malle  
et  al.  1998).  In  other  words,  it  is  possible  that  SAA  assumes  the  same  hexameric  
conformation  when  unbound  and  when   in  a   complex  with  HDL.   Indeed,   some  
signalling  pathways  are  activated  in  a  similar  fashion  by  the  two  states  of  SAA  
(Patel   et   al.   1998,   Cai   et   al.   2005),   whereas   the   exceptions  might   ref lect   the  
inhibitory  effect  of  HDL  that  was  demonstrated  in  the  present  study  as  well.  Thus,  
in   light  of  current  knowledge,  neither  of   the   lipidic  states  of  SAA,   lipid-­free  or  
HDL-­bound,  can  be  considered  less  relevant  physiologically  than  the  other.
Lipoprotein oxidation
The   modification   of   LDL   is   considered   one   of   the   key   events   in   the  
?????????????????????????????????????????????????????????????? ????????????????????
acetylated  LDL  that  is  not  found  in  vivo,  the  physiological  relevance  of  oxLDL  is  
supported   by   the   presence   of   oxLDL   in   atherosclerotic   lesions,   or   in   fractions  
extracted  from  them,  and  the  presence  of  oxLDL-­reactive  autoantibodies  in  the  
serum  of  both  humans  and  animals  (Steinberg  1997,  Steinberg  and  Witztum  2010).  
However,  the  exact  mechanism  by  which  LDL  is  oxidized  in  vivo  is  not  known.  The  
incubation  of  LDL  with  ECs  and  also  other  cell  types  has  been  shown  to  result  in  the  
?????????? ?????????????????????????????et  al.  1981,  Steinbrecher  et  al.  1984),  and  
the  suggested  pathways  include  reactions  involving  metalloprotein  lipoxygenase,  
peroxidase-­mediated   oxidation   (with   myeloperoxidase   and   heme)   as   well   as  
oxidation  mediated  by  ceruloplasmin  and  copper  or  by  iron  (Jiang  et  al.  2011).  A  
mere  presence  of  copper  ions  has  been  shown  to  oxidize  LDL  in  a  way  that  mimics  
the  cell-­induced  oxidation  of  LDL  in  many  ways  (Esterbauer  et  al.  1989),  and  this  
procedure  has  become  one  of  the  most  commonly  used  methods  for  in  vitro  LDL  
oxidation.  Depending  on  the  oxidation  mechanism,  the  chemical  properties  of  the  
acquired  oxLDL  can  differ  to  some  extent;;  copper  oxidation  may,  for  example,  create  
more  malondialdehyde,  which  can  modify  the  apoB  fraction  or  the  net  charge  of  the  
??????????????????????? ???????????????????? ????????????????????????????????????
for  oxLDL.   Instead,   it   can  be  characterized  as  a   complex  mixture  of  numerous  
chemical  entities,  and  even  in  identical  oxidative  conditions  the  end  product  can  
vary  from  experiment  to  experiment,  depending  on  the  initial  composition  of  LDL  
(Steinberg  1997).  To  date,  the  oxidation  of  HDL  has  drawn  much  less  attention,  but  
Results and Discussion
82
it  has  been  suggested  to  be  oxidized  as  readily  as  LDL  (Parthasarathy  et  al.  1990,  
Shuhei  et  al.  2010).  Based  on  the  available  data,  it  is  reasonable  to  assume  that  the  
copper-­oxidized  lipoproteins  used  in  the  present  study  resemble  their  physiological  
????????????????????????????????????????????????????????????????????
5.2  The  current  treatment  of  SAA-­related  diseases
In  AA  amyloidosis,   the  primary   treatment   strategy  has   traditionally   been   the  
alleviation  of  the  primary  disease,  which  usually  results  in  a  decrease  in  the  hepatic  
?????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????? ??????????????? ???????????????????? ???
effectively  treated  (Elkayam  et  al.  2002),  and  maintaining  the  serum  levels  of  SAA  
below  5  mg/ml  is  usually  associated  with  the  regression  of  amyloid  deposition  and  
the  maintainance  of  renal  function  (Pinney  and  Hawkins  2012).  Besides  colchicine,  
?????? ??? ???????? ???????? ??????????????????? ??????? ???? ??????????? ???????????
deposition  has  also  been  achieved  by  immunosuppressive  strategies  with  biological  
agents,  such  as  anti-­TNF  therapy  or  treatment  with  IL1R  antagonists  (Keersmaekers  
et  al.  2009,  Fernandez-­Nebro  et  al.  2010),  or  by  targeting  the  expression  of  SAA  
directly.   Kluve-­Beckerman   et   al.   recently   demonstrated   a   suppression   of   the  
production  of  SAA  by  utilizing  antisense  oligonucleotides.  In  their  study,  the  serum  
levels  of  SAA  in  mice  were  decreased  by  65%  relative  to  controls,  and  the  amyloid  
????? ???????????????????????????????????????et  al.  2011).  
The   third   approach   to   fight   AA   amyloid   deposition   is   to   disturb   the  
formation  or  stability  of  amyloid  fibrils.  Serum  amyloid  P  (SAP)   is  a  universal  
component  of  all  amyloid  deposits  (Pepys  et  al.  1996),  and  strategies  aiming  to  
deplete  SAP  have  been  described  (Botto  et  al.  1997,  Pepys  et  al.  2002,  Bodin  et  al.  
2010).   In   addition,   a   new   type   of   therapy   utilizing   small-­molecule   anionic  
sulfonates  or  sulfates  is  under  study.  These  HS-­resembling  molecules  inhibit  the  
polymerization  of  AA  fibrils  by  competing  with  the  AA  fibrils  on  binding  to  GAGs.  
They  have  been  shown  to  decrease  amyloid  deposition  in  mice  (Kisilevsky  et  al.  
1995)  as  well  as  to  have  a  beneficial  effect  on  the  deterioration  rate  of  renal  function  
in  a  preliminary  study  with  human  patients  (Dember  et  al.  2007,  Manenti  et  al.  
2008,  Rumjon  et  al.  2012).
Mast  cell-­derived  tryptase  was  shown  to  promote  the  formation  of  fibril-­like  
structures  in  the  present  study  (Study  I).  However,  the  extent  of  this  phenomenon  
in  vivo   requires   further   investigation.  More   importantly,  despite   its  numerous  
known  pathological  features,  tryptase  appears  to  play  protective  roles  as  well,  for  
example  in  neurogenic  inflammation  or  gut  infections  (Caughey  2011),  making  the  
targeting  of  tryptase  a  rather  challenging  approach.  
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On  the  other  hand,  the  demonstration  of  the  role  of  SAA  as  a  significant  
inf lammatory  mediator,   as   done   in   the   present   study   (Study   II),   has   obvious  
implications  in  terms  of  treatment  prospects.  Blocking  the  binding  of  SAA  to  its  
receptors  would  most   likely   be   an   unfeasible   approach   since   SAA   activates   a  
number  of   receptors,  which  are  also  structurally  different.   Instead,  SAA   itself  
represents  a  potential  target  for  anti-­inflammatory  therapies  and  it  is  also  unique  
in  the  sense  that  blocking  its  harmful  effects  or  reducing  its  serum  levels  would  
have  an  impact  not  only  on  AA  amyloidosis  but  also  on  a  range  of  inf lammatory  
diseases  and  even  on  atherosclerosis.  As  stated,  several  approaches  can  be  taken  to  
inhibit  the  activity  of  SAA.  In  addition  to  targeting  IL-­1  and  TNF,  another  feasible  
approach  could  be  to  reduce  the  levels  of  the  third  key  cytokine  that  mediates  the  
hepatic  synthesis  of  SAA,  IL-­6.  Interestingly,  anti-­IL-­6  therapy  by  tocilizumab,  a  
blocker  of  the  IL-­6  receptor  (Smolen  and  Maini  2006),  has  indeed  shown  promising  
results,   leading   to   its   recent   approval   for   use   in   the   treatment   of   RA.   Other  
conditions   that  might   respond   to   the   same   treatment   include   systemic-­onset  
juvenile  idiopathic  arthritis,  adult-­onset  Still’s  disease,  Castleman’s  disease  and  
Crohn’s  disease  (Navarro-­Millan  et  al.  2012).  Importantly,  the  blocking  of  IL-­6R  
has  also  been  associated  with  the  normalization  of  the  serum  levels  of  SAA  and  
with  the  relief  of  the  clinical  symptoms  of  AA  amyloidosis  (Okuda  and  Takasugi  
2006,  Magro-­Checa  et  al.  2011).
The   fact   that   serum   lipoproteins   are   capable   of   dimishing   the  
proinflammatory  activity  of  SAA  (Study  III)  is  an  interesting  finding  and  raises  
questions   in  relation   to   treatment.  One  can  speculate   that   therapies  aiming   to  
increase   the  concentration  of  HDL  (Badimon  and  Vilahur  2012)  could   then  be  
beneficial  not  only   for   the  antioxidant   effects   and  RCT  but   also   for   the  direct  
regulation  of  the  inflammatory  reaction.  However,  how  the  inhibitory  potential  of  
LDL  or  oxidized  lipoproteins  could  be  applied  to  practice  requires  further  study.  
Also,  in  the  present  work,  the  impact  of  HDL  was  assessed  only  from  the  point  of  
view  of  lipid-­free  SAA.  The  antioxidant  and  anti-­inf lammatory  features  of  HDL  
can  become  impaired  in  AP-­HDL  particles  (Tölle  et  al.  2012).  Furthermore,  SAA-­
containing  HDL  and  LDL  are  perhaps  more  efficiently  trapped  in  the  proteoglycan  
matrix   in   the   intima,   promoting   lipoprotein   modification   and   uptake   by  
macrophages  (O’Brien  et  al.  2005,  Wilson  et  al.  2008,  Chiba  et  al.  2011,  King  et  al.  
2011).  Thus,  the  net  effect  for  the  organism  could  be  harmful  despite  the  possible  
decrease  in  the  activity  of  SAA.
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VI Summary and Conclusions
The aim of this thesis was to investigate the interplay between SAA and two types of 
innate immune system cells, human mast cells and macrophages, and the consequences of 
this interplay on the pathogenesis of AA amyloidosis, atherosclerosis and inflammation in 
general. Potential mechanisms for the regulation of SAA were also studied. The findings 
presented in the publications I-III and discussed above can be summarized as follows:
1)  SAA  is  a  potent  inducer  of  degranulation  and  cytokine  production  
in   human  mast   cells,   and   these   features   can   contribute   to   the  
development  and  progression  of  AA  amyloidosis.  We  hypothesize  a  
pathway  with  the  following  events.  High  levels  of  SAA  activate  mast  
cells   to   degranulate   and   to   release   neutral   proteases,   notably  
tryptase.   Tryptase   releases   the   N-­terminus   of   SAA,   and   this  
amyloidogenic   fragment   can   then   function   as   a   local   amyloid-­
enhancing   factor   and   induce   AA   fibrillogenesis.   This   may   be  
enhanced  by  heparin,  a  component  of  mast  cell  granules  as  well  as  
??? ????????????????????????????????????????????????????????????
mast  cells  by  SAA  further  promotes  the  hepatic  and/or  extrahepatic  
expression  of  SAA,  creating  a  positive  feedback  loop.  In  addition  to  
mast  cells,  resident  macrophages  may  potentially  contribute  to  AA  
amyloidogenesis   in   two   ways:   via   extracellular   processing   by  
cathepsin  B,  the  secretion  of  which  is  also  induced  by  SAA,  and  by  
?????????????????????????????????????????????????????????????????
induced  by  SAA  itself.  The  suggested  chain  of  events  is  supported  by  
?????????????????????????????????????????????????????????????????????
??? ????????????????? ???????????????????? ????? ????????????
?????????????????????????????? ?????????????????????????????????????
No  additional  activator  is  required  as  SAA  is  able  to  both  prime  the  
macrophages,  i.e.  induce  the  expression  of  IL1B  and  NLRP3,  and  
?????????????????????????????????????????????????????????????
the   receptors  TLR2  and  TLR4,  and   the  activation  of  NLRP3   is  
mediated  via  direct  interaction  with  the  ATP  receptor  P2X7  and  an  
increase   in   cathepsin   B   activity.   However,   neither   lysosomal  
?????????????????????????? ????????????????????????????? ??????????
mechanism   for   the   activation   of   NLRP3   by   SAA   is   yet   to   be  
elucidated.   Considering   the   relevance   of   the   innate   immune  
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Figure 9. A schematic representation of the SAA-induced activation of human mast 
cells and macrophages and the proposed pathway for AA amyloidogenesis. The dashed 
arrows represent hypothetical pathways that were not experimentally verified in the present 
study. AA, amyloid A; IL, interleukin; SAA, serum amyloid A; TNF, tumor necrosis factor.
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are  illustrated  in  Figure  10.
3)  The   activity   of   SAA   is   regulated  by   serum   lipoproteins.   The  
ability  of  SAA  to  induce  cytokine  production  in  human  macrophages  
is  decreased  not  only  by  its  common  carrier  HDL3  but  also  by  LDL.  
Furthermore,   the   oxidation   of   these   lipoproteins   enhances   the  
inhibitory  effect.  In  terms  of  the  mechanism,  divergent  pathways  are  
involved  in  the  regulation  of  SAA  by  native  and  oxidized  lipoproteins.  
Native   lipoproteins  most   likely   bind   to   SAA   extracellularly   and  
Figure 10. A schematic representation of the SAA-induced activation of 
NLRP3 in human macrophages. AP, activating protein; ASC, apoptosis-associated 
speck-like protein containing a CARD (caspase activation and recruitment domain); 
Ca074Me, cathepsin B inhibitor; CatB, cathepsin B; IL, interleukin; NF-?B, nuclear 
factor kappa B; NLRP, nucleotide-binding domain leucine-rich repeat containing 
receptor with a pyrin domain; SAA, serum amyloid A; TLR, Toll-like receptor.
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prevent   it   from   interacting  with   cell-­surface   receptors,   such   as  
TLR2  and  TLR4,   thus   inhibiting   the   induction  of  IL1B  by  SAA.  
Oxidized  lipoproteins  also  have  a  direct  effect  on  macrophages,  i.e  
they  inhibit  both  the  expression  of  IL1B  and  the  activation  of  the  
?????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????in  vivo,  
as  demonstrated   in  a  mouse  model  of  SAA-­induced  peritonitis.  
???????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????
Taken   together,   the   presence   of   both   native   and   oxidized  
lipoproteins   in   the   circulation   and   tissues   may   represent   an  
important   regulatory   mechanism   by   which   the   effects   of   the  
powerful   proinf lammatory   factor   SAA   are   regulated   during  
????????????
Figure 11. A schematic representation of the regulation of the SAA-induced 
activation of NLRP3 by serum lipoproteins in human macrophages. AP, 
activating protein; HO-1, heme oxygenase 1; IL, interleukin; NF-?B, nuclear factor 
kappa B; NLRP, nucleotide-binding domain leucine-rich repeat containing receptor 
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